

# 2021–2022 ANNUAL REPORT



**CENTRAL COUNCIL FOR RESEARCH  
IN UNANI MEDICINE**

Ministry of Ayush, Government of India



# Annual Report

---

## 2021-2022



CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE  
Ministry of Ayush, Government of India



CENTRAL COUNCIL FOR RESEARCH  
IN UNANI MEDICINE  
Ministry of Ayush, Government of India

*Published by*  
**CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE**  
Ministry of Ayush, Government of India  
61 – 65, Institutional Area, Janakpuri, New Delhi – 110 058  
Telephone: +91-11-28521981, 28525982  
E-mail: [unanimedicine@gmail.com](mailto:unanimedicine@gmail.com)  
Website: <https://ccrum.res.in>

*Printed at*  
Hi-Tech Graphics  
F-28/3, Okhla Industrial Area, Phase-II, New Delhi-110 020

## CONTENTS

1. OVERVIEW	5
1.1. Objectives of the Council	5
1.2. Programme-wise Achievements	5
2. MANAGEMENT	9
2.1. Governing Body	9
2.2. Executive Committee	9
2.3. Standing Finance Committee	10
2.4. Scientific Advisory Committee	10
2.4.1. Research Sub-Committees	10
2.5. Ethics Committee	11
2.5.1. Central Ethics Committee	11
2.5.2. Institutional Ethics Committee	11
2.6. Organisational Set-Up	15
2.7. Budget (Actual Expenditure)	21
3. TECHNICAL REPORT	23
3.1. Intramural Research	23
3.1.1. Centre-wise Activities	23
3.1.2. Programme-wise Activities	27
3.1.2.1. Survey and Cultivation of Medicinal Plants Programme	27
3.1.2.2. Drug Standardization Research Programme	29
3.1.2.3. Clinical Research Programme	33
Preclinical Studies	33
Clinical Studies	44
Randomised Controlled Trials	47
Validation of Unani Pharmacopoeial Drugs	48
Validation of Regimen Therapies	59
Validation of Fundamentals	60
Research-oriented Healthcare	62
3.1.2.4. Literary Research Programme	63
3.2. Studies under IMR Policy	64
3.3. Collaborative Research	66
3.4. Publications	70
3.4.1. Books, Monographs, Reports, etc.	70
3.4.2. Journals / Periodicals	70
3.4.3. Research Papers	70
3.5. Extension of Healthcare Services	80
3.5.1. School Health Programme	80
3.5.2. Unani Medical Centres in Allopathic Hospitals	81
3.5.3. Health Camps	81
3.5.4. Activities under Gender Component Plan for Women	81

3.5.5. Activities in the North-Eastern Region	81
3.5.6. Mobile Healthcare Programme under Scheduled Caste Sub-Plan	81
3.5.7. Mobile Healthcare Programme under Tribal Sub Plan	82
3.6. Linking Education with Research	82
4. INFORMATION, EDUCATION & COMMUNICATION	83
4.1. Library Services	83
4.2. Organization of Conferences, Seminars, Workshops, etc.	83
4.2.1. Unani Day Celebration and International Conference on Unani Medicine	83
4.2.2. Ayush Minister visits CCRUM, appreciates research work	91
4.2.3. Ayush Minister inaugurates BUMS at GUMC&H, J&K	92
4.2.4. Ayush Minister visits RRIUM, Srinagar, leads plantation drive	93
4.2.5. Ayush Minister visits RRIUM, Srinagar	93
4.2.6. National seminar on IPR	94
4.2.7. Training rogramme on implementation of NABH accreditation	95
4.2.8. National seminar on research methodology	95
4.2.9. National seminar on IPR	96
4.2.10. Webinar on healthcare standards	97
4.2.11. Webinar on 'Bio-ethics with emphasis on GCP guidelines'	98
4.2.12. Seminar on mental health	98
4.2.13. Webinar on research methodology	99
4.2.14. Webinar on managerial effectiveness	99
4.2.15. Webinar on drug development	99
4.2.16. Webinar on lifestyle	99
4.2.17. Webinar on Unani Medicine	100
4.2.18. Webinar on Pharmacovigilance	100
4.2.19. Webinar on COV ID-19	100
4.2.20. Webinars on information technology	101
4.2.21. Webinar on pharmacovigilance	101
4.3. Participation in Arogya Fairs/ Expos	101
4.4. Participation in Promotion of Official Language	102
4.5. Appointments	103
4.6. Promotions	103
4.7. Retirements	103
4.8. Deaths	104
5. FINANCIAL STATEMENT	105
5.1. Audit Report	105
5.2. Audited Statement of Accounts	109
5.3. Notes on Accounts	178

## 1. OVERVIEW

### 1.1. Objectives of the Council

The Central Council for Research in Unani Medicine (CCRUM) is an autonomous organization under the Ministry of Ayush, Government of India. It was established on March 30, 1978 under the Societies Registration Act, 1860 and started functioning from January 10, 1979. The main objectives of the CCRUM are as follows:

- Formulation of aims and patterns of research on scientific lines in Unani Medicine
- To undertake research or any other programmes in Unani Medicine
- Prosecution of and assistance in research and propagation of knowledge and experimental measures generally in connection with the causation, mode of spread and prevention of diseases
- To initiate, aid, develop and coordinate scientific research on different aspects, fundamental and applied, of Unani Medicine, and to promote and assist institutions of research for the study of diseases, their prevention, causation and remedy
- To finance enquiries and researches for the furtherance of the objectives of the council
- To exchange information with other institutions, associations and societies interested in the objectives similar to those of the council, especially in the observation and study of diseases in the East in general, and in India in particular
- To prepare, print, publish and exhibit any papers, posters, pamphlets, periodicals and books for furtherance of the objectives of the council and to contribute to such literature

### 1.2. Programme-wise Achievements

The year 2021–2022 was a challenging one like the previous year due to the COVID-19 pandemic. However, it provided opportunities for research institutions like CCRUM to conduct research on newer health challenges and explore the potentials of Unani Medicine in combating pandemics like COVID-19.

During the reporting period, the CCRUM took various initiatives to counter the spread of COVID-19 besides continuing its ongoing research activities in the areas of core research, namely Survey and Cultivation of Medicinal Plants, Drug Standardization Research, Clinical Research and Literary Research, and supplementary areas like information, education and communication and extension of healthcare services through a network of 22 centres throughout the country.

The continuing research activities delivered satisfactory outcomes during the reporting period in spite of COVID-19 preventive measures in place. Under the Survey and Cultivation of Medicinal Plants Programme, ethnopharmacological surveys were conducted in different forest divisions/areas. As a result of these surveys, 1,761 botanical specimens were collected and 439 plant species identified. Later, herbarium sheets of 1,341 specimens including new and previous collections containing their basic details were prepared and 634 index cards were updated. A total of 479 herbarium sheets were digitized as well. The survey teams collected 2,064 saplings of important medicinal species for plantation and 228 kg of raw drugs. The surveyors recorded 148 folk medicinal claims from the tribal inhabitants and other rural folks of the study areas. Experimental and large-scale cultivation of some important medicinal species was also undertaken which yielded 83 kg of raw drugs. A total of 437 common

species of medicinal plants used in Unani Medicine were maintained in the nurseries of the CCRUM centres.

Under the Drug Standardization Research Programme, SOPs for manufacture of 29 Unani formulations and their pharmacopoeial standards were developed. Besides, pharmacopoeial standards for 18 single drugs were developed and quality control work of 43 Unani formulations was carried out. The drug testing laboratory at the RRIUM, Chennai analysed 20 ASU drug samples received from different organizations. In an effort to revisit the existing Unani Pharmacopoeia of India (UPI), monographs of 25 Unani single drugs from UPI, part-I, vol. II and 20 drugs from part-I, vol. IV were revised as per the new format provided by the Pharmacopoeia Commission of Indian Medicine and Homoeopathy (PCIM&H). Under the grant-in-aid scheme of the CCRUM, phytoconstituents were isolated from two Unani single drugs at the Chemical Research Unit located at Aligarh Muslim University, Aligarh.

Under the Clinical Research Programme, preclinical safety evaluation studies, clinical studies and validation of safety and efficacy of classical/pharmacopoeial formulations, regimen therapies and fundamentals of Unani Medicine continued. Besides, research under intramural research (IMR) policy and collaborative research also continued.

During the reporting period, preclinical safety and pharmacological studies on 17 Unani drugs were undertaken. These included preclinical studies of six drugs conducted at RRIUM, Srinagar and 11 drugs conducted at NRIUMSD, Hyderabad.

In clinical research, five randomised controlled trials (RCTs) - one each on *Faqr al-Dam* (iron deficiency anaemia), *Tahajjur al-Mafāṣil* (osteoarthritis), *Ḍīq al-Nafas* (bronchial asthma), *Dhayābīṭus Sukkarī Qism Thānī* (diabetes mellitus type II) and *Shaqīqa* (migraine) were initiated. As much as 38 studies for clinical validation of Unani pharmacopoeial formulations in different diseases were conducted, 20 studies were initiated and another 20 studies were allotted. Various regimen therapy procedures were performed on 5,280 patients of different diseases. *Hijāma bilā-Sharṭ* (dry cupping) was performed on 2,586 patients, *Hijāma bi'l-Sharṭ* (wet cupping) on 461, *Hijāma bi'l-Nār* (fire cupping) on 34, *Hijāma Muzliqa* (moving cupping) on 1,369, *Hammām al-Bukhār* (steam bath) on 49, *Dalk Mu'tadil* (moderate massage) on 13, *Hammām Yābis* (sauna) on 11, *Naṭūl* (fomentation) on 66, *Inkibāb* (vaporization) on 270, *Munḍij-Mushil* therapy on 46, *Ta'īlq* (leeching) on 15 and *Takmīd* (fomentation) on 360 patients.

Under the validation of fundamentals of Unani Medicine, three projects continued, three new projects were initiated and book compilation on seven completed studies on theory of *Akhlāṭ* (humours) was in process during the reporting period. Clinical assessment of *Mizāj* (temperament) also continued and assessment of temperament of 222 patients attending the OPD of NRIUMSD, Hyderabad was done. Six different projects were undertaken under the IMR policy.

The CCRUM also undertakes research in collaboration with other prestigious institutes. During the reporting period, 21 collaborative studies continued/were initiated at Jamia Hamdard, New Delhi; Jamia Millia Islamia, New Delhi; Interactive Research School for Health Affairs, Pune; SVKM's NMIMS, Mumbai; All India Institute of Medical Sciences, New Delhi; Jadavpur University, Kolkata; University of Mumbai, Mumbai; South Asian University, New Delhi; National Institute of Pharmaceutical Education and Research, Hyderabad; and CSIR-Central Drug Research Institute, Lucknow.

Under the Literary Research Programme, the CCRUM published '*Adwiyā Kabidiyya: Qadeem-o-Jadeed Tahqiqat ki Raushni mein*' and '*Riyad al-Adwiyā*'. Urdu translation of



Arabic book '*Al-Masā'il fi'l-Ṭibb*' was completed, while Urdu translation of Arabic book '*Man lā yaḥḍuruḥu al-Ṭabīb*' and Urdu translation of Persian books '*Khulāṣat al-Tajārib*' and '*Kitāb al-Abniya 'an Ḥaqā'iq al-Adviya*' continued. English translation of Urdu book '*Intikhāb-i-Jalīl*' also continued. Besides, work on the monographs on '*Ḥammām* (bath) – An effective component of Regimenal Therapy of Unani Medicine' and '*Amrād-i-Tanaffus* (respiratory diseases) in Unani Medicine' was in progress. The work related to the WHO's project on international terminologies of Unani Medicine continued during the reporting period and revision of priority terms incorporating the comments and suggestions of experts from 'WHO Technical Experts Consultation Meeting' was completed. Further review of the terms, as required by the WHO, was also performed. Under the project of 'National Systematised Nomenclature of Medicine Clinical Terms (SNOMED-CT) Extension for Unani Medicine', various works like collection and assortment of 12,021 Unani terms from classical Unani texts, identification of 11,507 terms relating to different hierarchies, e-prescription from SNOMED-CT browser, translation of 10,298 identified terms in three categories - fully specified name, preferred term and synonym, '1<sup>st</sup> India AYUSH Extension Release' of 1,084 terms, '2<sup>nd</sup> India AYUSH Extension Release' of 4,006 terms, '3<sup>rd</sup> India AYUSH Extension Release' of 5,842 terms and '4<sup>th</sup> India AYUSH Extension Release' of 6,446 terms were completed. The work on developing high level structure and review of already existing structure of NAMASTE-P Unani diagnoses classification was completed besides continuing retrieval and compilation of NUMC data from NAMASTE-P and developing ICD-11 Ayurveda-Siddha-Unani TM Module-2. Certain related works like development of template for revision of 'NUMC Version-1' as well as revision itself and development of subset of Unani Medicine under Clinical Trials Registry-India (CTRI) was completed. Taking inspiration from the Ministry of Ayush campaign for "Ayush Aahar", the CCRUM compiled a booklet on 'Important Food Recipes in Unani Medicine'. Information on the topics, veterinary medicine in Unani Medicine, '*Ilāj bi'l-Ghidhā*' (dietotherapy) and '*Asbāb Sitta Ḍarūriyya*' (six essential factors) was also compiled during the reporting period.

With a view to disseminating the research findings, 130 research papers were published in national and international scientific journals. During the reporting period, eight books were also brought out. Besides, publication of the quarterly bulletin CCRUM Newsletter, quarterly Urdu journal *Jahan-i Tib*, quarterly English journal Hippocratic Journal of Unani Medicine, and IEC materials continued.

Research-oriented healthcare services continued at GOPDs and special OPDs of clinical centres of the CCRUM. During the reporting period, a total of 2,82,859 patients comprising 2,30,762 patients in GOPDs, 18,361 in Geriatric OPDs, 4,915 in RCH / MCH OPDs, 9,263 in NCD's OPDs and 19,558 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres.

Under the Mobile Clinical Research Programme, 17 rural pockets/urban slums covering over 2.44 lakh population were adopted and a total of 12,879 patients were treated with Unani pharmacopoeial formulations in 482 mobile visits made to these pockets during the reporting period.

The Unani Medical Centres functioning under the scheme of co-location of AYUSH centres in Dr. Ram Manohar Lohia Hospital, Deen Dayal Upadhyay Hospital and VMMC & Safdarjung Hospital, New Delhi treated 11,655, 8,674 and 5,917 patients respectively.

Under the Gender Component Plan for Women, 1,48,279 female patients were treated in different OPDs. Clinical studies on the diseases specific to women, such as *Sayalān al-*

*Rahim* (leucorrhoea), *Ihtibās al-Tamth* (amenorrhoea) and *Kathrat al-Tamth* (menorrhagia) also continued. Under the Activities in North Eastern Region, 1,823 patients were treated for their common and chronic ailments at the Regional Research Centre located at Silchar, Assam.

Under the Special Component Plan – Scheduled Caste Sub-Plan (SCSP) and Tribal Sub-Plan (TSP), 11,93,391 total population including 8,37,825 SC population were covered under SCSP, whereas 1,31,914 total population including 96,614 ST population were covered under TSP. A total of 44,933 and 14,177 individuals benefited from SCSP and TSP, respectively.

The academic activities under the postgraduate programmes in Unani Medicine successfully continued. A total of 29 new scholars in addition to continuing MD (Unani) scholars were actively engaged in academic, research and training activities at NRIUMSD, Hyderabad and RRIUM, Srinagar.

During the period under report, the CCRUM celebrated Unani Day and organized International Conference on Unani Medicine at Sher-i-Kashmir International Conference Centre (SKICC), Srinagar during March 10–11, 2022. Themed on ‘Diet and Nutrition in Unani Medicine for Good Health and Well-being’, the conference was the first of its kind in the Kashmir Valley and made a very good impact through scientific deliberations. Apart from this, the CCRUM organized more than 20 webinars, workshops and such other events.

The CCRUM participated in 22 Arogya fairs/expos and similar events to propagate Unani Medicine and highlight its activities and achievements.

The council continued the promotion of the Official Language and organized Hindi Pakhwada at the headquarters and different centres. Quarterly workshops on Hindi language were also organized.

We hope that the CCRUM work even more efficiently in the coming years for the fulfilment of its aims and objectives in the area of research and development in Unani Medicine.

New Delhi  
October 26, 2022



**Prof. Asim Ali Khan**  
Director General

## 2. MANAGEMENT

The management of the affairs of the CCRUM is entrusted to the Governing Body (GB), the Executive Committee (EC) and the Standing Finance Committee (SFC). The research activities are conducted with the recommendations of the Scientific Advisory Committee and ethical clearance of the Central Ethics Committee (CEC) / Institutional Ethics Committee (IEC).

### 2.1. Governing Body

During the reporting period, the constitution of the GB of the CCRUM was as given below:

#### President

Minister of State (Independent Charge), Ministry of Ayush, Government of India

#### Vice-President

Secretary, Ministry of Ayush, Government of India

#### Official Members

- Financial Advisor, Ministry of Ayush, Government of India
- Additional Secretary / Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India
- Adviser (Unani), Ministry of Ayush, Government of India
- Director, National Institute of Unani Medicine, Bengaluru

#### Non-Official Members

- Dr. M A Waheed, Former Officiating Director, NRIUMSD, Hyderabad
- Prof. Aftab Ahmad, Jamia Hamdard, New Delhi
- Prof. Misbahuddin Siddiqui, Aligarh Muslim University, Aligarh
- Dr. Mohd Zafar Hasan, Private Practitioner, Bhopal
- Prof. Mohammad Haroon, Uttranchal Unani Medical College, Haridwar
- Prof. Akhilesh Verma, Department of Chemistry, University of Delhi, New Delhi
- Dr. Veena Gupta, National Bureau of Plant Genetic Resources, New Delhi
- Prof. Surender Singh, AIIMS, New Delhi
- Prof. Rajesh S. Sharma, District Homeopathic Medical College & Hospital, Ratlam

#### Member Secretary

- Director General, CCRUM

### 2.2. Executive Committee

The constitution of the EC during the reporting period was as given below:

#### Chairperson

Secretary, Ministry of Ayush, Government of India

#### Official Members

- Financial Advisor, Ministry of Ayush, Government of India
- Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India
- Adviser (Unani), Ministry of Ayush, Government of India
- Director, National Institute of Unani Medicine, Bengaluru

#### Non-Official Members

- Dr. M. A. Waheed, Former Officiating Director, NRIUMSD, Hyderabad

- Prof. Misbahuddin Siddiqui, Aligarh Muslim University, Aligarh
- Dr. Mohd. Zafar Hasan, Private Practitioner, Bhopal
- Dr. Veena Gupta, National Bureau of Plant Genetic Resources, New Delhi
- Prof. Rajesh S. Sharma, District Homeopathic Medical College & Hospital, Ratlam, Madhya Pradesh

#### Member Secretary

- Director General, CCRUM

### 2.3. Standing Finance Committee

During the reporting period, the composition of the SFC was as follows:

- |  |                    |
|--|--------------------|
| • Additional Secretary/Joint Secretary (dealing with CCRUM), Ministry of Ayush, Government of India  | : Chairman         |
| • Financial Advisor or his nominee not below the rank of Deputy Secretary, Integrated Finance Division, Ministry of Ayush, Government of India | : Member           |
| • Adviser (Unani), Ministry of Ayush, Government of India  | : Member           |
| • Prof. Tajuddin, Former Chairman, Department of Ilmul Advia, Aligarh Muslim University, Aligarh   | : Technical Member |
| • Director General, CCRUM  | : Member-Secretary |

### 2.4. Scientific Advisory Committee

The following was the composition of the SAC as on March 31, 2022:

- |   |                    |
|---|--------------------|
| • Dr. Ram Vishvakarma, Director, CSIR-IIIM, Jammu   | : Chairperson      |
| • Dr. M. A. Waheed, Former Officiating Director, NRIUMSD, Hyderabad   | : Member           |
| • Prof. Abdul Wadud, Director, NIUM, Bengaluru  | : Member           |
| • Prof. Imamuddin, Former Principal, Government Unani Medical College, Chennai  | : Member           |
| • Prof. D. S. Arya, Department of Pharmacology, AIIMS, New Delhi  | : Member           |
| • Prof. Sunil Kohli, Hamdard Institute of Medical Sciences & Research, New Delhi  | : Member           |
| • Dr. (Mrs.) Sunita Garg, Chief Scientist (Retd.), National Institute of Science Communication and Information Resources, CSIR, New Delhi | : Member           |
| • Dr. Arun Kumar Sinha, Chief Scientist, Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow                   | : Member           |
| • Director General, CCRUM   | : Member Secretary |

#### 2.4.1. Research Sub-Committees

The SAC is assisted by five research sub-committees, namely Clinical Research Sub-committee, Drug Standardization Sub-committee, Literary Research Sub-committee, Survey and Cultivation of Medicinal Plants Sub-committee and Claim of Cure Sub-committee. However, there was no sub-committee in place during the reporting period.

## 2.5. Ethics Committee

It is mandatory that all the proposals on biomedical research involving human participants are approved by a duly constituted ethics committee to protect their welfare and rights. At the end of the reporting period, there were 11 Institutional Ethics Committees (IEC) functioning at various institutes/units of the CCRUM. These committees review and approve research proposals involving human participants. They also examine the compliance with regulatory requirements, applicable guidelines and laws. Besides, the CCRUM has a central ethics committee (CEC) at its headquarters to examine the multi-centric clinical trials or human clinical trials which may have to be carried out in certain specific conditions like COVID-19 pandemic or any other clinical trials referred to it by the CCRUM headquarters for examination and approval. The composition of the CEC as well as IEC as on March 31, 2022 was as follow:

### 2.5.1. Central Ethics Committee

- |   |                    |
|---|--------------------|
| • Prof. Sunil Kohli, Department of Medicine, Hamdard Institute of Medical Sciences and Research, New Delhi. | : Chairperson      |
| • Dr. D. S. Arya, Professor, Department of Pharmacology, AIIMS, New Delhi                                   | : Member           |
| • Prof. Shakeel Ahmad Tamanna, Sr. Unani Physician, Tughlaqabad, New Delhi                                  | : Member           |
| • Prof. Idris Ahmed, A&U Tibbia College, New Delhi  | : Member           |
| • Shri Kumar Onkareshwar, Advocate, High Court, New Delhi   | : Member           |
| • Shri Mohd. Sulemaan, Former Teacher, Jamia Secondary School, Jamia Millia Islamia, New Delhi              | : Member           |
| • Dr. Mohammed Jamshed, Assistant Professor, Department of Management Studies, Jamia Hamdard, New Delhi     | : Member           |
| • Assistant Director (Unani), CCRUM headquarters, New Delhi   | : Member Secretary |

### 2.5.2. Institutional Ethics Committee

#### National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad

- |  |               |
|--|---------------|
| • Prof. Akhtarul Wasey, Former President, Maulana Azad University, Jodhpur, Rajasthan                    | : Chairperson |
| • Dr. M. U. R. Naidu, Former Dean, Faculty of Medicine, Nizam's Institute of Medical Sciences, Hyderabad | : Member      |
| • Dr. M. A. Wajid, Associate Professor & Head, Department of Microbiology, ESIC, Hyderabad               | : Member      |
| • Prof. Ahsan Farooqui, Government Nizamia Tibbi College, Hyderabad                                      | : Member      |
| • Shri Abdul Fatah Khan, Advocate, Hyderabad   | : Member      |
| • Smt. Chandana Pal, Apollo Hospitals, Hyderabad   | : Member      |

- Hafiz Mohammed Ajaz Ahmed, Imam, Hyderabad : Member
- Dr. Qamar Uddin, NRIUMSD, Hyderabad : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Chennai

- Hakim Syed Imamuddin Ahmed, Former Principal, Government Unani Medical College, Chennai : Chairperson
- Dr. P. Elango, Ramachandra Medical College & Research Institute, Chennai : Member
- Dr. R. Ilavarasan, Assistant Director Incharge, CSM Drug Research Institute of Ayurveda, Chennai : Member
- Dr. V. Md. Habibullah, Head, Department of Jarahat, Government Unani Medical College, Chennai : Member
- Dr. Syed Hissar, Scientist C, ICMR-NIRT, Chennai : Member
- Dr. K. Amjath Khan, Advocate, Madras High Court, Chennai : Member
- Dr. C. Ponnuraja, Scientist D, NIRT, Chennai : Member
- Dr. S. Nagasubramanian, Chennai : Member
- Shri Abdul Samad, Institute of Management, The New College, Chennai : Member
- In-charge, RRIUM, Chennai : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Srinagar

- Prof. Mohammad Afzal Zargar, Central University of Kashmir, Srinagar : Chairperson
- Dr. Shajrul Amin, Associate Professor, Department of Biochemistry, University of Kashmir, Srinagar : Member
- Dr. Shabir Ghaffari, Sr. Medical Officer, ISM, Nodal Officer Govt. Unani Medical College, Ganderbal : Member
- Dr. Zilhumma, Medical Officer, ISM, Jammu & Kashmir : Member
- Dr. Syed Mushtaq Saif Andrabi, Consultant - Medicine, Srinagar : Member
- Dr. Zubair Ashai, Associate Professor, Government Medical College, Srinagar : Member
- Prof. S. M. Afzal Qadri, Central University of Kashmir, Ganderbal, Jammu & Kashmir : Member
- Prof. Peerzada Mohammad Amin, Head, Department of Sociology, University of Kashmir, Srinagar : Member
- Shri Mohammad Farooq Rathar, Srinagar : Member
- In-charge, RRIUM, Srinagar : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Aligarh

- Prof. K. M. Y. Amin, Department of Ilmul Advia, Ajmal Khan Tibbiya College, Aligarh Muslim University, Aligarh : Chairperson



- Dr. Zameer Ahmed, Associate Professor, Ajmal Khan : Member  
Tibbiya College, Aligarh Muslim University, Aligarh
- Dr. Jamal Azmat, Assistant Professor, Ajmal Khan Tibbiya : Member  
College, Aligarh Muslim University, Aligarh
- Dr. Arshi Khan, Professor, Department of Political Science, : Member  
Aligarh Muslim University, Aligarh
- Ms. Asma Farheen, Advocate, Aligarh : Member
- Dr. Syed Sirajuddin Ajmali, Professor, Department of Urdu, : Member  
Aligarh Muslim University, Aligarh
- In-charge, RRIUM, Aligarh : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), New Delhi

- Prof. Prem Kapoor, Department of Medicine, Hamdard : Chairperson  
Institute of Medical Sciences & Research, New Delhi
- Prof. Surender Singh, AIIMS, New Delhi : Member
- Dr. K. K. Sharma, Former Head, Department of : Member  
Pharmacology, Guru Teg Bahadur Hospital, New Delhi
- Dr. Mohammad Maaz, Jamia Hamdard, New Delhi : Member
- Prof. Aftab Ahmad, Department of Ilmul Advia, Jamia : Member  
Hamdard, New Delhi
- Dr. Rubina Mansoori, Zakir Nagar, New Delhi : Member
- Shri M. H. Zaidi, Advocate, New Delhi : Member
- Prof. Nimatullah Khan, Jamia Millia Islamia, New Delhi : Member
- Prof. Nusratullah Khan, New Delhi : Member
- In-charge, RRIUM, New Delhi : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Kolkata

- Dr. Anjan Adhikari, Associate Professor, Department of : Chairperson  
Pharmacology, R. G. Kar Medical College, Kolkata
- Prof. Anwarul Haq, Head, Department of Ilaj bit Tadbeer, : Member  
The Calcutta Unani Medical College & Hospital, Kolkata
- Dr. Hakimuddin Akhtar, Consultant Physician, BM Birla : Member  
Heart Research Centre, Kolkata
- Shri Haider Ali, President, Howrah Health Awareness : Member  
Mission, Kolkata
- Shri Md. Salamuddin, Advocate, Kolkata : Member
- Shri Saptarishi Sanyal, Social Worker, Kolkata : Member
- In-charge, RRIUM, Kolkata : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Patna

- Prof. Alauddin Ahmad, Former Vice-Chancellor, Jamia : Chairperson  
Hamdard, New Delhi
- Prof. Abdul Aziz, Nalanda Medical College, Patna : Member
- Prof. Shahnawaz Akhtar, Government Tibbi College & : Member  
Hospital, Patna

- Shri Nadim Akhtar, Advocate, Civil Court & Patna High Court, Patna : Member
- Dr. Haroon Rasheed, Programme Manager for Rural Development, Government of Bihar : Member
- Prof. Shakil Ahmad Qasmi, Formerly Head, Department of Urdu, Oriental College, Patna : Member
- Shri Mohammad Azam, Social Worker, Patna : Member
- In-charge, RRIUM, Patna : Member Secretary

#### Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

- Prof. Debashish Hota, Head, Department of Pharmacology, AIIMS, Bhubaneswar : Chairperson
- Dr. Dharendra Kumar Roy, Medical Director, Institute of Medical Sciences & SUM Hospital, Bhubaneswar : Member
- Dr. Jhasaketan Mohanty, Former Sr. Medicine Specialist, District Headquarters Hospital, Bhadrak : Member
- Dr. Sayed Mozammil Ali, Medical Officer (Unani), Government Unani Dispensary, Balasore : Member
- Shri Shaikh Zulfiqar Ali, Advocate, Bhadrak District Court, Bhadrak : Member
- Shri S. M. Farooque, Secretary, Fellowship (NGO), Bhadrak : Member
- Shri Basant Kumar Nayak, Bhadrak : Member
- Dr. Abdur Rasheed, Research Officer (Unani), RRIUM, Bhadrak : Member Secretary

#### Regional Research Centre (RRC), Silchar

- Dr. Dolly Roy, Chairperson / Associate Professor of Pharmacology, Silchar Medical College and Hospital, Silchar : Chairperson
- Dr. Riturag Thakuria, Assistant Professor, Department of Medicine, Silchar Medical College and Hospital, Silchar : Member
- Dr. Wahiduzzaman, Former Deputy Director, RRIUM, Patna : Member
- Shri Ramizur Rahman Barlaskar, Advocate, Silchar Bar Association, Silchar : Member
- Shri Lutfur Rahman Laskar, Secretary, Bank Sangha (NGO), Neairgram, Cachar : Member
- Maulana Ikramuddin Mazumder, Assistant Teacher, Ghoniwala Hafizia Madarsa, Silchar : Member
- Shri Saleh Ahmed Mazumder, Silchar : Member
- In-charge, RRC, Silchar : Member Secretary

#### Clinical Research Unit (CRU), Meerut

- Dr. Surbhi Gupta, Head, Department of Pharmacology, Subharti Medical College, Meerut : Chairperson
- Dr. Sabahatullah, Physician, Amroha : Member



- Dr. Mohd Sakir, Muzaffarnagar Medical College & Hospital, : Member  
Mansoorpur, Muzaffarnagar
- Dr. Mushtaq Hussain, Allama Iqbal Unani Medical College, : Member  
Muzaffarnagar
- Shri Mohd Aslam, Advocate, Collectorate of Meerut : Member
- Maulvi Tanveer Akhtar, Religious Teacher, Meerut : Member
- Shri Mohd Parvaz, Social Worker, Meerut : Member
- Shri Sarfaraz Ahmad, Social Worker, Meerut : Member
- In-charge, CRU, Meerut : Member Secretary

#### Research Research Centre (RRC), Prayagraj

- Dr. (Prof.) Shiv Prakash, Head, Department of Community : Chairperson  
Medicine, Moti Lal Nehru Medical College, Prayagraj
- Prof. Irfan Ahmad, State Unani Medical College, Prayagraj : Member
- Dr. Abhinav Agarwal, Assistant Professor, Moti Lal Nehru : Member  
Medical College, Prayagraj
- Shri Vinay Singh, Advocate, High Court of Judicature, : Member  
Prayagraj
- Prof. Najeeb Hanzla Ammar, State Unani Medical College, : Member  
Prayagraj
- Shri Mohd Arif, Kareli, GTB Nagar : Member
- In-charge, RRC, Prayagraj : Member Secretary

## 2.6. Organisational Set-Up

The CCRUM is headquartered in New Delhi and has a network of 22 centres functioning in different parts of the country. These centres are as follows:

Centre	Number
National Research Institute of Unani Medicine for Skin Disorders	01
Central Research Institute of Unani Medicine	01
Regional Research Institute of Unani Medicine	08
Regional Research Centre	02
Clinical Research Unit	06
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine	01
Drug Standardization Research Institute	01
Drug Standardization Research Unit	01
Chemical Research Unit (Grant-in-aid)	01

The CCRUM centres are based in different States. The following is the State-wise institutional network.

#### Andhra Pradesh

- Clinical Research Unit (CRU), Kurnool

#### Assam

- Regional Research Centre (RRC), Silchar

### Bihar

- Regional Research Institute of Unani Medicine (RRIUM), Patna

### Delhi

- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi
- Drug Standardization Research Unit (DSRU), New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), Dr. Ram Manohar Lohia Hospital, New Delhi
- Unani Speciality Centre (Extension Centre of RRIUM, New Delhi), Deen Dayal Upadhyay Hospital, New Delhi
- Unani Medical Centre (Extension Centre of RRIUM, New Delhi), VMMC & Safdarjung Hospital, New Delhi

### Jammu & Kashmir

- Regional Research Institute of Unani Medicine (RRIUM), Srinagar

### Karnataka

- Clinical Research Unit (CRU), Bengaluru

### Kerala

- Clinical Research Unit (CRU), Edathala (Alwaye) with an extension centre at Pattiam, Kannur

### Madhya Pradesh

- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur

### Maharashtra

- Regional Research Institute of Unani Medicine (RRIUM), Mumbai

### Odisha

- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak

### Tamil Nadu

- Regional Research Institute of Unani Medicine (RRIUM), Chennai

### Telangana

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad


### Uttar Pradesh

- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Institute (DSRI), Ghaziabad
- Regional Research Centre (RRC), Prayagraj
- Clinical Research Unit (CRU), Meerut
- Chemical Research Unit (Grant-in-aid), Aligarh


### West Bengal

- Regional Research Institute of Unani Medicine (RRIUM), Kolkata


## Management of CCRUM




## Organizational Set-up of CCRUM



\*With three extension centres in New Delhi  
\*\* With one extension centre in Pattiam



## Organizational Structure at CCRUM Headquarters



## 2.7. Budget (Actual Expenditure)

The centre-wise actual expenditure of the Council during 2021–22 was as follows:

S. No.	Name of State and Centre	Rupees in Thousand
1.	Andhra Pradesh	
	(i) CRU, Kurnool	10,579
2.	Assam (NER)	
	(i) RRC, Silchar	4,882
3.	Bihar	
	(i) RRIUM, Patna	38,554
4.	Jammu & Kashmir	
	(i) RRIUM, Srinagar	110,739
5.	Karnataka	
	(i) CRU, Bengaluru	9,897
6.	Kerala	
	(i) CRU, Alwaye	10,262
7.	Madhya Pradesh	
	(i) CRU, Burhanpur	8,009
	(ii) CRU, Bhopal	20,625
8.	Maharashtra	
	(i) RRIUM, Mumbai	49,077
9.	Manipur (NER)	
	(i) Clinical Research Pilot Project	-
10.	New Delhi	
	(i) HAKILHRUM, New Delhi	32,066
	(ii) RRIUM, New Delhi	94,172
	(iii) Headquarters, New Delhi	146,433
	(iv) DSRU, New Delhi	15,677
11.	Odisha	
	(i) RRIUM, Bhadrak	55,732
12.	Tamil Nadu	
	(i) RRIUM, Chennai	91,418
13.	Telangana	
	(i) NRIUMSD, Hyderabad	180,623
14.	Uttar Pradesh	

S. No.	Name of State and Centre	Rupees in Thousand
	(i) DSRI, Ghaziabad	21,304
	(ii) CRIUM, Lucknow	97,230
	(iii) RRC, Prayagraj	16,831
	(iv) RRIUM, Aligarh	59,666
	(v) CRU, Meerut	16,322
15.	West Bengal	
	(i) RRIUM, Kolkata / Howrah	19,608
16.	Other Charges	
	(i) AHMIS	72
	(ii) Contribution to NPS	35,949
	(iii) CGHS Contribution	2,476
	(iv) Pension Fund Transfer	366,218
	(v) IEC	344
	(vi) DLIS	120
	(vii) Swatchhta Action Plan	3,028
	(viii) EOI Project Expenses	4
	(ix) Hindi Pakhwada	24
	(x) Health Mela	141
	(xi) Collaborative Research Projects	15,935
	(xii) Hindi Workshop	60
	(xiii) Arogya Mela	79
	(vix) EMR	2
	(xv) Ethics Committee	65
	(xvi) IPR	12
	(xvii) NPCDCS	4,248
	(xviii) Seminar/Workshop	1,564
	(xix) COVID-19	51
	(xx) Training Programme	141
	(xxi) Capital Works	65,600
	(xxii) Advance to Govt. Servants	3,723
	(xxiii) Contribution to GIS	536
	<b>Grand Total S. No. 1 to 16</b>	<b>1,610,098</b>



### 3. TECHNICAL REPORT

#### 3.1. Intramural Research

##### 3.1.1. Centre-wise Activities

CENTRE	ACTIVITIES
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	<ul style="list-style-type: none"> <li>• Survey and Cultivation of Medicinal Plants Programme</li> <li>• Drug Standardization Research Programme</li> <li>• Clinical Research Programme                             <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Validation of Regimen Therapies</li> <li>○ Validation of Fundamentals</li> </ul> </li> <li>• Research-oriented Healthcare                             <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>• School Health Programme</li> <li>• Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Central Research Institute of Unani Medicine (CRIUM), Lucknow	<ul style="list-style-type: none"> <li>• Clinical Research Programme                             <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Validation of Regimen Therapies</li> </ul> </li> <li>• Research-oriented Healthcare                             <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>• School Health Programme</li> <li>• Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Chennai	<ul style="list-style-type: none"> <li>• Survey and Cultivation of Medicinal Plants Programme</li> <li>• Drug Standardization Research Programme</li> <li>• Clinical Research Programme                             <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Validation of Regimen Therapies</li> </ul> </li> <li>• Research-oriented Healthcare                             <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>• School Health Programme</li> <li>• Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	<ul style="list-style-type: none"> <li>• Survey and Cultivation of Medicinal Plants Programme</li> <li>• Clinical Research Programme                             <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> </ul>

CENTRE	ACTIVITIES
	<ul style="list-style-type: none"> <li>○ Validation of Regimen Therapies</li> <li>● Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>● School Health Programme</li> <li>● Mobile Healthcare Programme under Tribal Sub Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Patna	<ul style="list-style-type: none"> <li>● Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Validation of Regimen Therapies</li> </ul> </li> <li>● Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>● School Health Programme</li> <li>● Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	<ul style="list-style-type: none"> <li>● Survey and Cultivation of Medicinal Plants Programme</li> <li>● Drug Standardization Research Programme</li> <li>● Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>● Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>● Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	<ul style="list-style-type: none"> <li>● Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Validation of Regimen Therapies</li> </ul> </li> <li>● Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>● School Health Programme</li> <li>● Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	<ul style="list-style-type: none"> <li>● Survey and Cultivation of Medicinal Plants Programme</li> <li>● Drug Standardization Research Programme</li> <li>● Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> <li>○ Pharmacological Research Programme</li> <li>○ Validation of Regimen Therapies</li> </ul> </li> </ul>

CENTRE	ACTIVITIES
	<ul style="list-style-type: none"> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> <li>Mobile Clinical Research Programme</li> </ul> </li> <li>School Health Programme</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> <li>Mobile Clinical Research Programme</li> </ul> </li> <li>Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> <li>Validation of Regimen Therapies</li> </ul> </li> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> <li>Mobile Clinical Research Programme</li> </ul> </li> <li>Unani Speciality Clinics at Allopathic Hospitals</li> <li>Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Centre (RRC), Prayagraj	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> <li>Mobile Clinical Research Programme</li> </ul> </li> <li>School Health Programme</li> <li>Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Regional Research Centre (RRC), Silchar	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> </ul> </li> </ul>
Clinical Research Unit (CRU), Bengaluru	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>Research-oriented Healthcare <ul style="list-style-type: none"> <li>General Outpatient Department (GOPD) Programme</li> </ul> </li> </ul>
Clinical Research Unit (CRU), Meerut	<ul style="list-style-type: none"> <li>Clinical Research Programme <ul style="list-style-type: none"> <li>Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>Research-oriented Healthcare</li> </ul>

CENTRE	ACTIVITIES
	<ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> </ul>
Clinical Research Unit (CRU), Bhopal	<ul style="list-style-type: none"> <li>• Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>• Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> </ul> </li> <li>• Mobile Healthcare Programme under Scheduled Caste Sub-Plan</li> </ul>
Clinical Research Unit (CRU), Burhanpur	<ul style="list-style-type: none"> <li>• Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>• Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> <li>○ Mobile Clinical Research Programme</li> </ul> </li> <li>• School Health Programme</li> <li>• Mobile Healthcare Programme under Tribal Sub Plan</li> </ul>
Clinical Research Unit (CRU), Edathala	<ul style="list-style-type: none"> <li>• Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>• Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> </ul> </li> </ul>
Clinical Research Unit (CRU), Kurnool	<ul style="list-style-type: none"> <li>• Clinical Research Programme               <ul style="list-style-type: none"> <li>○ Validation of Unani Pharmacopoeial Drugs</li> </ul> </li> <li>• Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> </ul> </li> <li>• Mobile Healthcare Programme under Tribal Sub Plan</li> </ul>
Drug Standardization Research Unit (DSRU), New Delhi	<ul style="list-style-type: none"> <li>• Drug Standardization Research Programme</li> </ul>
Drug Standardization Research Institute (DSRI), Ghaziabad	<ul style="list-style-type: none"> <li>• Drug Standardization Research Programme</li> </ul>
Hakim Ajmal Khan Institute for Literary & Historical Research in Unani Medicine (HAKILHRUM), New Delhi	<ul style="list-style-type: none"> <li>• Literary Research Programme</li> <li>• Research-oriented Healthcare               <ul style="list-style-type: none"> <li>○ General Outpatient Department (GOPD) Programme</li> </ul> </li> </ul>
Chemical Research Unit (CRU) (Grant-in-aid), Aligarh	<ul style="list-style-type: none"> <li>• Chemical Investigation of Unani Medicinal Plants</li> </ul>

### 3.1.2. Programme-wise Activities

#### 3.1.2.1. Survey and Cultivation of Medicinal Plants Programme

The CCRUM has a programme for extensive survey of medicinal plants in different parts of the country, primarily with a view to collect and identify medicinal plants and record basic data on ethno-pharmacological uses of plants from the tribal and other rural folks of the study area. The broad objectives of the programme are:

- To survey, collect and identify medicinal plants in different forest zones of the country;
- To study distribution, availability, ethno-pharmacological uses and threats of medicinal plants;
- To carry out experimental and field-scale cultivation of medicinal plants;
- To maintain a herbarium of medicinal plants and raw drugs for demonstration purposes;
- To maintain a demonstrable herb garden;
- To document folk knowledge on medicinal uses of plants;
- To collect samples of genuine drugs from the forests for pharmacopoeial standardization; and
- To develop nurseries of medicinal plants for demonstration purpose with a view to popularize them among masses.

This programme is carried out at the following research centres:

- National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
- Regional Research Institute of Unani Medicine, Chennai
- Regional Research Institute of Unani Medicine, Srinagar
- Regional Research Institute of Unani Medicine, Bhadrak
- Regional Research Institute of Unani Medicine, Aligarh

#### Ethnopharmacological Survey

Under this programme, the CCRUM undertook ethno-pharmacological surveys in different forest divisions/areas during the period under report. These include Salem Forest Division and Cauvery North Wildlife Sanctuary, Dharmapuri, Tamil Nadu; Achampet Forest Division, Telangana; Nainital Soil Conservation Forest Division, Uttarakhand; and Special Forest Division Tangmarg, and Anantnag Forest Division, Union Territory of Jammu and Kashmir. As a result of the survey tours conducted, 1,761 botanical specimens were collected and 439 plant species identified.

#### Herbarium

The plant specimens collected from the study areas, including the previous collection, were mounted on herbarium sheets. During the reporting period, 1,341 such herbarium sheets were prepared and information pertaining to the botanical name, family, local name, Unani name (wherever available), date of collection, brief morphological features and medicinal / other uses of the plants were recorded on each herbarium sheet. Besides, 634 index cards were updated.

The survey team members collected 2,064 saplings of important medicinal species for plantation in the nurseries attached to the institutes.

The survey teams also collected 228 kg of raw drugs and sent them to the pharmacy section of NRIUMSD, Hyderabad for preparation of Unani formulations.

### Digitization of Herbarium Specimens

Under this activity, 479 herbarium sheets were digitized by the CCRUM research centres at Chennai and Hyderabad.

### Folk Claims

The surveyors enquired from the local communities about traditional uses of plants after obtaining oral informed consent. The information was systematized taxonomically and efforts were made to develop a database for comparative analysis of the information recorded. As a result, 148 folk medicinal claims were recorded from the tribal inhabitants and other rural folks of the study areas. The CCRUM publishes the information in the form of books providing details comprising botanical name and family, synonym, local name, Unani name, habit and habitat, wild or cultivated, medicinal efficacy claimed and name of the tribe, locality, collection number, part(s) used, mode of application, and biodynamic notes.

### Experimental and Field-Scale Cultivation of Medicinal Plants

Under this activity, the CCRUM cultivates some important medicinal plants used in Unani medicines. These include *Atrilāl* (*Ammi majus* L.), *Afsantīn* (*Artemisia absinthium* L.), *Bābchī* (*Psoralea corylifolia* L.), *Gulnār Fārsī* (*Punica granatum* L. abortive var.), *Gurmārbūtī* (*Gymnema sylvestre* (Retz.) R.Br. ex Sm.), *Gul-i-Bābūna* (*Matricaria chamomilla* L.), *Sudāb* (*Ruta graveolens* L.), *Gilo* (*Tinospora cordifolia* (Willd.) Miers), *Janglī Piyāz* (*Drimia indica* (Roxb.) Jessop), *Nāgdawn* (*Artemisia nilagirica* (Clarke) Pamp), *Darmana Turkī* (*Artemisia maritima* L.), *Asgand* (*Withania somnifera* (L.) Dunal), *Ajwāyin Khurāsāni* (*Hyoscyamus niger* L.), etc. As a result of the field-scale cultivation, 83 kg raw drugs were obtained and supplied to the pharmacy section of NRIUMSD, Hyderabad from Chennai and Srinagar for preparation of Unani formulations.

### Herbal Garden and Nursery of Medicinal Plants

With a view to popularize medicinal plants among the masses, the CCRUM maintained about 437 plant species in its herbal gardens at NRIUMSD, Hyderabad; and RRIUM, Aligarh, Chennai and Srinagar. Some of the important and interesting species grown under this activity include: *Āmla* (*Phyllanthus emblica* L.), *Anār* (*Punica granatum* L.), *Ashok* (*Saraca asoca* (Roxb.) Willd.), *Atrilāl* (*Ammi majus* L.), *Afsantīn* (*Artemisia absinthium* L.), *Arūsā* (*Justicia adhatoda* L.), *Aspghol* (*Plantago ovata* Forsk.), *Aṣl al-Sūs* (*Glycyrrhiza glabra* L.), *Asrol* (*Rauvolfia serpentina* (L.) Benth. ex Kurz.), *Bed Mushk* (*Salix caprea* L.), *Bijāsar* (*Pterocarpus marsupium* Roxb.), *Belgirī* (*Aegle marmelos* (L.) Correa.), *Bābchī* (*Psoralea corylifolia* L.), *Banafshā* (*Viola odorata* L.), *Bhāngrā* (*Eclipta prostrata* (L.) L.), *Brinjāsif* (*Achillea millefolium* L.), *Fūfal* (*Areca catechu* (L.f.) Willd.), *Ghīkawār* (*Aloe vera* (L.) Burm.f.), *Gulnār Fārsī* (*Punica granatum* L. abortive var.), *Gurmārbūtī* (*Gymnema sylvestre* (Retz.) R.Br. ex Sm.), *Hinā* (*Lawsonia inermis* L.), *Irsā* (*Iris ensata* Thunb.), *Jadwār* (*Delphinium denudatum* Wall. ex Hook.f. & Thoms.), *Keorā* (*Pandanus tectorious* Soland. ex Parkinson), *Kājū* (*Anacardium occidentale* L.), *Khulanjān* (*Alpinia galanga* Willd.), *Konch* (*Mucuna pruriens* L.), *Mako* (*Solanum americanum* Mill.), *Marorphālī* (*Helicteres isora* L.), *Muqil* (*Commiphora mukul* (Hook. ex Stocks) Engl.), *Pālas* (*Butea monosperma* (Lam.) Taub.), *Qinnāb* (*Cannabis sativa* L.), *Qurṭūm* (*Carthamus tinctorius* L.), *Qusṭ* (*Saussurea costus* (Falc.) Lipsch.), *Rasan* (*Inula racemosa* C.B. Clarke), *Rivand Chīnī* (*Rheum emodi* Wall ex Meissn), *Sadābahār* (*Catharanthus roseus* (L.) G. Don), *Ṣandal Surkh* (*Pterocarpus*



*santalinus* L. f.), *Satāwar* (*Asparagus racemosus* Willd.), *Sudāb* (*Ruta graveolens* L.), *Raiḥān* (*Ocimum tenuiflorum* L.), *Tagar* (*Valeriana jatamansi* Jones), *Turbud* (*Operculina turpethum* (L.) Silva Manso), *Waj* (*Acorus calamus* L.), etc.

### 3.1.2.2. Drug Standardization Research Programme

The Drug Standardization Research Programme is mainly concerned with evolving pharmacopoeial standards for single drugs and compound formulations of Unani Medicine included in various volumes of *National Formulary of Unani Medicine (NFUM)* and *Essential Drugs List* for their incorporation in *Unani Pharmacopoeia of India (UPI)*. The work on compound formulations includes development of standard operating procedures (SOPs) for their manufacture followed by the development of their pharmacopoeial standards. Besides, standardization of investigational drugs for clinical trials at the CCRUM and estimation of heavy metals, microbial load, aflatoxin content and pesticidal residues and chemical investigations of Unani medicinal plants are also carried out under this programme. The standardization work is carried out in accordance with the format approved by the Unani Pharmacopoeia Committee of the Government of India through the following research centres:

- Drug Standardization Research Institute (DSRI), Ghaziabad
- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Drug Standardization Research Unit (DSRU), New Delhi

During the reporting period, the following works were carried out:

#### Development of SOPs for Manufacture of Unani Formulations and their Pharmacopoeial Standards

Under this programme, SOPs for the method of preparation and pharmacopoeial standards of the following 29 Unani formulations were developed:

S. N.	Formulation	S. N.	Formulation
1	<i>Qayrūṭī Muḥallil</i>	16	<i>Jawārish Kundur</i>
2	<i>Qayrūṭī Musakkin</i>	17	<i>Jawārish ‘ūd Shīrīn</i>
3	<i>Qayrūṭī Bazr-i-Katān</i>	18	<i>Jawārish Fanjnosh</i>
4	<i>Ḍimād Sumbul al-Ṭīb</i>	19	<i>Jawārish Muqawwī-i-Mi‘da</i>
5	<i>Sikanjabīn Buzūrī Mu‘tadil</i>	20	<i>Jawārish Usqf</i>
6	<i>Sikanjabīn Lemūnī</i>	21	<i>Qurş Saraṭān</i>
7	<i>Sikanjabīn Na‘nā‘ī</i>	22	<i>Qurş Nuqra</i>
8	<i>Sikanjabīn Sāda</i>	23	<i>Ḥabb Pachnola</i>
9	<i>Sharbat-i-Dīnār (Post Bīkh-i-Kāsnī)</i>	24	<i>Sharbat ‘Unnāb</i>
10	<i>‘Araq-i-Afsantīn</i>	25	<i>‘Araq Muṣaffī-i-Khūn</i>
11	<i>‘Araq-i-Aswād Bārid</i>	26	<i>Sharbat Banafsha</i>

S. N.	Formulation	S. N.	Formulation
12	<i>‘Araq-i-Bed Mushk</i>	27	<i>Ḍimād Waram-i-Unthayayn Ḥādd</i>
13	<i>‘Araq-i-Chob Chīnī</i>	28	<i>Sharbat Buzūrī Mu‘tadil</i>
14	<i>‘Araq-i-Ga‘uzabān</i>	29	<i>Ḍimād Waram-i-Unthayayn Muzmin</i>
15	<i>Ḍimād Waram-i-Pistān</i>		

#### Development of Pharmacopoeial Standards of Single Drugs

Under the programme, pharmacopoeial standards of the following 18 single drugs were developed:

S. N.	Drug	Botanical / English Name	Part Studied
1.	<i>Ga‘uzabān</i>	<i>Onosma bracteata</i> Wall.	Whole plant
2.	<i>Maghz-i-Karanjwā</i>	<i>Ceasalpinia bonduc</i> (L.) Roxb.	Kernel
3.	<i>Ilā‘ichī Khurd</i>	<i>Elettaria cardamomum</i> (L.) Maton	Fruit
4.	<i>Shaqāqul Miṣrī</i>	<i>Elettaria cardamomum</i> (L.) Maton	Root
5.	<i>Taj</i>	<i>Cinnamomum cassia</i> Blume	Stem bark
6.	<i>Pudīna</i>	<i>Mentha arvensis</i> L.	Dried herb
7.	<i>Ḥabb al-Ās</i>	<i>Myrtus communis</i> L.	Fruit
8.	<i>Nāg Kesar</i>	<i>Mesua ferrea</i> L.	Flower
9.	<i>Maghz Tukhm-i-Kaddū Shīrīn</i>	<i>Cucurbita moschata</i> Duch.	Kernel
10.	<i>Chironjī</i>	<i>Buchanania lanzan</i> Spreng.	Fruit
11.	<i>Pista</i>	<i>Pistacia vera</i> L.	Kernel
12.	<i>Maghz-i-Balādur</i>	<i>Semecarpus anacardium</i> L.f.	Kernel
13.	<i>Tukhm-i-Nilofar</i>	<i>Nelumbo nucifera</i> Gaertn.	Seed
14.	<i>Darūnaj ‘Aqrabī</i>	<i>Doronicum hookeri</i> Hook. f.	Root
15.	<i>Gul-i-Nilofar</i>	<i>Nelumbo nucifera</i> Gaertn.	Flower
16.	<i>Ṣa‘tar Fārsī</i>	<i>Zataria multiflora</i> Boiss.	Herb
17.	<i>Filfil Darāz</i>	<i>Piper longum</i> L.	Root
18.	<i>Singhārā Khushk</i>	<i>Trapa bispinosa</i> Roxb.	Dried fruit

#### Quality Control Work of Compound Drugs

Under this activity, quality control of the following 43 Unani formulations was carried out. The quality parameters including physicochemical, microscopic and WHO parameters, viz. heavy metals, microbial load, aflatoxins and pesticidal residue were studied for raw material as well as prepared compound formulations in the GMP-certified pharmacy of DSRI.

S. N.	Drug	S. N.	Drug
1.	<i>Ḥabb Kibrīt Saghīr</i>	2.	<i>Ma‘jūn Balādur</i>
3.	<i>Marham Ai‘jāz</i>	4.	<i>Ḥabb Banafsha</i>
5.	<i>Qurṣ Zirishk</i>	6.	<i>Kundrī</i>



S. N.	Drug	S. N.	Drug
7.	<i>Qurş 'Aṭash</i>	8.	<i>Ḥabb Mubārak</i>
9.	<i>Rowghan Nafa '-i-Waram-i-Niqrīs</i>	10.	<i>Ḥabb Mafāṣil</i>
11.	<i>Rowghan Banfsha</i>	12.	<i>Ḍimād Muḥallil</i>
13.	<i>İṭrīfal Kabīr</i>	14.	<i>Ma 'jūn Tīwāj</i>
15.	<i>Jawārish Qurṭūm S-1</i>	16.	<i>Ḥabb Kalaf</i>
17.	<i>Ma 'jūn La 'na</i>	18.	<i>Ḥabb Qulā '</i>
19.	<i>İṭrīfal Kishnīzī</i>	20.	<i>Ḥabb Irq al-Nasā</i>
21.	<i>La 'uq Ḥulba</i>	22.	<i>Qurş Dawā ' al-Shifā '</i>
23.	<i>Jawārish Qurṭūm S-2</i>	24.	<i>Ḥabb Lu 'āb Behidāna</i>
25.	<i>Sāfūf Dama Haldī Wālā</i>	26.	<i>Qurş Mafāṣil</i>
27.	<i>Tiryāq Raḥim</i>	28.	<i>Sufūf Sūranjān Za 'frānī</i>
29.	<i>Ma 'jūn Zanjabīl</i>	30.	<i>Sufūf Hāḍim Kalān</i>
31.	<i>Ḥabb Khunāq</i>	32.	<i>Ma 'jūn Yahya bin Khālīd</i>
33.	<i>Qurş Aşfar</i>	34.	<i>Jawārish Zar 'ūnī Sāda</i>
35.	<i>Ma 'jūn Adhārāqī</i>	36.	<i>Jawārish Kundur</i>
37.	<i>Rowghan Surkh</i>	38.	<i>La 'uq Fālīj</i>
39.	<i>İṭrīfal Mundī</i>	40.	<i>Marham Gulābī</i>
41.	<i>Marham Ras Kapūr</i>	42.	<i>Khamīra Ga 'uzabān Sāda</i>
43.	UNIM-D-2000 (Powder)		

#### Analysis of ASU Drugs

The drug testing laboratory at the RRIUM, Chennai analysed the following 20 ASU drug samples received from different organizations:

S. N.	Sample	Source	Parameters Analysed
1.	<i>Vishasura Kudineer</i>	Siddha Research Institute, Chennai	Microbial load and aflatoxin detection
2.	<i>Uṣṭukhūdūs</i>	NIUM, Bengaluru	HPTLC studies
3.	Coded sample – Leaf	Queen Mary's College, Chennai	HPTLC studies
4.	Coded sample – Seed		
5.	Coded sample – Stem bark		
6.	<i>Amirtha Gandhi Kukkil Vallathi Mezhgu</i>	Siddha Central Research Institute, Chennai	HPTLC studies and microbial load detection
7.	<i>Vithu Rasa Mezhgu</i>	National Institute of Siddha, Chennai	HPTLC, microbial load and antimicrobial studies
8.	Coded sample SI		Microbial load

S. N.	Sample	Source	Parameters Analysed
9.	Coded sample DG	Madras Veterinary College, Chennai	
10.	Coded sample UP		
11.	Coded sample SS		
12.	Coded sample TT		
13.	Coded sample F		
14.	<i>Dhasalavana Dravagam</i> (DLD)		
15.	<i>Uraria picta</i> (Jacq.) Desv. ex DC.	National Institute of Siddha, Chennai	Microscopical studies
16.	<i>Solanum indicum</i> L.	Madras Veterinary College, Chennai	Microscopical studies
17.	<i>Solanum surattense</i> Burm.f.		
18.	<i>Tribulus terrestris</i> L.		
19.	Formulations (Powder analysis)		
20.	Lavendula ABCDEF and G extracts		Antimicrobial activity

#### Revision of Unani Pharmacopoeia of India

In an effort to revisit the existing Unani Pharmacopoeia of India (UPI), monographs of 25 Unani single drugs from UPI, part-I, vol. II and 20 drugs from part-I, vol. IV were revised as per the new format provided by the Pharmacopoeia Commission of Indian Medicine and Homoeopathy (PCIM&H).

#### Isolation of Phytoconstituents from Unani Single Drugs

Under the Grant-in-aid scheme of the CCRUM, the following phytoconstituents were isolated from two Unani single drugs at the Chemical Research Unit located at Aligarh Muslim University, Aligarh as mentioned below:

S. N.	Drug	Botanical/English Name	Part Studied	Compound Isolated	
				Pet. Ether (Extract)	Methanol (Extract)
1.	<i>Rīwand Chīnī</i>	<i>Rheum australe</i> D. Don	Root	1,8-dihydroxy-3-methyl-6-methoxy-9(10H)-anthracenone-10-oxyoleate	6-methyl-aloe-emodin
2.	<i>Tukh-i-Ispāst</i>	<i>Boerhavia diffusa</i> L.	Seed	1,8-dihydroxy-3-methyl-9(10H)-anthracenone-10-oxyoctacosanoate	

### 3.1.2.3. Clinical Research Programme

#### Preclinical Studies

Preclinical safety and/or efficacy studies on Unani formulations are performed at National Research Institute of Unani Medicine for Skin Disorders (NRIUM), Hyderabad and Regional Research Institute of Unani Medicine (RRIUM), Srinagar.

During the reporting period, experimental part of acute and repeated dose (28-day) oral toxicity studies of five Unani formulations, namely *Jawārish Āmla Sāda*, *Jawārish ‘ūd Shīrīn*, *Jawārish Kamūnī*, *Safūf Zahīr* and *Sharbat Zūfā Murakkab*, was performed at NRIUMSD, Hyderabad. In addition, final reports of studies on previously allotted formulations *Qurş Mafāşil* and *Capsule Nazla* (including histopathological findings) and interim reports of studies on *Sharbat Belgīrī* and *Khamīra Ābresham Shīra ‘Unnāb Wālā* were also compiled. Interim reports of repeated dose 90-day oral toxicity studies on *Ma’jūn Māsik al-Bawl* and *Qurş Damawī* were also compiled. Histopathology reports of these studies were yet to be received from the National Institute of Nutrition (NIN), Hyderabad. All the studies were conducted after prior approval from the Institutional Animal Ethics Committee. All animal experiments/procedures were performed with strict adherence to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).

While at the RRIUM, Srinagar, preclinical studies of six drugs, namely *Ma’jūn Piyāz*, *Tiryāq Afā’ī*, *Habb Surfa*, *Ma’jūn ‘Ushba*, *Khamīra Ga’uzabān Sāda* and *Ma’jūn Dabīd al-Ward*, and 50% hydroalcoholic extracts of *Ma’jūn Piyāz* and *Tiryāq Afā’ī* were carried out in both sexes of Albino Wistar rats following the OECD Test Guidelines on GLP pattern.

Summaries of the studies conducted at NRIUMSD and RRIUM, Srinagar are as below:

#### Acute and sub-acute (28-day repeated dose) toxicity study of *Jawārish Āmla Sāda*

Acute oral toxicity potential of *Jawārish Āmla Sāda* (JAS) was assessed in Sprague Dawley (SD) rats. Considering the low acute toxicity potential of the test drug, a limit test at the dose of 2000 mg/kg bw (i.e., maximum feasible dose) was conducted as per the OECD Test Guideline 425. The animals were administered single dose of the formulation and observed for lethality and toxic signs and symptoms for 14 days post-treatment. As no lethality was observed following treatment with JAS in 5 consecutive animals, respectively, dosing to further animals was stopped. All the five animals were sacrificed on day-15 and necropsy was performed. No treatment related gross pathological abnormality was observed. Under the given conditions, no toxic signs and symptoms or mortality was observed at the dose of 2000 mg/kg bw. Therefore, oral LD<sub>50</sub> (medial lethal dose) of JAS in female SD rat was estimated to be greater than 2000 mg/kg body weight.

Repeated dose 28-day oral toxicity study on JAS was performed in SD rats. The animals were divided into four groups (n=05 per sex per group). JAS was orally administered at the dose levels of 500, 1000 and 2000 mg/kg bw/day (i.e., approximately 1X, 2X and 4X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered water as vehicle. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the dosing period, blood samples were collected for haematological and biochemical analysis and the animals were euthanized and their vital organs were examined and harvested for organ weight determination and histopathological

evaluation. Tissue samples would be submitted for histopathological investigations. The finding of the study showed no toxicologically significant adverse effect with respect to body weight, feed intake, behavioural pattern, haematology, biochemical parameters, and relative organ weight in JAS treated groups or control animals. Therefore, JAS would be considered safe based on the above observations. The conclusive statement regarding the safety of JAS could possibly be made after including histopathological findings which were in process.

#### Acute and sub-acute (28-day repeated dose) toxicity study of *Jawārish 'Ūd Shīrīn*

Acute and repeated dose 28-day oral toxicity of *Jawārish 'Ūd Shīrīn* (JUS) was evaluated in Sprague Dawley (SD) rats. For acute toxicity study, a limit test at the dose of 2000 mg/kg bw (i.e., maximum feasible dose) was conducted considering low acute toxicity potential as per the OECD Test Guideline 425. The animals were administered single dose of the formulation and observed for lethality and toxic signs and symptoms for 14 days post-treatment. As no lethality was observed following treatment with JUS in 5 consecutive animals respectively, dosing to further animals was stopped. All the five animals were sacrificed on day 15 and necropsy was performed. No treatment related gross pathological abnormality was observed. Under the given conditions, no toxic signs and symptoms or mortality was observed at the dose of 2000 mg/kg bw. Therefore, oral LD<sub>50</sub> of JUS in female SD rat was estimated to be greater than 2000 mg/kg body weight.

For repeated dose 28-day oral toxicity study, SD rats were randomly divided into four groups (n=05 per sex per group). JUS was orally administered at the dose levels of 500, 1000 and 2000 mg/kg bw/day (i.e., approximately 1X, 2X and 4X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered water. Body weight and feed intake for all animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the dosing period, blood samples were collected for haematological and biochemical analysis and the animals were euthanized and their vital organs were examined and harvested for organ weight determination and histopathological evaluation. Tissue samples would be submitted for histopathological investigations. No toxicologically significant observation was noted with respect to behavioural parameters, body weight, feed intake, haematology, biochemical parameters and relative organ weight in JUS treated groups or control animals. Therefore, JUS would be considered safe based on the above observations. However, histopathological report was awaited based on which final safety of the test drug would be assessed.

#### Acute and sub-acute (28-day repeated dose) toxicity study of *Jawārish Kamūnī*

Acute and repeated dose 28-day oral toxicity study of *Jawārish Kamūnī* (JK) was conducted in Sprague Dawley (SD) rats. Acute oral toxicity study was conducted at a limit dose of 2000 mg/kg bw as per the OECD Test Guideline 425. LD<sub>50</sub> of JK in female SD rats was found to be more than 2000 mg/kg bw, as no mortality was observed in five tested female SD rats observed till two weeks following treatment.

Repeated dose 28-day oral toxicity study on JK was performed in SD rats. The rats were divided into four groups (n=05 per sex per group). JK was orally administered at the dose levels of 1000, 1500 and 2000 mg/kg bw/day (i.e., approximately 1X, 1.5X and 2X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered water as vehicle. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the dosing period, blood samples were collected for haematological and biochemical analysis and animals were euthanized and their vital organs

were examined and harvested for organ weight determination and histopathological evaluation. Tissue samples would be submitted for histopathology investigations.

Data of the study revealed no toxicologically significant observation with respect to body weight, feed consumption, behavioural pattern, haematology, biochemistry, and relative organ weight in JK treated groups or control animals. The study drug JK showed glucose lowering property as it caused statistically significant reduction in glucose in both sexes at all the tested dose levels as compared to vehicle control animals. Though the fasting blood glucose level of JK treated rats remained in the physiological limits, this was the interesting finding which might be due to hypoglycemic potential of various ingredients of JK as reported in literature as hypoglycemic. Based on the 28-day toxicity study data, JK would be considered safe. However, histopathological report was still awaited based on which overall safety of the test drug would be assessed.

#### Acute and sub-acute (28-day repeated dose) toxicity of *Safūf Zahīr*

Acute and repeated dose 28-day oral toxicity of *Safūf Zahīr* (SZ) was evaluated in Sprague Dawley (SD) rats. Acute oral toxicity study was conducted at a limit dose of 2000 mg/kg bw as per the OECD Test Guideline 425. LD50 of SZ in female SD rats was found to be greater than 2000 mg/kg bw.

Repeated dose 28-day oral toxicity study on SZ was conducted in SD rats. The animals were randomly assigned to four treatment groups including one control group (n=05 per sex per group). SZ was orally administered at the dose levels of 300, 900 and 1500 mg/kg bw/day (i.e., approximately 1X, 3X and 5X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered water. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the dosing period, blood samples were collected for haematological and biochemical analysis and animals were euthanized and their vital organs were examined and harvested for organ weight determination and histopathological evaluation. Tissue samples would be submitted for histopathological investigations.

The study findings did not indicate any toxicologically significant observation in terms of body weight, feed intake, behavioural pattern, haematology, biochemistry, and organ weight in SZ treated groups at all the tested dose levels as compared to control animals. The conclusive statement regarding the safety of SZ could possibly be made based on histopathological findings which were awaited.

#### Acute and sub-acute (28-day repeated dose) toxicity of *Sharbat Zūfā Murakkab*

Acute and repeated dose 28-day oral toxicity of *Sharbat Zūfā Murakkab* (SZM) was evaluated in Sprague Dawley (SD) rats. The animals were administered single dose of the formulation and observed for lethality and toxic signs and symptoms for 14 days post-treatment as per the OECD Test Guideline 425. Considering the low acute toxicity potential of the test drug, a limit test at the dose of 20 mL/kg bw (i.e., maximum feasible dose) was conducted as per the OECD Test Guideline 425. As no mortality was observed following treatment with SZM in 5 consecutive animals respectively, dosing to further animals was stopped. All the five animals were sacrificed on day 15 and necropsy was performed. No treatment related gross pathological abnormality was observed. Under the given conditions, no toxic signs and symptoms or mortality was observed at the dose of 20 mL/kg bw.



Therefore, oral LD50 of SZM in female SD rat was estimated to be greater than 20 mL/kg body weight.

Repeated dose 28-day oral toxicity study of SZM was performed in rats. The animals were divided into four groups (n=05 per sex per group). SZM was orally administered at the dose levels of 2, 4 and 10 mL/kg bw/day (i.e., approximately 1X, 2X and 5X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered water as vehicle. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the dosing period, blood samples were collected for haematological and biochemical analysis and the animals were euthanized and their vital organs were harvested for organ weight determination and histopathological evaluation.

Finding of the study revealed neither treatment related mortality nor behavioural changes in acute or 28-day repeated dose oral toxicity assessment of SZM. No toxicologically significant observation with respect to body weight, feed intake, haematology, biochemistry, organ weight and relative organ weight in SZM treated groups or control animals was observed. Therefore, SZM would be considered safe based on the above observations. However, histopathological report was yet awaited based on which final safety of the test drug would be assessed.

#### Sub-acute (28-day repeated dose) toxicity of *Sharbat Belgiri*

Repeated dose 28-day oral toxicity study of *Sharbat Belgiri* (SBG) was conducted in SD rats as per the OECD Test Guideline 407. The animals were divided into four groups (n=05 per sex per group). SBG was administered at the dose levels of 2.5, 5 and 10 mL/kg bw/day p.o. for 28 days. Control animals were administered vehicle. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of 28-days, blood samples were collected for haematological and biochemical analysis and the animals were sacrificed and their organs were harvested for weight determination and histopathological evaluation. There was no treatment-related adverse effect on survival of both male and female rats after oral administration of SBG for 28 consecutive days. The SBG-treated animals did not show any significant alteration in haematological and biochemical parameters in both male and female rats at all the tested dose levels as compared to control animals except for few alterations which were toxicologically insignificant and remained within normal reference range. No significant alteration was observed in body weight, feed intake and relative organ weight of control and SBG-treated rats of either sex.

The study findings did not indicate any toxicologically significant observation in terms of body weight, feed intake, behavioural pattern, haematology, clinical chemistry, organ weight in SBG-treated group at all the tested dose levels as compared to control animals. The conclusive statement regarding the safety of SBG could possibly be made based on histopathological findings which were awaited.

#### Sub-acute (28-day repeated dose) toxicity of *Khamira Abresham Shira 'Unnab Wala*

Repeated dose 28-day oral toxicity study of *Khamira Abresham Shira 'Unnab Wala* (KASU) was conducted on SD rats as per the OECD Test Guideline 407. KASU was administered at the dose levels of 500, 1000 and 2000 mg/kg bw/day p.o. for 28 days. Control animals were administered water as vehicle. Body weight and feed intake for all the animals were measured weekly throughout the study duration. Detailed clinical observations were made

periodically to detect signs of toxicity. After completion of 28 days, blood samples were collected for haematological and biochemical analysis and the animals were sacrificed and their organs were harvested for weight determination and histopathological evaluation.

No mortality and clinical sign of toxicity were observed in both male and female rats after oral administration of KASU for 28 consecutive days. Body weight and feed intake of KASU treated rats were comparable to respective vehicle control animals. No significant alteration was observed in relation to haematological and biochemical parameters in both male and female rats at any tested dose compared to control animals except for few alterations which were toxicologically insignificant and values remained within normal reference range. There was no toxicologically significant alteration in relative organ weight of control and KASU treated rats of either sex and gross necropsy did not reveal any overt changes.

The study findings did not indicate any toxicologically significant observation in terms of body weight, feed intake, behavioural pattern, haematology, clinical chemistry, organ weight in KASU treated groups at all tested dose levels as compared to control animals. The conclusive statement regarding the safety of KASU might possibly be made based on histopathological findings which were awaited.

#### Acute and sub-acute (28-day repeated dose) toxicity of *Qurş Mafāşil*

Toxicity potential of repeated administration of *Qurş Mafāşil* (QM) was studied in rats following 28-day repeated oral administration in Sprague Dawley (SD) rats of both sexes. The animals were segregated into four groups (n=05 per sex per group). QM was orally administered at the dose levels of 200, 1000 and 2000 mg/kg bw/day (i.e., approximately 1X, 5X and 10X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered 0.30% aqueous carboxymethyl cellulose (CMC) suspension. A satellite group (n=05 rats per sex per group) was also included in the control and high dose QM group to monitor the reversibility or persistence of treatment related changes (if any). The animals in satellite group received respective treatment for 28 days, followed by maintaining them for two weeks without dosing before euthanasia. Body weight and feed intake for all the animals were regularly measured throughout the study duration. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the respective dosing period, blood samples were collected for haematological and biochemical investigations and the animals were euthanized and their vital organs were collected for organ weight determination and histopathological evaluation. Tissue/organ samples were submitted to the NIN for histopathology.

No mortality was observed following administration of QM or vehicle for 28 days in any group. No behavioral changes indicative of systemic toxicity was observed following QM treatment. Body weight and feed intake of QM treated rats were found almost comparable to their respective control groups of either sex. QM treatment did not result in any overt and toxicologically significant alteration in haematological and biochemical parameters in either male or female rats at any tested dose level as compared to vehicle control animals except for few changes which were mostly observed in satellite group animals (both vehicle and QM; sacrificed after two weeks of recovery period). No gross pathological changes/lesions were observed during necropsy in any group. Relative organ weight of various treatment groups was found comparable to vehicle control.

The study findings did not indicate any toxicologically significant alteration in terms of survival, behaviour pattern, body weight, feed intake, haematology, clinical chemistry, and relative organ weight in any QM treated group as compared to vehicle control. No

toxicologically significant changes were observed during histopathological investigation in any organ except for certain changes which were observed in the liver of few animals in QM as well as vehicle treated groups. Based on the data generated, QM may be considered safe at the therapeutically used dosage and the liver might be the target organ of toxicity on repeated administration at high doses.

#### Acute and sub-acute (28-day repeated dose) toxicity of *Capsule Nazla*

Toxicity potential of repeated administration of *Capsule Nazla* (CNaz) was studied in rats following 28-day repeated oral administration in Sprague Dawley (SD) rats of both sexes. The animals were divided into six groups (n=05 per sex per group). CNaz was orally administered at the dose levels of 300, 900 and 1800 mg/kg bw/day (i.e., approximately 1X, 3X and 6X of therapeutic equivalent dose, respectively) for 28 days. Control animals were administered 0.30% aqueous carboxymethyl cellulose (CMC) suspension. A satellite group (n=05 rats per sex per group) was also included in the control and high dose CNaz group to monitor the reversibility or persistence of treatment related changes (if any). The animals in the satellite group received respective treatment for 28 days, followed by maintaining them for two weeks without dosing before euthanasia. Body weight and feed intake for all the animals were regularly measured throughout the study. Detailed clinical observations were made periodically to detect signs of toxicity. After completion of the respective dosing period, blood samples were collected for haematological and biochemical investigations and the animals were euthanized and their vital organs were collected for organ weight determination and histopathological evaluation.

No mortality was observed following administration of CNaz or vehicle for 28 days in any group. No behavioral changes indicative of systemic toxicity was observed following CNaz treatment. Body weight and feed intake of CNaz treated rats were found almost comparable to their respective control groups of either sex. CNaz treatment did not result any overt toxicologically significant alteration in haematological and biochemical parameters in either male or female rats at any tested dose level as compared to vehicle control animals except for few changes which were mostly observed in the satellite group animals (both vehicle and CNaz; sacrificed after two weeks of recovery period). No gross pathological changes/lesions were observed during necropsy in any group. Relative organ weight of various treatment groups was found comparable to vehicle control.

The study findings did not indicate any toxicologically significant alteration in terms of survival, behaviour pattern, body weight, feed intake, haematology, clinical chemistry, and relative organ weight in any CNaz treated group as compared to vehicle control. No toxicologically significant changes were observed during histopathological investigation in any organ except in the liver of few animals in CNaz as well as vehicle treated groups. Observed changes in the liver were entirely reversible in the satellite groups after recovery period. Based on the data generated, CNaz would be considered safe at the therapeutically used dosage and the liver might be the target organ for toxicity on repeated administration at high doses.

#### Preclinical safety evaluation of *Ma'jūn Māsik al-Bawl*

Report of repeated dose 90-day oral toxicity study of *Ma'jūn Māsik al-Bawl* (MMB) was compiled during the reported period. Safety of MMB was assessed by conducting 90-day repeated dose oral toxicity study as per the OECD Test Guideline 408 in Sprague Dawley rats. MMB was orally administered (gavage) at the doses of 1000 and 2000 mg/kg bw/day. The animals were periodically observed for clinical sign of toxicity, mortality, morbidity, body



weight changes and feed consumption. After the treatment duration of three months, the animals were anaesthetized using isoflurane and blood samples were collected from retro-orbital sinus puncture. Blood samples were subjected to haematological investigation and serum was subjected to different biochemical estimation. The animals were sacrificed using CO<sub>2</sub> euthanasia, gross necropsy was performed and internal organs/tissues were harvested and preserved in neutral buffered formalin for histopathological investigation.

Treatment with MMB showed no significant differences in survival, body weight gain, and haematology and biochemistry profile except for certain isolated changes in serum platelets, alkaline phosphatase and uric acid, which were considered toxicologically insignificant as the values were in the normal physiological range. No changes were observed in the gross necropsy and relative organ weight data of control and MMB treated rats.

No mortality or adverse changes in clinical signs and body weight gain were noted. No toxicologically significant changes in haematology, clinical chemistry, and organ weights were noted. Gross pathological examinations did not reveal treatment-related abnormalities. Any changes observed were incidental and within historical control range. Based on the results of this study, MMB may be considered safe up to 2000 mg/kg bw/day in rats. However, final conclusion may be stated based on the histopathological findings which were awaited at the end of the reporting period.

#### Preclinical safety evaluation of *Qurş Damawī*

Report of repeated dose 90-day oral toxicity study *Qurş Damawī* (QM) was compiled during the reported period. Safety of DM was assessed by conducting 90-day repeated dose oral toxicity study which was performed as per the OECD Test Guideline 408 in SD rats. DM was orally administered at the dose levels of 125 and 250 mg/kg bw/day (i.e., approximately 5X and 10X of therapeutic equivalent dose, respectively). The animals were periodically observed for clinical sign of toxicity, mortality, morbidity, body weight changes and feed consumption. At the end of the study, assessment of haematology, clinical biochemistry, gross necropsy and relative organ weight was performed.

Treatment with DM showed no adverse effect on survival and body weight gain in animals throughout the study duration. No overt findings were observed in the behaviour of animals and no clinical signs indicative of any systemic toxicity were observed during clinical examination. No adverse effects were observed in haematology and biochemistry profile except for certain changes which were clinically insignificant as the effects observed were not dose dependent and the values were well within normal physiological range. There were no remarkable changes in relative organ weight data of control and DM treated rats. Gross necropsy of DM treated or control animals did not reveal any adverse findings.

Based on the above findings, it can be concluded that oral administration of DM at the dose levels of 125 and 250 mg/kg bw did not show any significant adverse effects on survival, body weight gain, haematology, clinical biochemistry, and gross necropsy. Therefore, based on the study data, DM may be considered safe up to 250 mg/kg body weight in rats. However, conclusive statement regarding the safety of DM might finally be stated after considering the histopathological findings which were awaited.

#### Sub-chronic oral toxicity study of *Ma'jūn Piyāz*

A 90-day repeated oral toxicity study of *Ma'jūn Piyāz* was performed in Wistar albino rats as per the OECD Test Guideline 408. The drug was administered orally at the dose level of 1000 mg/kg body weight (limit dose) (corresponding to 2x the extrapolated dose in rats) in

both male and female rats. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 7 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female groups were orally administered *Ma'jūn Piyāz* at the dose of 1000 mg/kg body weight daily upto 90 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 91 of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing for the collection of tissues to evaluate histopathological studies. Statistical analysis/compilation of data were under process.

#### Sub-chronic oral toxicity study of 50% hydroalcoholic extract of *Ma'jūn Piyāz*

A 90-day repeated oral toxicity study of 50% hydroalcoholic extract of *Ma'jūn Piyāz* was conducted in Wistar albino rats as per the OECD Test Guideline 408. In this study, the extract of *Ma'jūn Piyāz* was studied at the dose level of 1000 mg/kg body weight in both male and female Wistar albino rats. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 7 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female groups were orally administered the extract of *Ma'jūn Piyāz* at the dose of 1000 mg/kg body weight daily upto 90 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the study. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 91 of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing in which tissue was collected for histopathological studies. Statistical analysis / compilation of data were under process.

#### Chronic oral toxicity study of *Tiryāq Afā'ī*

Chronic oral toxicity study of *Tiryāq Afā'ī* was performed at the dose level of 1000 mg/kg body weight (corresponding to 3x the extrapolated dose in rats) in both male and female Wistar albino rats. The drug was administered daily for a period of 180 days. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 8 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female groups were orally administered *Tiryāq Afā'ī*. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the experimentation. The physiological parameters such as

body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 181 of the oral drug administration. The rats were kept on fasting overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing for the collection of tissues to evaluate histopathological studies. Statistical analysis/compilation of data were under process.

#### Chronic oral toxicity study of 50% hydroalcoholic extract of *Tiryāq Afāʿ*

Chronic oral toxicity study of 50% hydroalcoholic extract of *Tiryāq Afāʿ* was conducted in both male and female Wistar albino rats. The drug was administered orally at the dose level of 1000 mg/kg body weight daily for a period of 180 days. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 8 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female groups were orally administered extract daily upto 180 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 181 of the oral drug administration. The rats were kept on fasting overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record organ weight followed by grossing for the collection of tissues to evaluate histopathological studies. Statistical analysis/compilation of data were under process.

#### Chronic oral toxicity study of *Khamīra Gaʿuzabān Sāda*

Chronic oral toxicity study of *Khamīra Gaʿuzabān Sāda* was performed at the dose level of 1000 mg/kg body weight (corresponding to 2x the extrapolated dose in rats) in both male and female Wistar albino rats. The drug was administered daily for a period of 180 days. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 8 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female groups were orally administered *Khamīra Gaʿuzabān Sāda* daily upto 180 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 181 of the oral drug administration. The rats were kept on fasting overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing for the collection of tissues to

evaluate histopathological studies. Statistical analysis/compilation of data were under process.

#### Acute oral toxicity study of *Habb Surfa*

Acute oral toxicity study of *Habb Surfa* was performed as per the OECD Test Guideline 425 in Wistar albino rats. The drug was administered orally at the dose level of 2000 mg/kg body weight (corresponding to 66x the extrapolated dose in rats) in both male and female rats. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control) each consisting of 6 rats. The male and female control groups were orally treated with RO water (vehicle only). The male and female treated groups were orally administered *Habb Surfa* at the dose of 2000 mg/kg body weight as a single dose. Cage side observation of rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and daily twice thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed after 14 days of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from the dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic morphology of the body organs. Statistical analysis/compilation of data were under process.

#### Subacute oral toxicity study of *Habb Surfa*

Subacute oral toxicity study of *Habb Surfa* was performed as per the OECD Test Guideline 407. The drug was studied at the dose level of 1000 mg/kg body weight (corresponding to 33x the extrapolated dose in rats) in both male and female Wistar rats. The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control) each consisting of 7 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female rat groups were orally administered *Habb Surfa* drug at the dose of 1000 mg/kg body weight daily upto 28 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 4 hours at an interval of 30 minutes after the administration of the drug and twice daily thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 29 of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record organ weight followed by grossing in which tissue was collected for histopathological studies. Statistical analysis/compilation of data were under process.

#### Acute oral toxicity study of *Ma'jūn Dabīd al-Ward*

Acute oral toxicity study of *Ma'jūn Dabīd al-Ward* was performed as per the OECD Test Guideline 425 in Wistar albino rats. The drug was administered orally at the dose level of 2000 mg/kg body weight (corresponding to 4x the extrapolated dose in rats). The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control) each consisting of 6 rats. The male and female control groups were orally treated with RO water (vehicle only). The male and female treated groups were orally administered



*Ma'jūn Dabīd al-Ward* at the dose of 2000 mg/kg body weight as a single dose. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 24 hours after the administration of the drug and twice daily thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed after 14 days of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from the dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic morphology of the body organs. Statistical analysis/compilation of data were under process.

#### Subacute oral toxicity study of *Ma'jūn Dabīd al-Ward*

Subacute oral toxicity study of *Ma'jūn Dabīd al-Ward* was performed as per the OECD Test Guideline 407 in both male and female Wistar albino rats. The drug was administered orally at the dose level of 1000 mg/kg body weight (corresponding to 2x the extrapolated dose in rats). The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control) each consisting of 7 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female rat groups were orally administered *Ma'jūn Dabīd al-Ward* at the dose of 1000 mg/kg body weight daily upto 28 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 4 hours at an interval of 30 minutes after the administration of the drug and twice daily thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 9 of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing in which tissue was collected for histopathological studies. Statistical analysis/compilation of data were under process.

#### Subacute oral toxicity study of *Ma'jūn 'Ushba*

Subacute oral toxicity study of *Ma'jūn 'Ushba* was performed as per the OECD Test Guideline 407 in both male and female Wistar albino rats. The drug was administered orally at the dose level of 1000 mg/kg body weight (corresponding to 2x the extrapolated dose in rats). The rats were randomly divided into 4 groups (Male treated, female treated, male control and female control groups) each consisting of 7 rats. The male and female control groups were orally treated with RO water (vehicle only). The treated male and female rats were orally administered *Ma'jūn 'Ushba* at the dose of 1000 mg/kg body weight daily upto 28 days. Cage side observation of the rats was carried out for any behavioural and neurological changes for next 4 hours at an interval of 30 minutes after the administration of the drug and twice daily thereafter till the completion of the experimentation. The physiological parameters such as body weight change, water consumption and feed consumption were recorded on weekly basis. The rats were sacrificed on day 29 of the oral drug administration. The rats were kept on fasting for overnight prior to sacrifice. Blood was collected for haematological and biochemical parameters from dorsal vena cava after opening the abdomen under the mild effect of Isoflurine anaesthesia. All the animals were

dissected to check macroscopic examination of vital organs of the body. The vital organs such as the liver, lung, kidney, adrenal gland, pancreas, spleen, ovary/testes and heart were collected to record the organ weight followed by grossing in which tissue was collected for histopathological studies. Statistical analysis/compilation of data were under process.

## Clinical Studies

The Clinical Research Programme of the CCRUM deals with the methods of diagnosis and treatment of diseases and aims at critical appraisal of the theory of pathogenesis, symptomatology, clinical methods of diagnosis, principles and methods of treatment, and the drug and diet therapies peculiar to Unani Medicine. Under this programme, clinical studies on different diseases were undertaken with a view to develop safe and effective Unani treatments. Besides, clinical validation of safety and efficacy of Unani pharmacopoeial formulations was conducted. The programme continued at the following centres:

- National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
- Central Research Institute of Unani Medicine (CRIUM), Lucknow
- Regional Research Institute of Unani Medicine (RRIUM), Chennai
- Regional Research Institute of Unani Medicine (RRIUM), Bhadrak
- Regional Research Institute of Unani Medicine (RRIUM), Patna
- Regional Research Institute of Unani Medicine (RRIUM), Aligarh
- Regional Research Institute of Unani Medicine (RRIUM), Mumbai
- Regional Research Institute of Unani Medicine (RRIUM), Srinagar
- Regional Research Institute of Unani Medicine (RRIUM), Kolkata
- Regional Research Institute of Unani Medicine (RRIUM), New Delhi
- Regional Research Centre (RRC), Prayagraj
- Regional Research Centre (RRC), Silchar
- Clinical Research Unit (CRU), Bengaluru
- Clinical Research Unit (CRU), Meerut
- Clinical Research Unit (CRU), Bhopal
- Clinical Research Unit (CRU), Burhanpur
- Clinical Research Unit (CRU), Edathala
- Clinical Research Unit (CRU), Kurnool

## CENTRE-WISE ALLOCATION OF DISEASES FOR CLINICAL STUDIES ON SAFETY AND EFFICACY OF UNANI DRUGS

Centre	Diseases
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad	<i>Litha Dāmiya</i> (bleeding gums), <i>Su'āl Yābis</i> (dry cough), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Sū' al-Qinya</i> (anaemia), <i>Ḥummā</i> (fever), <i>Kathrat al-Bawl</i> (overactive bladder), <i>Amrāḍ-i-Jild</i> (skin eruptions), <i>Dhayābīṭus Sukkarī</i> (diabetes mellitus) and <i>Qūbā</i> (dermatophytosis)

Centre	Diseases
Central Research Institute of Unani Medicine (CRIUM), Lucknow	<i>Nazla</i> (common cold), <i>Tahajjur al-Mafāṣil</i> (osteoarthritis), <i>Sū' al-Qinya</i> (anaemia), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Ḥummā</i> (fever), <i>Ihtibās al-Ṭamth</i> (amenorrhoea), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Su' al-Haḍm</i> (dyspepsia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis) and <i>Mālankhūliyā</i> (mixed anxiety depressive disorder)
Regional Research Institute of Unani Medicine (RRIUM), Chennai	<i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Ṣudā'</i> <i>Muzmin</i> (chronic headache), <i>Shaqīqa</i> (migraine), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Ḥummā</i> (fever), <i>Qūbā</i> (dermatophytosis), <i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Sahar</i> (insomnia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Fālij</i> (hemiplegia) and <i>Sayalān al-Raḥim</i> (leucorrhoea)
Regional Research Institute of Unani Medicine (RRIUM), Bhadrak	<i>Zahīr</i> (dysentery), <i>Buthūr al-Jild</i> (skin eruptions), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Sur'at al-Inzāl</i> (premature ejaculation), <i>Khafaqān</i> (palpitation), <i>Jarab</i> (scabies), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Bahaq Abyaḍ / Aswad</i> (pityriasis alba/nigra)
Regional Research Institute of Unani Medicine (RRIUM), Patna	<i>Nazla</i> (common cold), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Sū' al-Qinya</i> (anaemia), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Qūbā</i> (dermatophytosis), <i>Niqris</i> (gout), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Bawāsīr Dāmiya</i> (bleeding piles) and <i>Sahar</i> (insomnia)
Regional Research Institute of Unani Medicine (RRIUM), Aligarh	<i>Litha Dāmiya</i> (bleeding gums), <i>Su'āl Yābis</i> (dry cough), <i>Sahar</i> (insomnia), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Ghathayān</i> (nausea), <i>Dhayābītus Sukkarī Qism Thānī</i> (diabetes mellitus type II), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥummā Ajāmiyya</i> (malaria), <i>Sayalān al-Raḥim</i> (leucorrhoea), <i>Ḍu'f al-Dimāgh</i> (cerebrasthenia), <i>Qulā'</i> (stomatitis), <i>Niqris</i> (gout), <i>Ḥumūḍat al-Mi'da</i> (hyperacidity), <i>Jildī Qurūḥ</i> (cutaneous ulcers), <i>Waram al-Ḥanjara</i> (laryngitis) and <i>Sū' al-Haḍm</i> (functional dyspepsia)
Regional Research Institute of Unani Medicine (RRIUM), Mumbai	<i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḥaṣāt al-Kulya</i> (nephrolithiasis), <i>Sū' al-Qinya</i> (anaemia), <i>Ihtibās al-Ṭamth</i> (amenorrhoea), <i>Niqris</i> (gout), <i>Qūbā</i> (dermatophytosis), <i>Khafaqān</i> (palpitation),



Centre	Diseases
	<i>Mālankhūliyā</i> (mixed anxiety depressive disorder), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Nisyān</i> (amnesia), <i>Salas al-Bawl</i> (stress urinary incontinence) and <i>Qurūḥ</i> (healing ulcers)
Regional Research Institute of Unani Medicine (RRIUM), Srinagar	<i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Ḍu'f al-Mi'da</i> (functional dyspepsia), <i>Ḥummā</i> (fever), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Mālankhūliya</i> (mixed anxiety depressive disorder), <i>Dhayābītus Sukkarī</i> (diabetes mellitus), <i>Ḍagḥ al-Dam Qawī</i> (hypertension), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Iḥtibās al-Ṭamth</i> (amenorrhoea) and <i>Niqris</i> (gout)
Regional Research Institute of Unani Medicine (RRIUM), Kolkata	<i>Surfa Yābis</i> (dry cough), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Sū' al-Qinya</i> (anaemia) and <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis)
Regional Research Institute of Unani Medicine (RRIUM), New Delhi	<i>Su'āl Yābis</i> (dry cough), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Faqr al-Dam</i> (iron deficiency anaemia), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Buthūr al-Jild</i> (skin eruptions), <i>Kathrat al-Ṭamth</i> (heavy menstrual bleeding), <i>Sū' al-Qinya</i> (anaemia), <i>Khafaqān</i> (palpitation), <i>Sū' al-Haḍm</i> (dyspepsia), <i>Dhayābītus Sukkarī</i> (diabetes mellitus), <i>Irq al-Nasā</i> (sciatica), <i>Nisyān</i> (amnesia) and <i>Ḍu'f al-A'ṣāb</i> (neurasthenia)
Regional Research Centre (RRC), Prayagraj	<i>Zaḥīr</i> (dysentery), <i>Nazla Ḥārr</i> (common cold), <i>Niqris</i> (gout), <i>Sū' al-Qinya</i> (anaemia), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Su'āl Yābis</i> (dry cough), <i>Sahar</i> (insomnia) and <i>Ḍīq al-Nafas</i> (bronchial asthma)
Regional Research Centre (RRC), Silchar	<i>Surfa Yābis</i> (dry cough), <i>Nazla</i> (common cold), <i>Waja' al-Mafāṣil</i> (rheumatoid arthritis), <i>Ghathayān</i> (nausea), <i>Buthūr al-Jild</i> (skin eruptions), <i>Waja' al-Asnān</i> (toothache), <i>Sū' al-Qinya</i> (anaemia), <i>Sahar</i> (insomnia) and <i>Bahaq Abyaḍ / Aswad</i> (pityriasis alba/nigra)
Clinical Research Unit (CRU), Bengaluru	<i>Sū' al-Qinya</i> (anaemia), <i>Nazla Ḥārr</i> (common cold), <i>Waja' al-Asnān</i> (toothache), <i>Dhayābītus Sukkarī</i> (diabetes mellitus), and <i>Fālij</i> (hemiplegia)
Clinical Research Unit (CRU), Meerut	<i>Nazla</i> (common cold), <i>Sū' al-Qinya</i> (anaemia), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Ḍīq al-Nafas</i> (bronchial asthma), <i>Nazla Muzmin</i> (chronic rhinosinusitis), <i>Sayalān al-Raḥīm</i> (leucorrhoea), <i>Sū' al-Haḍm</i> (dyspepsia), <i>Su'āl Yābis</i> (dry cough), <i>Salas al-Bawl</i> (stress urinary incontinence), <i>Bawāsīr Dāmiya</i> (bleeding piles), <i>Ghathayān</i> (nausea) and <i>Waram al-Ḥanjara</i> (laryngitis)
Clinical Research	<i>Nazla</i> (common cold), <i>Ṣudā' Muzmin</i> (chronic

Centre	Diseases
Unit (CRU), Bhopal	headache), <i>Sahar</i> (insomnia), <i>Su'āl</i> (cough), <i>Şudā'</i> (headache), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Sayalān al-Raḥīm</i> (leucorrhoea) and <i>Mālankhūliya</i> (mixed anxiety depressive disorder)
Clinical Research Unit (CRU), Burhanpur	<i>Surfa Yābis</i> (dry cough), <i>Şudā' Muzmin</i> (chronic headache), <i>Sur'at al-Inzāl</i> (premature ejaculation), <i>Nazla Ḥārr</i> (common cold), <i>Sū' al-Qinya</i> (anaemia) and <i>Sū' al-Haḍm</i> (functional dyspepsia)
Clinical Research Unit (CRU), Kerala	<i>Nazla</i> (common cold), <i>Sahar</i> (insomnia), <i>Nazla Ḥārr</i> (common cold) and <i>Sur'at al-Inzāl</i> (premature ejaculation)
Clinical Research Unit (CRU), Kurnool	<i>Litha Dāmiya</i> (bleeding gums), <i>Ghathayān</i> (nausea), <i>Zaḥīr</i> (dysentery), <i>Ḍu'f al-Ishtihā'</i> (anorexia), <i>Waja' al-Asnān</i> (toothache), <i>Dhayābīṭus Sukkarī</i> (diabetes mellitus), <i>Qulā'</i> (stomatitis) and <i>Amrāḍ-i-Jild</i> (skin eruptions)

### Randomised Controlled Trials

The following studies under the randomised controlled trials were initiated during the reporting period:

[A single blind, randomised, parallel group study to compare the efficacy and safety of coded Unani formulation K2019 with Ferrous sulphate in the patients of \*Faqr al-Dam\* \(iron deficiency anaemia\)](#)

A randomised controlled clinical study of a coded Unani formulation K2019 with Ferrous sulphate was carried out in the patients of *Faqr al-Dam* (iron deficiency anaemia) at RRIUM, New Delhi. The patients were divided into two groups. The test group received UNIM K2019 in a dose of two tablets (500 g each), whereas the control group received ferrous sulphate one tablet (325 mg) once a day for 12 weeks. During the reporting period, 62 patients were screened, out of which 53 patients were registered.

[A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation \*Qurş-i-Mafāşil\* with Paracetamol in the patients of \*Taḥajjur al-Mafāşil\* \(osteoarthritis\)](#)

A randomised controlled clinical study of Unani formulation *Qurş-i-Mafāşil* with Paracetamol in the patients of *Taḥajjur al-Mafāşil* (osteoarthritis) was carried out at CRIUM, Lucknow. The patients were divided into two groups. The test group received *Qurş-i-Mafāşil* in a dose of two tablets (500 mg each), whereas the control group received Paracetamol one tablet (500 mg) once a day for eight weeks. During the reporting period, 13 patients were screened, out of which 09 patients were registered.

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Safūf-i-Dama Haldī Wālā* with Salbutamol in the patients of *Ḍīq al-Nafas* (bronchial asthma)

A randomised controlled clinical study of Unani formulation *Safūf-i-Dama Haldī Wālā* with Salbutamol in the patients of *Ḍīq al-Nafas* (bronchial asthma) was initiated at NRIUMSD, Hyderabad. The patients were divided into two groups. The test group received *Safūf-i-Dama Haldī Wālā* in powder form in a dose of 5 g once daily, whereas the control group received Salbutamol 2 mg once a day for 51 days.

A single blind, randomised, parallel group study to compare the efficacy and safety of coded Unani formulation UNIM-D 2000 with Metformin in the patients with *Dhayābīṭus Sukkarī Qism Thānī* (diabetes mellitus type II)

A randomised controlled clinical study of a coded Unani formulation UNIM-D 2000 with Metformin in the patients of *Dhayābīṭus Sukkarī Qism Thānī* (diabetes mellitus type II) was carried out at RRIUM, Aligarh. The patients were divided into two groups. The test group received UNIM-D 2000 (powder form) in a dose of 500 mg twice daily with water ½ hr before meals, whereas the control group received Metformin one tablet (850 mg) twice a day for 12 weeks. During the reporting period, 42 patients were screened, out of which 10 patients were registered.

A single blind, randomised, parallel group study to compare the efficacy and safety of Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine)

A randomised controlled clinical study of a coded Unani formulation *Cap. Shaqīqa* with Divalproate in the patients of *Shaqīqa* (migraine) was carried out at RRIUM, Chennai. The patients were divided into two groups. The test group received *Cap. Shaqīqa* in the dose of two capsules (500 mg each) twice a day, whereas the control group received Divalproate 500 mg once at night for 12 weeks. During the reporting period, 12 patients were screened, out of which six patients were registered.

### Validation of Unani Pharmacopoeial Drugs

Clinical validation of Unani pharmacopoeial formulation *Iṭṭīfal Fawlādī* in *Sū' al-Qinya* (anaemia)

A study on validation of Unani pharmacopoeial formulation *Iṭṭīfal Fawlādī* in the patients of *Sū' al-Qinya* (anaemia) was carried out at RRIUM, Patna; and CRU, Meerut and Bengaluru. The patients received *Iṭṭīfal Fawlādī* 7 g twice daily for six weeks.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 184 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

Clinical validation of Unani pharmacopoeial formulation *Habb-i-Sūranjān* in *Waja' al-Mafāṣil* (rheumatoid arthritis)

A study on validation of Unani pharmacopoeial formulation *Habb-i-Sūranjān* in the patients of *Waja' al-Mafāṣil* (rheumatoid arthritis) was carried out at RRIUM, Srinagar and Bhadrak; and RRC, Silchar. The patients received *Habb-i-Sūranjān* one pill (360 mg) twice daily for six weeks.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 86 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Iṭrīfal Mulayyin* in *Şudā' Muzmin* (chronic headache)

A study on validation of Unani pharmacopoeial formulation *Iṭrīfal Mulayyin* in the patients of *Şudā' Muzmin* (chronic headache) was carried out at RRIUM, Chennai; and CRU, Bhopal and Burhanpur. The patients received *Iṭrīfal Mulayyin* 7 g once a day at bedtime for seven days.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 166 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Safūf-i-Tīn* in *Zahīr* (dysentery)

A study on validation of Unani pharmacopoeial formulation *Safūf-i-Tīn* in the patients of *Zahīr* (dysentery) was carried out at RRIUM, Bhadrak; CRU, Kurnool; and RRC, Prayagraj. The patients received *Safūf-i-Tīn* 7 g twice daily for six weeks.

During the reporting period, 23 patients were studied, of which 17 completed the study. Out of the completed cases, 16 (94.12%) were relieved and one (5.88%) partially relieved. No patient was under study and six dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Qurş Hābis* in *Kathrat al-Ṭamth* (menorrhagia)

A study on validation of Unani pharmacopoeial formulation *Qurş Hābis* in the patients of *Kathrat al-Ṭamth* (menorrhagia) was carried out at NRIUMSD, Hyderabad; and RRIUM, Mumbai and Chennai. The patients received *Qurş Hābis* (250 mg) twice daily for nine days a month starting from the 1st day of the menstrual cycle for three consecutive months.

During the reporting period, 52 patients were studied, of which 48 completed the study. Out of the completed cases, 31 (64.58%) patients were relieved and 17 (35.42%) partially relieved. Two patients were under study and two dropped out of the study.

#### Clinical validation of Unani pharmacopoeial formulation *Jawārish Anārayn* in *Ghathayān* (nausea)

A study on validation of Unani pharmacopoeial formulation *Jawārish Anārayn* in the patients of *Ghathayān* (nausea) was carried out at RRIUM, Aligarh; RRC, Silchar; and CRU, Kurnool. The patients received *Jawārish Anārayn* 7 g twice daily for one week.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 160 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Iṭrīfal Zamānī* in *Nazla Muzmin* (chronic rhinosinusitis)

A study on validation of Unani pharmacopoeial formulation *Iṭrīfal Zamānī* in the patients of *Nazla Muzmin* (chronic rhinosinusitis) was carried out at RRIUM, Aligarh, New Delhi and Kolkata; and CRU, Meerut. The patients received *Iṭrīfal Zamānī* 7 g at bedtime for six weeks.

During the reporting period, 32 patients were studied, of which 16 completed the study. Out of the completed cases, 14 (87.50%) patients were relieved, whereas two (12.50%) showed no response. A total of 13 patients dropped out of the study and three patients were under study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Habb Mudirr* in the patients of *Ihtibās al-Ṭamth* (amenorrhoea)

A study on validation of Unani pharmacopoeial formulation *Habb Mudirr* was conducted in the patients of *Ihtibās al-Ṭamth* (amenorrhoea) at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, Mumbai. The study drug *Habb Mudirr* was given in the dose of 2 pills (500 mg) thrice daily for 5 days each month for three consecutive months.

During the reporting period, 135 patients were studied, of which 89 completed the study. Out of the completed cases, 48 (53.93%) patients were relieved and 31 (34.83%) partially relieved, whereas 10 (11.24%) showed no response. A total of 45 patients dropped out of the study and one patient was under study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Sharbat-i-Khāksī* in *Ḥummā* (fever)

A study on validation of Unani pharmacopoeial formulation *Sharbat-i-Khāksī* in the patients of *Ḥummā* (fever) was carried out at CRIUM, Lucknow; and RRIUM, Srinagar and Chennai. The patients received *Sharbat-i-Khāksī* 15 ml four times a day.

During the reporting period, one patient was studied and completed the study. The only patient (100%) was relieved. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Habb Muṣaffī-i-Khūn* in *Buthūr al-Jild* (skin eruptions)

A study on validation of Unani pharmacopoeial formulation *Habb Muṣaffī-i-Khūn* in the patients of *Buthūr al-Jild* (skin eruptions) was carried out at RRIUM, New Delhi and Bhadrak; and RRC, Silchar. The patients received *Habb Muṣaffī-i-Khūn* one pill (250 mg) twice daily for two weeks.

During the reporting period, three patients were studied, of which one completed the study and was partially relieved. A total of two patients dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Iṭrīfal Kishnīzī* in *Nazla Muzmin* (chronic rhinosinusitis)

A study on validation of Unani pharmacopoeial formulation *Iṭrīfal Kishnīzī* in the patients of *Nazla Muzmin* (chronic rhinosinusitis) was carried out at RRIUM, Kolkata and Patna; and CRU, Meerut. The patients received *Iṭrīfal Kishnīzī* 10 g twice daily for four weeks.

During the reporting period, 69 patients were studied, of which 60 completed the study. Out of the completed cases, 25 (41.67%) patients were relieved and 25 (41.67%) partially relieved, whereas 10 (16.67%) showed no response. A total of nine patients dropped out of the study and no patient was under study. The test drug was found well-tolerated and no adverse effect was observed.



### Clinical validation of Unani pharmacopoeial formulation *Jawārish Pudīna* in *Ḍuʿf al-Ishtihāʾ* (anorexia)

A study on validation of Unani pharmacopoeial formulation *Jawārish Pudīna* in the patients of *Ḍuʿf al-Ishtihāʾ* (anorexia) was carried out at RRIUM, Kolkata; and CRU, Meerut, Kurnool and Bhopal. The patients received *Jawārish Pudīna* 5 g twice daily for two weeks.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 163 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Safūf-i-Chobchīnī* in *Niqris* (gout)

A study on validation of Unani pharmacopoeial formulation *Safūf-i-Chobchīnī* in the patients of *Niqris* (gout) was carried out at RRIUM, Mumbai and Patna, and RRC, Prayagraj. The patients received *Safūf-i-Chobchīnī* 5 g twice daily for six weeks.

During the reporting period, 48 patients were studied, of which 35 completed the study. Out of the completed cases, 25 (71.43%) patients were relieved and four (11.43%) partially relieved, whereas six (17.14%) showed no response. A total of seven patients were under study and six patients dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulations *Maʿjūn-i-ʿUshba* and *Marham-i-Qūbā* in *Qūbā* (dermatophytosis)

A study on validation of Unani pharmacopoeial formulations *Maʿjūn-i-ʿUshba* and *Marham-i-Qūbā* in the patients of *Qūbā* (dermatophytosis) was carried out at RRIUM, Mumbai, Chennai and Patna. The patients received *Maʿjūn-i-ʿUshba* 5 g oral and *Marham-i-Qūbā* topical twice daily for five weeks.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 75 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Maʿjūn Ḥajr al-Yahūd* in *Ḥaṣāt al-Kulya* (nephrolithiasis)

A study on validation of Unani pharmacopoeial formulation *Maʿjūn Ḥajr al-Yahūd* in the patients of *Ḥaṣāt al-Kulya* (nephrolithiasis) was carried out at NRIUMSD, Hyderabad; and RRIUM, Mumbai and Chennai. The patients received *Maʿjūn Ḥajr al-Yahūd* 5 g twice daily for 8 weeks.

During the reporting period, 95 patients were studied, of which 55 completed the study. Out of the completed cases, 29 (52.73%) patients were relieved and four (7.27%) partially relieved, whereas 22 (40%) showed no response. A total of 27 cases dropped out of the study and 13 were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Qurṣ-i-Anjibār* in *Kathrat al-Ṭamth* (heavy menstrual bleeding)

A study on validation of Unani pharmacopoeial formulation *Qurṣ-i-Anjibār* in the patients of *Kathrat al-Ṭamth* (heavy menstrual bleeding) was carried out at NRIUMSD, Hyderabad; CRIUM, Lucknow; and RRIUM, New Delhi. The patients received *Qurṣ-i-Anjibār* 2 tablets (500 mg) thrice daily for 12 weeks.

During the reporting period, 156 patients were studied, of which 94 completed the study. Out of the completed cases, 47 (50%) patients were relieved and 29 (30.85%) partially relieved, whereas 18 (19.15%) showed no response. A total of 46 cases dropped out of the study and 16 were under study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Shamūn* in *Nazla Hārr* (common cold)

A study on validation of Unani pharmacopoeial formulation *La'ūq-i-Shamūn* in the patients of *Nazla Hārr* (common cold) was carried out at RRC, Prayagraj; and CRU, Burhanpur, Bengaluru and Kerala. The patients received *La'ūq-i-Shamūn* 5 g twice daily for seven days. During the reporting period, 16 patients were studied, of which 14 completed the study and were relieved. Two patients were under study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Ma'jūn-i-Suhāg Sonth* in *Sayalān al-Rahim* (excessive abnormal vaginal discharge)

A study on validation of Unani pharmacopoeial formulation *Ma'jūn-i-Suhāg Sonth* in the patients of *Sayalān al-Rahim* (excessive abnormal vaginal discharge) was carried out at CRIUM, Lucknow; RRIUM, Srinagar; and CRU, Meerut. The patients received *Ma'jūn-i-Suhāg Sonth* 5 g twice daily for four weeks.

During the reporting period, 37 patients were studied, of which 31 completed the study. Out of the completed cases, 17 (54.84%) were relieved and 12 (38.71%) partially relieved, whereas two (6.45%) showed no response. A total of six cases dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

#### Clinical validation of Unani pharmacopoeial formulation *Habb Khabath al-Hadīd* in *Sū' al-Qinya* (anaemia)

A study on validation of Unani pharmacopoeial formulation *Habb Khabath al-Hadīd* in the patients of *Sū' al-Qinya* (anaemia) was carried out at CRIUM, Lucknow; and RRIUM, New Delhi and Mumbai. The patients received *Habb Khabath al-Hadīd* 1 pill twice daily for 12 weeks.

During the reporting period, 106 patients were studied, of which 67 completed the study. Out of the completed cases, 10 (14.93%) were relieved, 29 (43.28%) partially relieved, whereas 28 (41.79%) showed no response. A total of 24 cases dropped out of the study and 15 were under study.

#### Clinical validation of Unani pharmacopoeial formulation *Ma'jūn-i-Ispand Sokhtānī* in *Sur'at al-Inzāl* (premature ejaculation)

A study on validation of Unani pharmacopoeial formulation *Ma'jūn-i-Ispand Sokhtānī* in the patients of *Sur'at al-Inzāl* (premature ejaculation) was carried out at RRIUM, Bhadrak; and CRU, Kerala and Burhanpur. The patients received *Ma'jūn-i-Ispand Sokhtānī* 5 g twice daily for two weeks.

During the reporting period, three patients were studied, of which none completed the study. All three patients dropped out of the study.



### Clinical validation of Unani pharmacopoeial formulation *Rawghan-i-Qaranful* in *Waja' al-Asnān* (toothache)

A study on validation of Unani pharmacopoeial formulation *Rawghan-i-Qaranful* in the patients of *Waja' al-Asnān* (toothache) was carried out at CRU, Kurnool and Bengaluru; and RRC, Silchar. The patients received *Rawghan-i-Qaranful* for local application twice daily for 3 days.

During the reporting period, no new patient was registered. Since inception of the study, a total of 99 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Habb Hindī Dīqī* in *Dīq al-Nafas* (bronchial asthma)

A study on validation of Unani pharmacopoeial formulation *Habb Hindī Dīqī* in the patients of *Dīq al-Nafas* (bronchial asthma) was carried out at RRIUM, Srinagar, Aligarh and Patna. The patients received *Habb Hindī Dīqī* one pill (125 mg) twice daily for four weeks.

During the reporting period, 105 patients were studied, of which 64 completed the study. Out of the completed cases, 22 (34.38%) were relieved, 33 (51.56%) partially relieved, whereas nine (14.06%) showed no response. A total of 15 patients dropped out of the study and 26 were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Sangdāna Murgh* in *Ḍu'f al-Mi'da* (functional dyspepsia)

A study on validation of Unani pharmacopoeial formulation *Ma'jūn Sangdāna Murgh* in the patients of *Ḍu'f al-Mi'da* (functional dyspepsia) was carried out at NRIUMSD, Hyderabad; and RRIUM, Srinagar and Aligarh. The patients received *Ma'jūn Sangdāna Murgh* 5 g twice daily for six weeks.

During the reporting period, 49 patients were studied, of which 30 completed the study. Out of the completed cases, 18 (60%) were relieved and eight (26.67%) partially relieved, whereas four (13.33%) showed no response. A total of 13 patients were under study and six dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Jawārish Pūdīna Wilāyatī* in *Sū' al-Haḍm* (dyspepsia)

A study on validation of Unani pharmacopoeial formulation *Jawārish Pūdīna Wilāyatī* in the patients of *Sū' al-Haḍm* (dyspepsia) was carried out at CRIUM, Lucknow; RRIUM, New Delhi; and CRU, Meerut. The patients received *Jawārish Pūdīna Wilāyatī* 5 g twice daily for six weeks.

During the reporting period, 270 patients were studied, of which 165 completed the study. Out of the completed cases, 60 (36.36%) patients were relieved and 79 (47.88%) partially relieved, whereas 26 (15.76%) showed no response. A total of 89 patients dropped out of the study and 16 were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *La'ūq Ḍīq al-Nafas* in *Ḍīq al-Nafas* (bronchial asthma)

A study on validation of Unani pharmacopoeial formulation *La'ūq Ḍīq al-Nafas* in the patients of *Ḍīq al-Nafas* (bronchial asthma) was carried out at NRIUMSD, Hyderabad; and RRIUM, Chennai and Bhadrak. The patients received *La'ūq Ḍīq al-Nafas* 5 g twice daily for four weeks.

During the reporting period, 48 patients were studied, out of which 35 completed the study. Out of the completed cases, 24 (68.57%) were relieved and seven (20.00%) partially relieved, whereas four (11.43%) showed no response. Six patients dropped out of the study and seven were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Sayalānī* in *Sayalān al-Raḥīm* (leucorrhoea)

A study on validation of Unani pharmacopoeial formulation *Sayalānī* in the patients of *Sayalān al-Raḥīm* (leucorrhoea) was carried out at RRIUM, Mumbai and Aligarh; and CRU, Bhopal. The patients received 2 tablets of *Sayalānī* twice daily for four weeks.

During the reporting period, 122 patients were studied, of which 111 completed the study. Out of the completed cases, 93 (83.78%) were relieved and 17 (15.32%) partially relieved, whereas one (0.90%) patient showed no response. A total of 11 patients dropped out of the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Najāḥ* in *Mālankhūliyā* (mixed anxiety depressive disorder)

A study on validation of Unani pharmacopoeial formulation *Ma'jūn Najāḥ* in the patients of *Mālankhūliyā* (mixed anxiety depressive disorder) was carried out at NRIUMSD, Hyderabad; and RRIUM, Srinagar, Chennai and Mumbai. The patients received *Ma'jūn Najāḥ* 5 g twice daily for six weeks.

During the reporting period, 88 patients were studied, of which 45 completed the study. Out of the completed cases, 25 (55.56%) were relieved, 13 (28.89%) patients were partially relieved and seven (15.56%) showed no response. A total of 23 patients dropped out of the study and 20 were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in *Waja'al-Mafāṣil* (rheumatoid arthritis)

A study on validation of Unani pharmacopoeial formulation *Ḥabb 'Irq al-Nasā* in the patients of *Waja'al-Mafāṣil* (rheumatoid arthritis) was carried out at CRIUM, Lucknow; RRIUM, Patna; and RRC, Prayagraj. The patients received two tablets of *Ḥabb 'Irq al-Nasā* thrice daily for 12 weeks.

During the reporting period, 146 patients were studied, of which 78 completed the study. Out of the completed cases, 20 (25.64%) were relieved and 47 (60.26%) partially relieved, whereas 11 (14.10%) showed no response. A total of 21 patients dropped out of the study and 47 were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Khabath al-Ḥadīd* in *Sū' al-Qinya* (anaemia)

A study on validation of Unani pharmacopoeial formulation *Ma'jūn Khabath al-Ḥadīd* in the patients of *Sū' al-Qinya* (anaemia) was carried out at CRIUM, Lucknow; RRIUM, Patna and Kolkata; RRC, Prayagraj and Silchar; and CRU, Burhanpur. The patients received *Ma'jūn Khabath al-Ḥadīd* 5 g twice daily for 12 weeks.

During the reporting period, 43 patient were studied, of which 18 completed the study. Out of the completed cases, five (27.78%) patients were relieved and nine (50%) partially relieved, whereas four (22.22%) showed no response. A total of 19 cases dropped out of the study and six were under study.

### Clinical validation of Unani pharmacopoeial formulation *Khamīra Ga'uzabān Sādā* in *Khafaqān* (palpitation)

A study on validation of Unani pharmacopoeial formulation *Khamīra Ga'uzabān Sādā* in the patients of *Khafaqān* (palpitation) was carried out at RRIUM, New Delhi, Mumbai and Bhadrak. The patients received *Khamīra Ga'uzabān Sādā* 5 g twice daily for four weeks.

During the reporting period, 70 patients were studied, of which 34 completed the study. Out of the completed cases, 24 (70.59%) patients were relieved and eight (23.53%) partially relieved, whereas two (5.88%) showed no response. A total of 22 cases dropped out of the study and 14 were under study.

### Clinical validation of Unani pharmacopoeial formulation *Ḥabb Mubārak* in *Ḥummā Ajāmiyya* (malaria)

A study on validation of Unani pharmacopoeial formulation *Ḥabb Mubārak* in the patients of *Ḥummā Ajāmiyya* (malaria) was carried out at RRIUM, Aligarh. The patients were to receive two pills (500 mg) of *Ḥabb Mubārak* twice daily for two weeks as per the protocol. However, no patient was registered in the study during the reporting period.

### Clinical validation of Unani pharmacopoeial formulation *Iṭṭīfāl Kabīr* in *Ḍu'f al-Dimāgh* (cerebrasthenia)

A study on validation of Unani pharmacopoeial formulation *Iṭṭīfāl Kabīr* in the patients of *Ḍu'f al-Dimāgh* (cerebrasthenia) was carried out at CRIUM, Lucknow; and RRIUM, Chennai, Aligarh and Patna. The patients received *Iṭṭīfāl Kabīr* 5 g twice daily for six weeks.

During the reporting period, 11 patients were studied, of which two patients completed the study. Out of the completed cases, one (50%) was relieved, and another one (50%) partially relieved. One patient dropped out of the study and eight patients were under study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Sapistān* in the patients of *Nazla* (common cold)

Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Sapistān* in the patients of *Nazla* (common cold) was conducted at CRIUM, Lucknow; CRU, Bhopal, Kerala and Meerut; and RRC, Silchar. The study drug *La'ūq-i-Sapistān* was given orally in the dose of 5 g twice daily for seven days.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 157 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Sharbat Şadr* in the patients of *Surfa Yābis* (dry cough)

Clinical validation of Unani pharmacopoeial formulation *Sharbat Şadr* in the patients of *Surfa Yābis* (dry cough) was conducted at RRIUM, Kolkata; CRU, Burhandpur; and RRC, Silchar. The study drug was given orally in the dose of 20 ml twice daily for two weeks.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 132 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Rawghan-i-Kāhū* in *Sahar* (insomnia)

Clinical validation of Unani pharmacopoeial formulation *Rawghan-i-Kāhū* in the patients of *Sahar* (insomnia) was conducted at RRIUM, Aligarh; and CRU, Bhopal and Kerala. The study drug *Rawghan-i-Kāhū* was applied locally on scalp at bedtime once a day for seven days.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 102 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *Khamīra Banafsha* in *Su'āl Yābis* (dry cough)

Clinical validation of Unani pharmacopoeial formulation *Khamīra Banafsha* was conducted in the patients of *Su'āl Yābis* (dry cough) at NRIUMSD, Hyderabad; and RRIUM, Aligarh and New Delhi. The study drug *Khamīra Banafsha* was given orally in the dose of 7 g twice daily for seven days.

During the reporting period, 57 patients were studied, of which 48 completed the study. Out of the completed cases, 26 (54.17%) were relieved and 18 (37.50%) were partially relieved, whereas four (8.33%) showed no response. Nine patients dropped out of the study.

### Clinical validation of Unani pharmacopoeial formulation *Sanūn Mukhrij-i-Ruṭūbat* in *Litha Dāmiya* (bleeding gums)

Clinical validation of Unani pharmacopoeial formulation *Sanūn Mukhrij-i-Ruṭūbat* was conducted in the patients of *Litha Dāmiya* (bleeding gums) at NRIUMSD, Hyderabad; RRIUM, Aligarh; and CRU, Kurnool. The study drug *Sanūn Mukhrij-i-Ruṭūbat* in the dose of 1 g was applied locally on the gums twice a day for seven days.

During the reporting period, one patient was studied who completed the study and was relieved. The test drug was found well-tolerated and no adverse effect was observed.

### Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Khiyar Shambar* in *Nazla* (common cold)

Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Khiyar Shambar* was conducted in the patients of *Nazla* (common cold) at CRIUM, Lucknow; RRIUM, Patna; and CRU, Kerala. The study drug *La'ūq-i-Khiyar Shambar* in the dose of 10 g was given twice daily for seven days.

During the reporting period, no new patient was registered in the study. Since inception of the study, a total of 161 cases have completed the study. The test drug was found well-tolerated and no adverse effect was observed.

### New studies initiated

The following studies under validation of Unani pharmacopoeial drugs were initiated during the reporting period:

- Clinical validation of Unani pharmacopoeial formulation *Habb Lu'āb-i-Behi Dāna* in *Su'āl Yābis* (dry cough)
- Clinical validation of Unani pharmacopoeial formulation *Habb-i-Qulā'* in *Qulā'* (stomatitis)
- Clinical validation of Unani pharmacopoeial formulation *Qurş-i-Zirishk* in *Sū' al-Qinya* (anaemia)
- Clinical validation of Unani pharmacopoeial formulations *Rawghan-i-Nārjīl* and *Qurş Aşfar* in *Qūbā* (dermatophytosis)
- Clinical validation of Unani pharmacopoeial formulations *Rawghan Nafa'-i-Waram-i-Niqris* and *Ma'jūn-i-Yahyā bin Khālīd* in *Niqris* (gout)
- Clinical validation of Unani pharmacopoeial formulation *Kushta Bayḍa-i-Murgh* in *Sayalān al-Raḥīm* (leucorrhoea)
- Clinical validation of Unani pharmacopoeial formulation *Habb-i-Karanjwā* in *Ḥummā* (fever)
- Clinical validation of Unani pharmacopoeial formulation *Qurş Dawā' al-Shifā'* in *Ḍagħṭ al-Dam Qawī* (hypertension)
- Clinical validation of Unani pharmacopoeial formulation *La'ūq-i-Ḥulba* in *Ḍīq al-Nafas* (bronchial asthma)
- Clinical validation of Unani pharmacopoeial formulation *Qurş-i-'Atash* in *Ḥumūḍat al-Mi'da* (hyperacidity)
- Clinical validation of Unani pharmacopoeial formulations *Ma'jūn-i-Adhārāqī* and *Rawghan Surkh* in *Waja' al-Mafāşil* (rheumatoid arthritis)
- Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Būlis* in *Nisyān* (amnesia)
- Clinical validation of Unani pharmacopoeial formulation *Habb 'Irq al-Nasā* in *'Irq al-Nasā* (sciatica)
- Clinical validation of Unani pharmacopoeial formulation *Habb-i-Banafsha* in *Ḍīq al-Nafas Ri'wī* (bronchial asthma)
- Clinical validation of Unani pharmacopoeial formulation *Kundurī* in *Salas al-Bawl* (stress urinary incontinence)
- Clinical validation of Unani pharmacopoeial formulation *Ma'jūn-i-Zanjabīl* in *Kathrat al-Ṭamth* (menorrhagia)
- Clinical validation of Unani pharmacopoeial formulation *Jawārish Dār Chīnī Qawī* in *Ḍu'f al-Mi'da* (dyspepsia)
- Clinical validation of Unani pharmacopoeial formulation *Marham Gulābī* in *Jildī Qurūḥ* (cutaneous ulcers)
- Clinical validation of Unani pharmacopoeial formulation *Rawghan-i-Banafsha* in *Sahar* (insomnia)
- Clinical validation of Unani pharmacopoeial formulations *Iṭrīfal Mundī* and *Marham-i-Raskapūr* in *Jarab* (scabies)



### New studies allotted

In addition to the above, the following studies under validation of Unani pharmacopoeial drugs were allotted during the reporting period:

- Clinical validation of Unani pharmacopoeal formulations *Habb Mafāṣil* and *Dimād Muḥallil* in *Waja' al-Mafāṣil* (rheumatoid arthritis)
- Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Balādur* in *Nisyān* (amnesia)
- Clinical validation of Unani pharmacopoeial formulation *Jawārish Kunder* in *Kathrat al-Bawl* (overactive bladder)
- Clinical validation of Unani pharmacopoeial formulation *Jawārish Zar'ūnī Sāda* in *Hasāt al-Kulya* (nephrolithiasis)
- Clinical validation of Unani pharmacopoeial formulation *La'ūq Dīq al-Nafas Balghamī* in *Dīq al-Nafas* (bronchial asthma)
- Clinical validation of Unani pharmacopoeial formulation *Ma'jūn La'na* in *Ḍu'f-i-A'sāb* (neurasthenia)
- Clinical validation of Unani pharmacopoeial formulation *Ma'jūn Tīwaj* in *Bawāsīr Dāmiya* (bleeding piles)
- Clinical validation of Unani pharmacopoeial formulation *La'ūq Fālij* and *Rowghan Mom* in *Fālij* (haemiplegia)
- Clinical validation of Unani pharmacopoeial formulation *Iṭrīfāl Aftīmūn* in *Mālankhūliyā* (mixed anxiety depressive disorder)
- Clinical validation of Unani pharmacopoeial formulation *Jawārish Qurṭūm* in *Iḥtibās al-Ṭamth* (amenorrhoea)
- Clinical validation of Unani pharmacopoeial formulation *'Araq Chirā'ita* in *Amrāḍ-i-Jild* (skin eruptions)
- Clinical validation of Unani pharmacopoeial formulation *Habb Pachlonā* in *Sū'i-Haḍm* (functional dyspepsia)
- Clinical validation of Unani pharmacopoeial formulation *Marham I'jāz* in *Qurūḥ* (healing ulcers)
- Clinical validation of Unani pharmacopoeial formulation *Rowghan Labūb Ṣabā Bārid* in *Sahar* (insomnia)
- Clinical validation of Unani pharmacopoeial formulation *Safūf Hāḍim Kalān* in *Ḍu'f al-Ishtihā'* (anorexia)
- Clinical validation of Unani pharmacopoeial formulation *Safūf Sūranjān Za'frānī* in *Niqris* (gout)
- Clinical validation of Unani pharmacopoeial formulation *Habb Kibrīt Ṣaghīr* in *Qūbā* (dermatophytosis)
- Clinical validation of Unani pharmacopoeial formulation *Habb Khunāq* in *Waram-i-Hanjara* (laryngitis)
- Clinical validation of Unani pharmacopoeial formulation *Tiryāq-i-Raḥim* in *Sayalān al-Raḥim* (leucorrhoea)
- Clinical validation of Unani pharmacopoeial formulation *Habb Kalaf* in *Bahaq Abyaḍ/Aswad* (pityriasis alba/nigra)

## Validation of Regimen Therapies

Besides pharmacotherapy, Unani Medicine offers *'Ilāj bi'l-Tadbīr* (regimen therapy), such as *Hijāma* (cupping), *Ta'liq al-'Alaq* (leeching), *Dalk* (massage), *Hammām Yābis* (sauna), *Hammām al-Bukhār* (steam bath), etc. for various disease conditions. During the reporting period, various regimen therapy procedures were performed in a total of 5,280 patients of different diseases. These procedures showed significant therapeutic effects in subsiding the signs and symptoms of the diseases.

*Hijāma bilā-Sharṭ* (dry cupping) was performed in 2,586 patients with different diseases including *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica), *Taḥajjur Mafāṣil al-'Unuq* (cervical spondylosis), *Taḥajjur Mafāṣil al-Zahr* (lumbar spondylosis), *Katif Mujammad* (frozen shoulder), *Waja' al-Zahr* (backache), *Waja' al-Katif* (shoulder pain), *Waja' al-'Unuq* (neck pain), *Waja' al-Rukba* (knee pain), *Waja' al-'Aqib* (achillodynia), *Dawālī* (varicose veins), *Kathrat al-Ṭamth* (menorrhagia), *'Usr al-Ṭamth* (dysmenorrhoea), *Ṣudā'* (headache), *Ṣala'* (baldness), *Huzn* (depression), etc. at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUM, Chennai, Bhadrak, New Delhi and Srinagar; and All India Institute of Ayurveda (AIIA), New Delhi.

*Hijāma bi'l-Sharṭ* (wet cupping) was performed in 461 patients with different diseases including *Nār Fārsī* (eczema), *Buthūr Labaniyya* (acne vulgaris), *Dā' al-Tha'lab* (alopecia), *Bawāsīr* (haemorrhoid), *Ḍaght al-Dam Qawī* (hypertension), *'Uqr* (infertility), *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica) and other musculoskeletal disorders at CRIUM, Lucknow; RRIUM, Chennai, Patna, New Delhi and Srinagar; and AIIA, New Delhi.

*Hijāma bi'l-Nār* (fire cupping) was performed in 34 patients with different diseases including *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *'Irq al-Nasā* (sciatica), *Waja' al-Zahr* (backache), *Katif Mujammad* (frozen shoulder), *Waja' al-Katif* (shoulder pain) and *Waja' al-Rukba* (knee pain) at RRIUM, Chennai, Bhadrak and Srinagar.

*Hijāma Muzliqa* (moving cupping) was performed in 1,369 patients with different diseases including *Waja' al-Zahr* (backache) and *Katif Mujammad* (frozen shoulder) at RRIUM, Chennai and Srinagar; and AIIA, New Delhi.

*Hammām al-Bukhār* (steam bath) was performed in 49 patients with diseases including *Waja' al-Katif* (shoulder pain), *Qūbā* (dermatophytosis) and *Siman Mufriṭ* (obesity) at CRIUM, Lucknow; and RRIUM, Srinagar.

*Dalk Mu'tadil* (moderate massage) was performed in 13 patients with different diseases including *Waja' al-Mafāṣil* (rheumatoid arthritis), *Taḥajjur al-Mafāṣil* (osteoarthritis), *Taḥajjur Mafāṣil al-'Unuq* (cervical spondylosis), *Katif Mujammad* (frozen shoulder), *Waja' al-Zahr* (backache), *Waja' al-Katif* (shoulder pain) and *Waja' al-'Aqib* (achillodynia) at RRIUM, Chennai.

*Hammām Yābis* (sauna) was performed in 11 patient with different diseases including *Waja' al-Katif* (shoulder pain), *Taḥajjur al-Mafāṣil* (osteoarthritis) and *Siman Mufriṭ* (obesity) at RRIUM, New Delhi.

*Naṭūl* (fomentation) was performed in 66 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis) at RRIUM, Srinagar.

*Inkibāb* (vaporisation) was performed in 270 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis) and *Waja' al-Katif* (shoulder pain) at RRIUM, Srinagar.

*Mundij-Mushil* therapy was performed in 46 patients of *Baraṣ* (vitiligo) at RRIUM, New Delhi.



*Ta'līq* (leeching) was performed in 15 patients of *Dawālī* (varicose veins) and *Takhaththur al-Dam* (deep vein thrombosis) at RRIUM, Chennai.

*Takmīd* (fomentation) was performed in 360 patients of *Waja' al-Mafāṣil* (rheumatoid arthritis), *Tahajjur al-Mafāṣil* (osteoarthritis), *Siman Mufriṭ* (obesity) and *Katif Mujammad* (frozen shoulder) at CRIUM, Lucknow; and RRIUM, Chennai.

## Validation of Fundamentals

### Theory of *Akhlāy wa Mizāj* (humours and temperament)

The CCRUM has been conducting studies to validate fundamentals of Unani Medicine at NRIUMSD, Hyderabad. The objective of the project under this initiative is to test scientifically the concept of *Akhlāy* (humours) and *Mizāj* (temperament) and its relevance to the states of health and disease. The project aims at studying the clinical, physiological, pathological, biochemical and genetic parameters of the subjects of different temperaments, conducting clinical assessment of *Mizāj* (temperament) in different diseases, and scientifically establishing correlation among them.

### Genetic studies on the theory of humours

Genetic studies on the theory of humours with special reference to diabetes mellitus, essential hypertension, vitiligo, gastritis and psoriasis were carried out wherein healthy volunteers served as control. Pharmacogenomic studies of Unani formulations in vitiligo were also conducted.

A total of 2,047 healthy volunteers and patients including 156 subjects enrolled during 2021–2022 completed the studies. The first part of the project is an observational study wherein the subjects are analyzed for dominant temperament according to *Ajnās 'Ashara*. Whereas the healthy volunteers and patients are subjected to genomic studies, biochemical, physiological, pathological and pulse wave analysis studies in the second part.

During the reporting period, book compilation on the following studies completed under the validation of fundamentals was in process.

- Genetic studies on theory of humours with special reference to diabetes mellitus
- Genetic studies on theory of humours with special reference to essential hypertension
- Genetic studies on theory of humours with special reference to vitiligo
- Genetic studies on theory of humours with special reference to hepatitis and other *Ṣafrāwī* related diseases (gastritis)
- Genetic studies on theory of humours with special reference to cancer and other *Sawdāwī* related diseases (psoriasis)
- Genetic studies on theory of humours with special reference to healthy volunteers
- Pharmacogenomics of Unani formulations in vitiligo

Apart from the above, three studies involving the following components continued during the reporting period:

- Determination of dominant temperament by *Ajnās 'Ashara*
- Determination of dominant temperament by special CRF on assessment of temperament
- Genetic marker studies in relation to temperament of each subject
- Study of biochemical, physiological and pathological parameters and pulse wave component analysis in relation to temperament of each subject

Study-wise summary of the progress made during the year 2021–2022 is as under:

#### A molecular approach towards understanding of Unani philosophy – Temperament susceptibility gene expression studies (IFN-gamma)

A total of 44 patients (*Damawī* - 16; *Balghamī* - 00; *Şafrāwī* - 22; *Sawdāwī* - 06) and 24 healthy subjects (*Damawī* - 08; *Balghamī* - 00; *Şafrāwī* - 08; *Sawdāwī* - 08) were enrolled during the reporting period.

Samples of all the subjects were collected for fundamental IFN- $\gamma$  studies and RNA isolation and gene expression studies were in progress. The isolated samples were kept at -80°C deep freezer. Two RNA isolated samples were converted into cDNA using cDNA kit and PCR experiment was performed with  $\beta$ -actin gene as internal control for protocol standardization.

#### Genetic studies of liver metabolism genes in relation to clinical phenotyping as per Unani philosophy (APOE gene)

A total of 44 patients (*Damawī* - 16; *Balghamī* - 00; *Şafrāwī* - 22; *Sawdāwī* - 06) and 24 healthy subjects (*Damawī* - 08; *Balghamī* - 00; *Şafrāwī* - 08; *Sawdāwī* - 08) were enrolled during the reporting period.

DNA was isolated from the previously collected 62 patient samples (20 *Balghamī*, 20 *Şafrāwī*, 08 *Sawdāwī* and 14 *Damawī*) and 65 control samples (22 *Balghamī*, 18 *Sawdāwī*, 10 *Şafrāwī*, and 10 *Damawī*) by using blood isolation kit. DNA quality and quantity were checked by using agarose gel electrophoresis and nano-drop reading. The isolated DNA samples were stored at -20°C. PCR amplification was performed with forward and reverse primers for the above samples. The PCR products were visualized by electrophoresis on 2% agarose gel containing 5  $\mu$ g ethidium bromide to confirm amplification of the respective gene. The amplified PCR product was then digested with restriction enzyme Hha1 for 15 min at 37 °C. The digested RFLP products were separated on 4% agarose gel at 100 V for 1 hr and analyzed using gel documentation system.

#### Genetic variants of IFN- $\gamma$ (+874/A and +2109A/G) gene polymorphism and its mRNA expression and inflammatory parameters in vitiligo

A total 20 healthy subjects of *Balghamī* temperament were enrolled during the reporting period. Vitiligo patient sample and control sample collection was completed in relation to IFN- $\gamma$  genetic variants. DNA isolation for all the control and patient samples was completed and DNA concentrations were checked and stored for further analysis.

ARMS PCR and 2% agarose gel electrophoresis to identify +874 IFN- $\gamma$  genetic variants for 100 vitiligo and 50 control samples were carried out. +2109A/G PCR was also completed for all the 100 patients and 50 control samples. RFLP was carried out for 50 control and 60 patient samples. 3% agarose gel electrophoresis was performed for RFLP samples and variants were visualized. RNA isolation was carried out for 120 samples (60 baseline, 25 follow-up and 35 control samples) and stored for further process. IFN- $\gamma$  qPCR studies were carried out for 100 samples (50 baseline, 20 follow-up and 30 control samples).

#### Clinical Assessment of Mizāj (Temperament)

During the reporting period, assessment of temperament of 222 patients attending the OPD of NRIUMSD, Hyderabad was done. Of them, 98 patients were *Damawī*, 62 *Balghamī*, 60 *Şafrāwī* and 02 were *Sawdāwī*. These included patients of *Kathra al-Tamth* (heavy menstrual bleeding), *Ḍīq al-Nafas* (bronchial asthma), *Ḍuʿf al-Dimāgh* (cerebroasthenia), *Nazla Muzmin* (chronic rhinosinusitis), *Ḥaşāt al-Kulya* (nephrolithiasis), *Iḥtibās al-Tamth* (amenorrhoea),

*Sū' al-Qinya* (anaemia), *Litha Dāmiya* (bleeding gums), *Nisyān* (amnesia), *Ḍu'f al-Mi'da* (functional dyspepsia), *Mālankhūliya* (mixed anxiety depressive disorder) and asymptomatic hepatitis B carriers.

In these patients, susceptibility for acquiring diseases in relation to different temperaments were also studied. An interim analysis of data revealed that the individuals of *Ṣafrāwī* temperament were more susceptible to *Kathra al-Ṭamth* (heavy menstrual bleeding) followed by *Damawī* and *Balghamī* temperament. The individuals of *Balghamī* temperament were more susceptible to *Sū' al-Qinya* (anaemia) followed by *Ṣafrāwī* and *Damawī* temperament. Similarly, individuals of *Damawī* temperament were more susceptible to *Ḍiḡ al-Nafas* (bronchial asthma) and *Ḥaṣāt al-Kulya* (nephrolithiasis) followed by *Balghamī* and *Ṣafrāwī* temperament.

#### New projects initiated

- Study on expression of miRNA 146a and complex Th1/17 cells in the treatment and disease pathogenesis of vitiligo
- Evaluation of *in-vitro* anti-psoriatic activity of a novel polyherbal Unani formulation by multiparametric analysis
- Effect of Unani formulation on diabetes mellitus in *in-vitro* studies on HepG2 cell line

#### Research-oriented Healthcare

##### General Outpatient Department (GOPD) Programme

The CCRUM undertakes GOPD Programme which also includes Geriatric OPD and RCH / MCH OPD. It is aimed at promoting, protecting and preserving public health through Unani Medicine. Besides, OPDs for Post-trial Treatment Access (PTA) is also conducted in order to provide treatment facility to the research patients after completing the trial. During the reporting period, this programme continued at National Research Institute of Unani Medicine (NRIUMSD), Hyderabad; Central Research Institute of Unani Medicine (CRIUM), Lucknow; Regional Research Institute of Unani Medicine (RRIUM), Chennai, Bhadrak, Patna, Aligarh, Mumbai, Srinagar, Kolkata and New Delhi; Regional Research Centre (RRC), Prayagraj and Silchar; Clinical Research Unit (CRU), Bengaluru, Bhopal, Burhanpur, Meerut, Kurnool and Edathala; Hakim Ajmal Khan Institute for Literary and Historical Research in Unani Medicine, New Delhi; AYUSH Wellness Centre, President's Estate, New Delhi; and All India Institute of Ayurveda, New Delhi. During the reporting period, a total of 2,82,859 patients comprising 2,30,762 patients in GOPDs, 18,361 in Geriatric OPDs, 4,915 in RCH/MCH OPDs, 9,263 in NCD's OPDs and 19,558 in OPDs for Post-trial Treatment Access (PTA) were treated at different centres. These patients were also assessed for their temperaments and various other factors responsible for occurrence of the disease, thus generating data for research feedback and Unani treatment was prescribed accordingly. These patients were treated with Unani pharmacopoeial formulations.

##### Mobile Clinical Research Programme

The Mobile Clinical Research Programme is aimed at providing healthcare to the population residing in rural areas, urban slums, scheduled caste and scheduled tribe pockets, besides reducing the disease burden in the society by creating health awareness among them. Under this programme, rural areas, urban slums and pockets predominantly inhabited by scheduled caste (SC) / scheduled tribe (ST) population with no medical facility are covered. CCRUM researchers visit the adopted pockets at regular intervals and provide free Unani treatment

to the patients at their door steps, and thus serve as a potential source of healthcare delivery to the masses. The cases of different ailments are referred to the CCRUM institutes/units as well as other hospitals for treatment of specific diseases or clinical research. Besides, health awareness is created among the population under coverage particularly the women and senior citizens through health lectures and group meetings on the preventive, promotive and curative health aspects based on the principles of Unani Medicine. They are also made aware of the therapeutic uses of medicinal plants growing in their vicinity in the management of different common/seasonal ailments.

During the reporting period, this programme continued at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad; Central Research Institute of Unani Medicine (CRIUM), Lucknow; Regional Research Institute of Unani Medicine (RRIUM), Patna, Mumbai, New Delhi and Srinagar; Regional Research Centre (RRC), Prayagraj; and Clinical Research Unit (CRU), Burhanpur and Kurnool. During the reporting period, 17 rural pockets/urban slums covering over 2.44 lakh population were covered. A total of 12,879 patients were treated with Unani pharmacopoeial formulations in 482 mobile visits made to these pockets. Predominant diseases as observed were rheumatoid arthritis, cough, fever, skin infections, joint pain, constipation, headache, dysentery, leucorrhoea, piles, etc.

#### 3.1.2.4. Literary Research Programme

Under the Literary Research Programme, the CCRUM published 'Adwiyā Kabidiyya: Qadeem-o-Jadeed Tahqiqat ki Raushni mein' and 'Riyad al-Adwiyā'. 'Adwiyā Kabidiyya: Qadeem-o-Jadeed Tahqiqat ki Raushni mein' is a compendium of classical and evidence-based Unani drugs acting on the liver in Urdu language. The compendium provides an account of Unani drugs useful in protection of the liver and treatment of its diseases. It presents timetested Unani prescriptions, useful Unani single drugs and classical formulations for liver diseases and evidence-based Unani single and compound drugs acting on the liver. 'Riyad al-Adwiyā' (Urdu translation) is an important Persian treatise by Yusuf bin Muhammad bin Yusuf, a 16<sup>th</sup> century Unani physician, on Unani single and compound drugs. It presents brief description of very important aspects of hundreds of Unani drugs. Easy availability in respect of single drugs and simplicity of pharmaceutical process in respect of formulations have been considered in their selection.

During the reporting period, Urdu translation of Arabic book 'Al-Masā'il fi'l-Ṭibb' was completed. Urdu translation of Arabic book 'Man lā yaḥḍuruhu al-Ṭabīb' and Urdu translation of Persian books 'Khulāṣat al-Tajārib' and 'Kitāb al-Abniya 'an Ḥaqqā'iq al-Adwiya' continued. English translation of Urdu book 'Intikhāb-i-Jalīl' also continued. Besides, work on the monographs on 'Ḥammām (bath) – An effective component of Regimenal Therapy of Unani Medicine' and 'Amrāḍ-i-Tanaffus (respiratory diseases) in Unani Medicine' also continued.

The work related to the WHO's project on international terminologies of Unani Medicine also continued during the reporting period. Revision of priority terms incorporating the comments and suggestions of experts from 'WHO Technical Experts Consultation Meeting' was completed. Further review of the terms, as required by the WHO, was also performed.

Under the project of 'National Systematised Nomenclature of Medicine Clinical Terms (SNOMED-CT) Extension for Unani Medicine', various works like collection and assortment of 12,021 Unani terms from classical Unani texts, identification of 11,507 terms relating to different hierarchies - disorders, findings, events, states of matter, qualifier value, procedure,

attribute, occupation, environment, physical object, regimen therapy, observable entity, products, medicinal products, organism, etc., e-prescription from SNOMED-CT browser, translation of 10,298 identified terms in three categories - fully specified name, preferred term and synonym, '1<sup>st</sup> India AYUSH Extension Release' of 1084 terms, '2<sup>nd</sup> India AYUSH Extension Release' of 4006 terms, '3<sup>rd</sup> India AYUSH Extension Release' of 5842 terms and '4<sup>th</sup> India AYUSH Extension Release' of 6446 terms were completed.

The work on developing high level structure and review of already existing structure of NAMASTE-P Unani diagnoses classification was completed besides continuing retrieval and compilation of NUMC data from NAMATE-P and developing ICD-11 Ayurveda-Siddha-Unani TM Module-2. Certain related works like development of template for revision of 'NUMC Version-1' as well as revision itself and development of subset of Unani Medicine under Clinical Trials Registry-India (CTRI) was completed.

Taking inspiration from the Ministry of Ayush campaign for "Ayush Aahar", the CCRUM compiled a booklet on 'Important Food Recipes in Unani Medicine'.

Information on the topics, veterinary medicine in Unani Medicine, '*Ilāj bi'l-Ghidhā*' (dietotherapy) and *Asbāb Sitta Ḍarūriyya* (six essential factors) was also compiled during the reporting period.

In the wake of COVID-19 pandemic, the researchers associated with literary research programme actively involved in dispensing AYUSH-64/Kabasura Kudineer to symptomatic - mild and moderate - COVID-19 patients in home isolation. They also compiled data for 'efficacy of AYUSH-64/Kabasura Kudineer to symptomatic - mild and moderate - COVID-19 patients in home isolation: a prospective multicentre community based study'. The researchers also performed tele-counselling in Unani Medicine for Ayush Covid-19 Helpline. Under the programme India@75, Azadi Ka Amrit Mahotsav, the researchers of literary research programme contributed in distribution campaign of prophylactic Ayush medicines and guidelines on diet and lifestyle with special focus on geriatric population along with distribution of medicinal plants.

### 3.2. Studies under IMR Policy

To utilize full potentials of the researchers working in the different centres and to conduct studies based on region-specific needs, the CCRUM has an Intramural Research (IMR) Policy. The policy aims to conduct studies in a time-bound manner. During the reporting period, the following studies under the IMR policy were conducted:

*Immunological study on Unani pharmacopoeial drugs Ma'jūn Jogrāj Gūgal and Rowghan Mālkanganī to validate their anti-inflammatory and anti-arthritic property in cases of Waja' al-Mafāṣil (rheumatoid arthritis)*

The study being conducted at NRIUMSD, Hyderabad aims to validate anti-inflammatory and anti-arthritic property of Unani pharmacopoeial drugs *Ma'jūn Jogrāj Gūgal* and *Rowghan Mālkanganī* in the cases of *Waja' al-Mafāṣil* (rheumatoid arthritis) by using specific biomarkers of rheumatoid arthritis.

The patients received *Ma'jūn Jogrāj Gūgal* 5 g orally twice daily with water after meals and *Rowghan Mālkanganī* was applied topically on the affected joint. The therapy duration was 84 days. The patients were followed-up clinically on every 14th day up to 84 days, whereas biomarker estimation was done at the baseline and at the end of the treatment.



During the reporting period, estimation of the immunological biomarkers, such as high sensitive C-reactive protein (Hs-CRP), IL-1 $\beta$ , IL-6, TNF- $\alpha$ , IL-11, and IL-17 from 30 patients and 10 from healthy volunteer samples was done by ELISA kits. The data was under analysis at the end of the reporting period.

#### *A comparative clinical study on Hijāma bi'l-Sharṭ (wet cupping) and Unani pharmacopoeial formulation Qurṣ Dawā' al-Shifā' in the management of Ḍaght al-Dam Qawī Ibtidā'ī (essential hypertension)*

A clinical study for evaluation of Unani pharmacopoeial formulation Qurṣ Dawā' al-Shifā' in the clinically stable patients of Ḍaght al-Dam Qawī Ibtidā'ī (essential hypertension) was done at RRIUM, Patna. The patients received Qurṣ Dawā' al-Shifā' 01 tablet twice daily with water after meals. The duration of the treatment was 06 weeks.

During the reporting period, 79 new patients were registered, whereas three patients continued from the previous year, bringing the total number of patients studied to 82. Of them, 37 patients completed the study. Out of the completed cases, 27 were relieved, 04 were partially relieved and 06 showed no response. A total of 26 patients dropped out and 19 were under study.

#### *Evaluation of a classical Unani formulation for putative anticancer activity*

A study to evaluate the anti-cancer potential of a Unani formulation containing *Terminalia chebula* Retz., *Cuscuta reflexa* Roxb., *Polypodium vulgare* L., *Lavandula stoechas* L., *Picrorhiza kurroa* Royle ex Benth., *Agaricus albus* Schaeff., and *Milḥ Naftī* (Kālā Namak) was conducted during the reported period. The polyherbal Unani formulation (PUF) along with its individual ingredients was subjected to preliminary phytochemical screening (qualitative analysis) for different phytochemical constituents like alkaloids, phenols, flavonoids and glycosides. Further, quantitative analysis was performed for total flavonoids using aluminum chloride colorimetric assay and total phenols were analysed by Folin-Ciocalteu method. Antioxidant assay on PUF was performed using DPPH free radical scavenging method.

#### *Preclinical efficacy and safety of a polyherbal Unani formulation for dengue*

A preclinical study to evaluate the anti-pyretic, analgesic, anti-inflammatory, anti-thrombocytopenic and immunomodulatory potential of a polyherbal Unani formulation for dengue (PUFD) was conducted during the reported period. Preliminary phytochemical screening (qualitative analysis) of the polyherbal Unani formulation for dengue was conducted for different phytochemical constituents like alkaloids, phenols, flavonoids and glycosides. Further, quantitative analysis was performed for total flavonoids using aluminum chloride colorimetric assay and total phenols were analysed by Folin-Ciocalteu method. Antioxidant assay of PUFD was performed using DPPH free radical scavenging method.

Acute oral toxicity on PUFD was evaluated in rats as per the limit test method of the OECD Test Guideline 425. Dose range finding study on PUFD was conducted in rats in order to select doses for animal experiments. Repeated dose 28-day oral toxicity study on PUFD was in progress in rats as per the OECD Test Guideline 407. Rats were being treated at three dose level of PUFD and regularly observed for mortality and behavioural signs of toxicity (if any), body weight changes, feed consumption and other parameters. Anti-pyretic and anti-inflammatory activity of PUFD was also performed in rats during the reporting period. The study was in progress.

### Evaluation of the efficacy of a Unani regimen *Iṭṛīfāl Sanaī, Naṭūl* (irrigation) and *Dalk* (massage) by *Rowghan-i-Kaddū* in *Shaqīqa* (migraine without aura) and its effect on serum biomarkers

A study for evaluation of the efficacy of a Unani regimen *Iṭṛīfāl Sanaī, Naṭūl* (irrigation) and *Dalk* (massage) by *Rowghan-i-Kaddū* in *Shaqīqa* (migraine without aura) and its effect on serum biomarkers was carried out at RRIUM, Srinagar. During the reporting period, a total of 66 patients were enrolled in the study. Out of them, 46 patients completed the study, 17 dropped out, and 3 patients were under study. Out of the completed cases, 26 patients got complete relief, 11 patients got partial relief and 9 patients did not get relief from signs and symptoms of migraine. The study drug was found well-tolerated and no adverse effect was reported in the patients.

### Effect of Unani formulation *Qurṣ Ḥudār* on serum biomarkers in patients with rheumatoid arthritis

A study to evaluate the effect of Unani formulation *Qurṣ Ḥudār* on serum biomarkers in the patients of rheumatoid arthritis was carried out at RRIUM, Srinagar. The patients were divided into two groups. The test group received Unani formulation *Qurṣ Ḥudār* one tablet twice daily with water after meals, whereas the control group comprised of healthy volunteers who did not receive any medication. The total duration of the treatment was 6 weeks.

During the reporting period, 38 patients were screened in the test group and 29 patients were registered. Of them, 26 completed the trial and good response was observed in 12 patients, moderate response in 11 patients and no response was observed in 3 patients. Three patients dropped out of the study. The number of control subjects was 26 and their samples were evaluated for biomarker analysis. The biochemical biomarkers evaluated that rheumatoid arthritis patients have high levels of anti-CCP, IL6, TNF-alpha receptor and CXCL as compared to healthy controls. Moreover, preliminary analysis revealed that Unani formulation *Qurṣ Ḥudār* showed effect on these biomarker levels.

## 3.3. Collaborative Research

### Evaluation of *Aftīmūn* (*Cuscuta reflexa* Roxb.) plant and seeds on different human cancer (*Saraṭān*) cell lines

A study on evaluation of *Aftīmūn* (*Cuscuta reflexa* Roxb.) plant and seeds on different human cancer (*Saraṭān*) cell lines was carried out at the Department of Chemistry, Jamia Millia Islamia, New Delhi. The plant extracts showed greater anticancer activities in breast cancer cell lines as well as lung cancer cell lines as compared to fractions obtained from extracts using flash chromatography.

### Delineating the anti-cancer potential and the mechanism of action of Unani medicinal formulation *Iṭṛīfāl Aftīmūn* in chronic myelogenous leukemia

A study to evaluate the potential of Unani pharmacopoeial formulation *Iṭṛīfāl Aftīmūn* in chronic myelogenous leukemia (CML) was carried out at the All India Institute of Medical Sciences, New Delhi.

The study showed that *Iṭṛīfāl Aftīmūn* possesses anti-tumor potential *in vitro*. The standard drug, imatinib, was found effective when used in combination with *Iṭṛīfāl Aftīmūn* even at lower doses, which suggests the utilization of this formulation as an adjuvant therapy for the better management of CML. A pilot clinical trial of *Iṭṛīfāl Aftīmūn* was going on in CML patients to check the efficacy of the formulation.



### Effect of Unani preparations on macrophage polarization and its role in increased browning of fat leading to amelioration of insulin resistance

A study to evaluate the effect of Unani preparations on macrophage polarization and its role in increased browning of fat leading to amelioration of insulin resistance was carried out at Jamia Hamdard, New Delhi.

During the reporting period, the objectives i.e. insulin assay, OGTT of standard diet and HFD fed mice with relative expression of markers for browning of fat were carried out.

### Phytochemical standardization and evaluation of anti-cancer and immune-modulatory activity of Unani formulation *Iṭṛīfāl Ghudadī*

A study to evaluate the anti-cancer and immune-modulatory effect and phytochemical standardization of Unani formulation *Iṭṛīfāl Ghudadī* was carried out at the Interactive Research School for Health Affairs, Pune, Maharashtra.

### Pharmacokinetics, stability and quality control studies of *Iṭṛīfāl*'s in Unani Pharmacopoeia of India (part II, vol. I & II) using chromatographic analysis by HPTLC and LC-MS

A study to evaluate the pharmacokinetics, stability and quality control studies on *Iṭṛīfāl*'s of Unani Pharmacopoeia of India (part II, vol. I & II) using chromatographic analysis by HPTLC and LC-MS was carried out at the Department of Pharmacognosy and Phyto-chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The main objective of the study is to develop quality control methods using HPTLC and GC-MS and to analyze metabolites present in them for their stability and pharmacokinetic profile.

### Identification of anti-dengue viral compounds from Unani medicinal plants and formulations

A study to evaluate anti-dengue viral compounds from Unani medicinal plants and formulations was initiated at the Institute of Molecular Medicine, School of Interdisciplinary Sciences, Jamia Hamdard, New Delhi. The main objective of the study is to prepare the drugs as per Unani Pharmacopoeia and to evaluate their potential anti-viral activities against dengue infection.

### *In vitro* evaluation of antiviral activity of Unani drugs and their green nanoparticles against dengue virus

A study for *in vitro* evaluation of antiviral activity of Unani drugs and their green nanoparticles against dengue virus was started at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi.

### Preclinical evaluation of UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM-004 and UNIM-005 for their efficacy against experimentally induced vitiligo in mice

A study for preclinical evaluation of UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM-004 and UNIM-005 for their efficacy against experimentally induced vitiligo in mice was initiated at the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad.

### Reverse pharmacology of *Asrin* and *Dawā' al-Shifā'* to evaluate their anti-hypertensive efficacy, safety and mechanism of action

A study for reverse pharmacology of *Asrin* and *Dawā' al-Shifā'* and to evaluate their anti-hypertensive efficacy, safety and mechanism of action was carried out at the Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow. The objective of the study is to generate scientific evidence for clinical efficacy of antihypertensive Unani formulations

as well as to envisage demonstration of anti-hypertensive and cardio-protective activity and safety by using various in vitro assays and rat model of hypertension.

#### Investigating and validation of the molecular mechanism of Unani medicines *in-vitro* and *in-vivo* for the treatment of atopic dermatitis

A study to evaluate anti-inflammatory properties of *Barg-i-Shāhtara*, *Bābchī*, *Bādām Shīrīn*, *Tukhm-i-Khurfa* and *Halela Siyāh* was carried out at the Faculty of Life Science and Technology, South Asian University, Chanakyapuri, New Delhi. The main objective of the study is to evaluate the anti-atopic dermatitic properties as well as molecular mechanism of the aforesaid Unani medicines in *in-vitro* and *in-vivo* models.

#### Drug proving studies, mechanistic insight and development of novel drug delivery systems of UNIM-H and UNIM-R used in the treatment of arthritis in Unani Medicine

A study to evaluate phytochemical standardization and HPTLC fingerprint studies of UNIM-H & UNIM-R by MTT assay, DPPH, FRAP, NO, LPO and elucidation of mechanism of anti-inflammatory and anti-arthritic activity of the selected drugs was carried out at the Department of Life Sciences, University of Mumbai. The objective of the study is to develop new drug delivery system using UNIM-H and UNIM-R for arthritis.

#### Pharmacological studies on the probable mechanism of action of *Khamīra Ga'ūzabān Sāda* (KGS) in the management of hypertension, involving quality control and formulation optimization studies for this age old Unani preparation

A study to evaluate the pharmacological studies on *Khamīra Ga'ūzabān Sāda* in the management of hypertension involving cardiac function and development of quality control standards and formulation optimization studies for the test drug was carried out at the Department of Pharmaceutical Technology, Jadavpur University, Kolkata.

#### Targeting Alzheimer's disease by a mixture of Unani plant extract via modulation of human kinase

A study to evaluate the efficacy of Unani plant extract in Alzheimer's disease was carried out at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi. The main objective of the study was to identify potent kinase inhibitors in the extract of mixture of Unani medicine plant extract.

#### Evaluation of anti-oxidant and anticancer effect of Unani medicine against liver cancer - A preclinical study

A study to evaluate hepato-protective and antioxidant activities of aqueous extract of herbs followed by formulation of extract into *Qurs*/suitable Unani formulation (UNIM-HC-I) was carried out at the School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The main objective of the study was to prevent tumor promotion by natural phytochemicals range from the inhibition of genotoxic effects, increased antioxidants and anti-inflammatory activity, inhibition of proteases and cell proliferation.

#### Elucidating the therapeutic potential of a Unani formulation in glaucoma

A study to validate the therapeutic potential of a Unani formulation in glaucoma was conducted at the Department of Ocular Biochemistry, All India Institute of Medical Sciences, New Delhi. The main objective of the study is to provide a substantial molecular/scientific evidence to prove efficacy of the proposed Unani formulation by targeting both TM and RGCs of glaucoma in scientific manner in a preclinical study and thus to ensure low cost, safer formulation having negligible side effects for the treatment of glaucoma.

#### Determination of anti-aging and antioxidant potential of a Unani formulation

A study to evaluate anti-aging and antioxidant potential of a Unani formulation was initiated at the Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi. The main objective of the study is to investigate the cytotoxic effects of the formulation *in-vitro* and to assess the immunomodulatory effects of the formulation.

#### Redesigning and pharmacological evaluation of some classical Unani formulations with specific reference to immune-modulatory activity, safety profile and stability studies

A study for redesigning and pharmacological evaluation of some classical Unani formulations was initiated at Department of Pharmacognosy and Phyto-chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The main objectives of the study was to compare developed classical Unani formulations with their sugar free capsules on the basis of *in vitro* and *in vivo* immunomodulatory activity and also to compare safety profile and stability studies of classical Unani formulations with their sugar free capsules.

#### Evaluation of immune modulatory and antioxidant potential of a Unani formulation

A study to validate the immune modulatory and antioxidant potential of a Unani formulation was conducted at the Department of Ocular Biochemistry, All India Institute of Medical Sciences, New Delhi. The main objective was to extract and identify the active components from the Unani formulation, investigate the cytotoxic effects of the formulation *in-vitro*, determine the anti-aging activity as well as to evaluate the immunomodulatory effects of the formulation.

#### Investigation of hepatoprotective activity of Unani formulations with emphasis on alleviation of antitubercular drugs' induced hepatotoxicity: Elucidation of molecular mechanism

A study to investigate the hepato-protective activity of Unani formulations was initiated at the Department of Pharmacognosy and Phyto-chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The main objective is to evaluate the pharmacokinetic profile of anti-TB drugs in co-administration with Unani formulations.

#### Evaluation of neuro protective potential of *Ma'jūn Nisyān*: A mechanistic study

A study to look into neuro protective potential of *Ma'jūn Nisyān* was initiated at Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai. The main objective of the study is to establish the proof of concept for the efficacy of Unani formulation and explore its mechanism of action in Alzheimer's disease.

#### Development of sugar free dosage forms, quality control and pharmacological evaluation of *Khamīra Banafsha*, *Khamīra Āabresham*, *La'ūq Katān*, *Sharbat Tūt Siyāh*, *La'ūq Sapistān* and *Sharbat Zūfā*

A study to explore quality control and pharmacological evaluation of above-mentioned Unani formulations was initiated at the Department of Pharmacognosy and Phyto-chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. The main objective is to develop sugar free dosage forms and to perform marker analysis.

### 3.4. Publications

#### 3.4.1. Books, Monographs, Reports, etc.

During the reporting period, the CCRUM brought out the following books, monographs and reports, etc.:

- Orientation Guidelines for Community Health Officers (Under Unani Stream) of AYUSH Health and Wellness Centres
- Advanced Analytical Methods for Quality Control of Unani Drugs – *Araqiyat* (Distillates)
- *Reyāḍ al-Adwiya* (Urdu translation)
- *Adwiya Kabidiyya: Qadeem-o-Jadeed Tahqiqat ki Raushni mein*
- Glimpses of Activities and Achievements of Central Council for Research in Unani Medicine
- Antiarthritic Plants of Unani Medicine
- Hepatoprotective Plants of Unani Medicine
- Important Food Recipes in Unani Medicine
- CCRUM Annual Report – 2020-21 (English)
- CCRUM Annual Report – 2020-21 (Hindi)
- Souvenir - Unani Day 2022 & International Conference on Unani Medicine
- Prevention and Control of *Siman Mufrit* (Obesity) through Unani Medicine (English)
- Prevention and Control of *Siman Mufrit* (Obesity) through Unani Medicine (Hindi)
- Prevention and Control of *Siman Mufrit* (Obesity) through Unani Medicine (Urdu)
- Prevention and Control of *Ḍaghṭ al-Dam Qawī* (Hypertension) through Unani Medicine (English)
- Prevention and Control of *Ḍaghṭ al-Dam Qawī* (Hypertension) through Unani Medicine (Hindi)
- Prevention and Control of *Dhayābīṭus Sukkarī* (Diabetes Mellitus) through Unani Medicine (English)
- Prevention and Control of *Dhayābīṭus Sukkarī* (Diabetes Mellitus) through Unani Medicine (Hindi)
- Prevention and Control of *Dhayābīṭus Sukkarī* (Diabetes Mellitus) through Unani Medicine (Urdu)

#### 3.4.2. Journals / Periodicals

During the reporting period, the CCRUM published the following periodicals:

- Hippocratic Journal of Unani Medicine, Volume-15, Number-3
- Hippocratic Journal of Unani Medicine, Volume-15, Number-4
- Jahan-e-Tib, Volume-22, Issue-3
- Jahan-e-Tib, Volume-22, Issue-4
- CCRUM Newsletter, Volume-41, Number-2
- CCRUM Newsletter, Volume-41, Number-3
- CCRUM Newsletter, Volume-41, Number-4

#### 3.4.3. Research Papers

During the reporting period, the following research papers authored by the CCRUM officers were published in reputed national and international journals:

- Abid, M., Khan, S., & Khan, N. (2020). Current treatment practices for dyslipidemia prevalent in Ayush Systems of Medicine. *European Journal of Pharmaceutical and Medical Research*, 7(10), 255–260.
- Abid, M., Khan, S., Khan, N., Nazli, T., & Sajid, M. (2021). Concept of *Zaght al-Dam-Qawi* (Hypertension) and its management modalities in Unani system of medicine. *Journal of Integrated Community Health*, 10(1), 11–16.
- Abid, M., Shazia, H., Khan, S., Nazli, T., & Mahto, R. R. (2021). Effect of *Hijamah* (Dry Cupping) on frozen shoulder: A case study. *Journal of Advance Research in Ayurveda, Yoga, Unani, Sidhha & Homeopathy*, 8(1&2), 14–17.
- Afreen, S., Bari, B., Bari, H., & Khan, M. N. (2022). *Warm-e-Kabid* (Hepatitis) its causes management in Unani medicine. Souvenir, *Unani Day 2022, 1st Edition*, 34–39.
- Afza, S. Khan, P., Rehman, S., Ayub, S., Singh, R., Verma, R. S., Akhtar, J., & Khan, A. A. (2021). Comparative study of efficacy and safety of Unani coded drug UNIM-904 with allopathic drug Amlodipine in the treatment of essential hypertension. *International Journal of Unani and Integrative Medicine*, 5(1), 01–08.
- Ahmad, F., Khatoon, S., Ahmad, M., Alam, M. M., & Imam, H., Parveen, S., Nazli, T., Raheem, A., Goswami, A., & Alam, M. I. (2021). Socio-demographic and Health Profile of Scheduled Castes of Patna, Vaishali and Nalanda Bihar, India. *International Journal of Preventive, Curative & Community Medicine*, 7(1), 11–19.
- Ahmad, F., Naime, M., Salam, M., Rauf, E., Khatoon, A., & Khan, M. N. (2022). Erythrocyte sedimentation rate (ESR) in rheumatoid arthritis. *World Journal of Pharmaceutical Sciences*, 11(1), 1999–2005.
- Ahmad, K., Ahmed, N. Z., Ezhil, R., Anjum, N., & Khan, A. A. (2021). Evaluation of analgesic effect of unanipharmacopoeial formulation *Habb-e-Suranjan* and *Raughan-e-Suranjan* in *Wajaul Mafasil* (joints pain) patients: an open prospective clinical trial. *Journal of Drug Delivery & Therapeutics*, 11(2-s), 44–49.
- Ahmad, Z., Azhar, M., & Mustehasan. (2021). Palmar plaque psoriasis successfully treated with Unani medicine: A case study. *International Journal of Advances in Pharmacy Medicine and Bioallied Sciences*, 9(2), 51–56.
- Ahmed, A. I. U. A. M., Qamaruddin., Ismail, B. A., & Juveria, J. (2022). Etiopathogenesis and management of *Waja-al-Mafasil* (Rheumatoid Arthritis) an evidence based comprehensive review. *International Journal of Ayurveda and Pharm.*, 12(6), 96–103.
- Ahmed, N. Z., Agibothu Kupparam, H. K., Akbar, S., Hissar, S., Anwar, N., Thiruvengadam, K., Anjum, N., Khan, A. A., Dar, S., & Natarajan, S. (2021). Effects of co-administration of Unani pharmacopoeia formulations *Qurs Tabasheer Sartani* and *Arq Hara Bhara* with CAT-I antitubercular drugs in rats. *Journal of complementary & integrative medicine*, 18(3), 517–525. <https://doi.org/10.1515/jcim-2020-0262>
- Ahmed, N. Z., Ahmed, K., Anwar, N., Ezhil, R., Anjum, N., & Khan, A. A. (2020). Lithotriptic effect of *Safuf Hajar-al Yahud* in patients of *Hasat-ul Kilya* (Nephrolithiasis) – an open prospective clinical validation trial. *J Complement Integr Med*, 18(1), 139–146. <https://doi.org/10.1515/jcim-2019-0301>
- Ahmed, N. Z., Anwar, N., Begum, S., Parvez, A., Ezhil, R., & Anjum, N. (2021). Effect of *Hijama* (wet cupping), *Dalk* (massage) & *Bukhur* (medicated steam) in amelioration of *Waja al-Zahr* (non-specific low back pain) – an open prospective clinical trial. *Journal of Complementary and Integrative Medicine*, 10.1515/jcim-2021-0099. Advance online publication. <https://doi.org/10.1515/jcim-2021-0099>



- Ahmed, N. Z., Davis, G. D. J., Anwar, N., Khan, A. A., Meena, R. P., Afnaan, Z., & Sri, M. D. (2021). In-Silico Evaluation of *Tiryag-e-Wabai*, an Unani Formulation for its Potency against SARS-CoV-2 Spike Glycoprotein and Main Protease. *Journal of Drug Delivery & Therapeutics*, 11(4-S), 86–100.
- Ahmed, N. Z., John Davis, G. D., Khan, A. A., Prabhakar, L., Ram Paratap, M., Afnaan, Z., Devi Sri, M., & Anwar, N. (2021). Arq Ajīb - a wonder Unani formulation for inhibiting SARS-CoV-2 spike glycoprotein and main protease - an *in silico* approach. *Journal of complementary & integrative medicine*, 10.1515/jcim-2021-0241. Advance online publication. <https://doi.org/10.1515/jcim-2021-0241>
- Ain, Q., Nawab, M., Ahmad, T., Kazmi, M. H., Naikodi, M. A. R. (2022). Evaluating the safety and efficacy of a polyherbal Unani formulation in dyslipidaemia-a prospective randomised controlled trial. *Journal of Ethnopharmacology*, *Journal of ethnopharmacology*, 289, 115036. <https://doi.org/10.1016/j.jep.2022.115036>
- Alam, A., Siddiqui, J., Viquar, U., Naikodi, M. A. R., & Ahmad, I. (2022). The traditional uses, phytochemistry, pharmacological, and botanical description of *Quercus infectoria* galls (Mazuphal): A review. *Journal of Drug Delivery and Therapeutics*, 12(1), 214–221.
- Alam, K., Nawab, M., & Kazmi, M. H. (2021). A randomized controlled clinical study to evaluate efficacy and safety of a topical Unani formulation in the management of *Nār Fārsī* (Eczema). *Indian Journal of Traditional Knowledge*, 20(3), 644–650.
- Alam, M., Alam, I., Salam, M., Sehar, N., Goswami, A., Ahmad, M., Rajesh., Imam, H., Parveen, A., & Bano, S. (2021). Clinical validation of Unani pharmacopoeial formulation *Majoon-e-Suparipak* in *Sayalān al-Rahim* (Leucorrhoea). *Research & Reviews: Journal of Unani, Siddha and Homeopathy*, 8(2), 28–35.
- Anas, M., Husain, G. M., Ahmed, T., Viquar, U., Naikodi, M. A. R., Minhajuddin, A., Javed, G., & Zakir, M. (2022). Antidiabetic activity of a Unani formulation in nicotinamide-streptozotocin-induced diabetic Rats. *SSRN Electronic Journal*, 10.2139/ssrn.4032377.
- Anas, M., Zakir, M., Maseehullah, M. D., & Kazmi, M. H. (2021). Ethno-Pharmacological Profile of *Corallium Rubrum* L., An important marine drug, in the Unani system of medicine. *Natural Product Science*, 27(2), 61–67.
- Anju., & Javed, G. (2021). *Sharbat-e-Unnab*: A review on potent Unani formulation. *Journal of Drug Delivery & Therapeutics*, 11(3-s), 142–144.
- Ansari, A. P., Sana, S. H., Dar, M. Y., Goswami, P., & Ahmed, N. Z. (2021). Validation of Unani concept of *Abadāl-i-Adwiya* (drug substitution) by physicochemical standardization and hepatoprotective activity of *Aristolochia rotunda* Linn. and its substitute *Curcuma Zedoaria* Rosc. in albino Wistar rats. *Journal of complementary & integrative medicine*, 10.1515/jcim-2020-0378. Advance online publication. <https://doi.org/10.1515/jcim-2020-0378>
- Ansari, S. A., Khan, A. S., Meena, R. P., Asif, M. (2022). Pharmacognostical and HPTLC studies of *Habb-e-Hindi Sual* – A traditional Unani formulation. *European Journal of Biomedical and Pharmaceutical Sciences*, 9(4), 541–552.
- Ansari, U. A. M. A., Qamaruddin., Juveria, J., Ismail, B. A. (2021). Effect of poly herbal Unani drug in Rheumatoid Arthritis. Management. A case study, *International journal of AYUSH Case Reports*, 5(4), 277–282.
- Anwar, N., Ahmed, N. Z., & Begum, S. (2021). Plausible role of *Arq Ajīb* in combating COVID-19: A multi-faceted review. *Journal of Drug Delivery & Therapeutics*, 11(4), 141–148.



- Ara, I., Bukhari, B., Kousar., & Rasool, S. (2021). Efficacy of herbal drugs *Habb-e-Bawaseer* and *Marham Hina* in haemorrhoids. *European journal of pharmaceutical and medical research*, 8(4), 458–461.
- Ara, M. I., Kalam, M. A., Maqbool, M., & Zehravi, M. (2021). Phytochemical standardization and anti-anxiety (*Izterab-e-Nafsani*) study of *Aftimoon Hindi* (*Cuscutareflexa* Roxb.) on An animal. *CellMed*, 11(3), e14.
- Ara, S. A., Viqar, U., Zakir, M., Husain, G. M., Naikodi, M. A. R., Urooj, M., & Kazmi, M. H. (2021). TLC, HPTLC fingerprinting and acute oral toxicity evaluation of Habb-e-Azaraq: A nux-vomica-based traditional Unani formulation. *CellMed*, 11(3): e13.
- Azeem, M., A., Salam, M., Khan, M. N. (2021). Phytochemical and pharmacological studies and evidence-based indications of *Babuna* (*Matricaria Chamomillal.*): A review. *Ayushdhara*, 8(6), 3700–3708.
- Azhar, M., & Ahmad, Z. (2021). Effect of coded Unani formulation UNIM-401 and Soranil with NB-UV-B therapy in a case of chronic Palmo-plantar plaque psoriasis- A case study. *International Journal of Ayush Case Reports (IJA-CARE)*, 5(2), 71–77.
- Azhar, M., & Mustehasan. (2021). Medical Importance of Aabnoos (*Diospyrosebenum Koeing*): A Review. *International Journal of Advances in Pharmacy Medicine and Bioallied Sciences*, 9(2), 62–67.
- Azhar, M., Ansari, R. I., Ayub, S., Anjum, N., & Rej, A. (2021). A study on patients drop-out in Unani pharmacopeial validation of an anti-obesity drug. *Journal of Pharmacovigilance and Drug Safety*, 18(1), 2–7.
- Azhar, M., Ayub, S., & Mustehasan. (2021). *Bābchī* (*PsoraleaCorylifolia* Linn.) Unani medicinal plant-a possible therapeutic candidate for covid syndrome. *Indo American Journal of Pharmaceutical Sciences*, 08(07), 78–93.
- Azhar, M., Ayub, S., & Mustehasan. (2021). Bio-active compound and pharmacology of Atees (*Aconitum heterophyllum* Wall.)- A Unani drug. *Indo American Journal of Pharmaceutical Research*, 11(06), 1720–1726.
- Azmi, F., & Bano, H. (2022). Respiratory infectious disease and the COVID-19 pandemic: A review of medieval Unani medical literature. *Journal of Natural Remedies*, 22(1), 01–11. <https://doi.org/10.18311/jnr/2022/26624>
- Bano, H., Urooj, M., & Qureshi, M. A. (2021). Management of Acne in Unani system of medicine: A case report. *Journal of Medicine and Healthcare*, 3(4), 1–3.
- Bashir, F., Akhtar, J., Anjum, N., & Alam, S. (2021). *Banafsha* (*Viola odorata* L.), an important drug of Unani system of medicine with recent advances. *International Journal of Unani and Integrative Medicine*, 5(2), 73–78.
- Chaithra, D., Venkatesham, B., Nazeer, M., Naikodi, M. A. R., Siddiqui, A., Siddiqui, J. I., & Minhajuddin, A. (2021). Ethnomedicinal uses and therapeutic potential of some selected medicinal plants: A review. *Journal of Phytonanotechnology and Pharmaceutical Science*, 1(2), 25–32.
- Chisht, D. K. (2020). Glycirrhizaglabra (Liquorice): Astounding medical benefits. *Paripex - Indian Journal of Research*, 9(7), 71–73.
- Chisht, D. K. (2020). Incredible Medicinal Uses of Black Pepper: A view. *Paripex - Indian Journal of Research*, 9(7), 69–70.

- Fatima, S. H., Ahmad, T., Latha, S., Javed, G., & Minhajuddin, A. (2022). A study of anemia profile in a research hospital in Telangana, South India. *International Journal of Advances in Medicine* 9(3), 273–277.
- Fatima, S. H., Ahmad, T., Latha, S., Minhajuddin, A., & Javed, G. (2021). Prevalence of dermatophytosis in south Indian populations: A research hospital based study. *International Journal of Tropical Disease & Health*, 42(21), 41–47.
- Fatima, S. H., Shashikala., Sreedhar, V., Viqar, U., & Minhajuddin, A. (2021). A study of Her-2/Neuoncogene expression in benign and malignant endometrial lesions and its association with clinicopathologic variables. *IP Arch Cytol Histopathol Res*, 6(4), 255–262.
- Ghali, S. K., Chakraborty, A., Pallapolu, P., Rafeeqi, T. A., Hussain, G. M., Javed, G., Waheed, M. A., & Kazmi, M. H. (2021). Expression of MITF Gene in Melanogenesis with *Psoralea corylifolia*, *Zingiber officinale*, *Terminalia chebula*, *Punica granatum* and *Eclipta alba* based on Poly-Herbal Formulation. *Journal of Biologically Active Products from Nature*, 11(2), 82–96.
- Husain, G. M., Ahmad, T., Fatima, S. H., Javed, G., Kazmi, M. H., & Urooj, M. (2021). 90-Days repeated dose oral toxicity study of *Sharbat-e-Deenar* (a hepato-protective Unani herbal formulation). 6(1), 5–18.
- Husain, G. M., Urooj, M., Mustehsan., Javed, G., Kumar, P., & Kazmi, M. H. (2020). Beneficial Effect of *Qurs-e-Damavi*, A traditional Unani formulation in cyclophosphamide induced haematological perturbations in Rats. *Advances in Complementary & Alternative Medicine*, 6(2). 576–592.
- Husain, M. T., & Islam, A. (2022). Pharmaco vigilance in ASU and H drugs standard in health care. *International Journal of recent advances in multidisciplinary topics*, 3(1), 2582–7839.
- Husain, M. T., Islam, A., & Khan, N. (2021). *Su-al-Qiniya* (Aneamia) and its management in Unani Medicine. *Peripex Indian Journal of Research*, 10(12), 2250–1991.
- Husain, M. T., Khan, N., & Sajid, M. (2022). *Nazla* and *Muzmin* and its management in Unani system of medicine. *Peripex Indian Journal of Research*, 11(1), 2250–1991.
- Hussain, N., Qamruddin., Kazmi, M. H., & Khalid, M. (2021). A non inferiority randomized controlled clinical trial comparing unani formulations & PUVA sol in non-segmental vitiligo. *Journal of Complementary and Integrative Medicine*, 10.1515/jcim-2021-0057. Advance online publication. <https://doi.org/10.1515/jcim-2021-0057>
- Jahan, F., Tanveer., Viqar, U., Ahmad, N., Minhajuddin, A. (2021). Ethnopharmacology of *Rumex vesicarius* Linn. (*Hummaz*) and it's importance in Unani system of medicine. *Ijppr.Human*, 23(1), 58–69.
- Jamali, M. A. H., Siddiqui, U., Amir, M., Khan, S. A., Alam, M. M., & Mustehasan. (2021). *Marjan* (Coral) for containment of COVID-19 in Unani medicine. *Indian Journal of Unani Medicine*, 14(2), 114–122.
- Jameela, M., Meena, R., Khan, M. M. A., Jamil, S. S., & Khan, A. A. (2021). Comparative physicochemical and histo-anatomical study of vague traditional and magical herb *Lavandulastoechas* L. with *Lavandula officinalis* Chaix. *Indian Journal of Traditional Knowledge*, 20(3): 723–730.

- Kalam, M. A. (2021). Chinar ke Aushadhiya Gun. *Vigyan Pragati, NISCARE*, 48(05), 69–70.
- Kalam, M. A. (2021). *Zumurrud* (Emerald): medicinal potential of a gemstone from *Jawahar-i-Tis'a* (Navratan) in the perspective of Unani medicine. *Perspective of Unani Medicine*, 8(1&2), 1–5.
- Kalam, M. A., & Alam, T. (2021). Management of Non-Healing ulcer with topical application of *Marham-i-Asal*: A casestudy. *Int. J. of Ayush Case Report*, 5(2), 78–83.
- Kalam, M. A., & Habeeb, A. (2021). *Gul-i-Aftabparast* (*Helianthus annuus* L.): An under exposed, useful flower of Unani medicine having nutraceutical and medicinal properties. *Acta Scientific Pharmaceutical Sciences*, 5(7), 117–123.
- Kalam, M. A., & Noor, A., & Huma. (2021). Gilo (*Tinosporacordifolia*): A wonder drug of Unani system of medicine. *Indian Journal of Unani Medicine*, 14(1), 1–8.
- Khan, A. A., Meena, R., Raiza, J., Sri, P. M. D., Mageswari, S., Subhani, S., Akhtar, J., Anjum, N., & Ahmed, N. Z. (2021). Pharmacopoeial and In-silico studies of Unani *Joshanda*: A potent drug for management of Infectious diseases. *International Journal of Herbal Medicine*, 9(6): 32–49.
- Khan, A. A., Meena, R., Sri, M. D., Davis, D. J., Ahmed, N. Z., Mageswari, S., Raiza, J. A., Subhani, S., & Selvarani, R. (2021). Antimicrobial, HPTLC and in-Silico Studies of *Habb-e- Bukhar*– widely used in Unani System of Medicine. *International Journal of Recent Scientific Research*, 12(08), 42788–42793.
- Khan, A. A., Parveen, N., Raza, R., Akbar, S., Lari, H. A., Khan, P., Fazil, M., Javed, G., Kumar, P., Meena, R. P., Akhtar, J., Anjum, N., Urooj, S., Rej, A., & Mumtaz, S. (2021). Effectiveness and outcome of Unani medicine interventions on population at risk of COVID-19. *Annals of Phytomedicine*, 10(2), S5–S11.
- Khan, A. S., Ansari, S. A., Ahmed, F., Negi, K., Alvi, A. I., & Mirza, A. (2021). Physicochemical and HPTLC studies of *Qurs-e-Mulaiyin* – A potent Unani laxative. *European Journal of Biomedical and Pharmaceutical Sciences*, 8(6), 506–513.
- Khan, A. S., Ansari, S. A., Sajwan, A., Sagar, P. K., Ahmed, R., Hashmi, S. A. A. (2022). Pharmacognostical and HPTLC evaluation of *Jawarish-e-Ood Tursh*: An anti-emetic Unani formulation. *European Journal of Biomedical and Pharmaceutical Sciences*, 9(1), 431–443.
- Khan, M. F., Siddiqui, S., Zia, Q., Ahmad, E., Jafri, A., Arshad, M., Jamal, A., Alam, M. M., Banawas, Alshehri, B. A., Baazeem, A., Althobaiti, F., Ansari, A. H., & Mohammadi, A. A. (2021). Characterization and in vitro cytotoxic assessment of zinc oxide nano-particles in human epidermoid carcinoma cells. *Journal of Environmental Chemical Engineering*, 9, 105636.
- Khan, M. N., Salam, M., Arshad, M., Siddiqui, Z. H., Sehar, N., Ahmad, F., Naime, M., Azeem, M. A., Akhtar, J., & Goswami, A. (2021). Clinical validation of Unani pharmacopoeial formulation *Qurs-e-Dīdān in Dīdān al-Am'ā'* (Intestinal Worms). *Ayushdhara*, 8(6), 3607–3615.
- Khan, N. (2020). Acne vulgaris (*Busoor-e-Labaniya*) with references to Unani medicine: Review. *Paripex - Indian Journal of Research*, 9(4), 57–59.

- Khan, N., Abid, M., & Raza, R. (2020). Prevention and management of *Ziabetus Shakari* (Diabetes Mellitus) through Unani system of medicine: An overview. *Paripex - Indian Journal of Research*, 9(8), 122–124.
- Khan, N., Abid, M., Sajid, M., & Raza, R. (2020). *Saman-e-Mufrit* (Obesity): Prevention and control through Unani system of medicine. *International Journal of Pharmaceutical and Medicinal Research*, 8(4), 1–4.
- Khan, N., Raza, R., & Khan, R. (2021). Unani Medicine- A Guiding tool for the management and control of *Su-al Qiniya* (Anaemia). *Paripex - Indian Journal of Research* 10(03), 225–227.
- Khan, P., Bano, H., Verma, R. S., Rehman, S., Ayub, S., Devi N. M. K., Singh, R., Afza, S., Akhtar, J. & Khan, A. A. (2021). Efficacy and safety of Unani drugs to combat chronic gout- A preliminary study. *International Journal of Recent Scientific Research*, 12(5B), 41723–41728.
- Khatoon, A., Ahmad, F., Rauf, E., & Khan, M. N. (2022). *Suranjan* (Colchicum Autumnale): A review. *World Journal of Pharmacy and Pharmaceutical Sciences*, 11(2), 945–950.
- Khatoon, F., Azhar, M., Jabeen, A., Qamar, U., Khan, S., Moin, M. S., Ahmed, K., & Zaki, M. K. (2021). A comprehensive review on *Buthur Labaniyya* (Ance vulgaris) with special references of unani system of medicine. *The Journal of Phytopharmacology*, 10(6), 468–477.
- Kumar, J., Sagar, P. K., Sajwan, S., Ahmed, M. W., & Ansari, S. A. (2021). Pharmacognostical and Physico-chemical studies of Unani single drug *Hasha* (*Thymus serpyllum* L.) (Whole Plant). *International Journal of Multidisciplinary Education Research*, 10(8:1), 12–21.
- Kumar, S. T. S., Christopher, J. J., Akram, S. A. W., Mageswari, S., Raiza, A. J., Meena, R. P., & Ahmed, N. Z. (2022). Pharmacognostical and HPTLC Fingerprint analysis of *Pterocarpus santalinus* Linn.- Heart Wood in Chloroform extract. *Journal of Emerging Technologies and Innovative Research*, 9(2), e631–e639.
- Mannan, M. N. (2021). A simplified review on *Aftimoon* (*Cuscuta Reflexa* Roxb.), A parasitic vine with special reference to Unani medicine. *New Horizons*, 18, 113–127.
- Maseehullah, M. D., Husain, G. M., Zakir, M., Husain, M. K., Javed, G., Kazmi, M. H., & Urooj, M. (2021). Antipyretic, analgesic and anti-inflammatory activity of *Qurs Afsanteen Sagir* (A Polyherbal Unani Tablet) in experimental animals. *Traditional and Integrative Medicine*, 6(4), 320–332.
- Maseehullah, M. D., Zakir, M., Anas, M., & Kazmi, M. H. (2021). Ethno-pharmacology of *Asaroon* (*Asarum europaeum* L.) with special reference to Unani system of medicine. *Journal of Complementary and Integrative Medicine*, 19(2), 181–192. <https://doi.org/10.1515/jcim-2021-0021>
- Moin, M. S., Siddiqui, J. I., Alam, M. A., Khatoon, F., Khan, S., & Minhajuddin, A. (2021). Ethnomedicinal potential of widely used plant *Azadirachta indica* A. Juss: A comprehensive review. *Journal of Phytopharmacology*, 10(6), 456–467.
- Munim, A., Qamaruddin., Minhajuddin, A., Qurishi, A., Zaki, M. K., Faiza, K., & Asad, K. (2021). *Atrialal* (*Ammi Majus* Linn) an herbal plant: A comprehensive review of the medical uses. *International Journal Pharm. Pharm. Res. Human*, 23(1), 47–57.



- Mustehasan., & Azhar, M. (2021). Historical and Pharmacological Review on a Unani Drug Of Mineral Origin: *Nuqra* (Silver). *Indo American Journal of Pharmaceutical Sciences*, 08 (08), 82–88.
- Mustehasan., Azhar, M., & Naushin, S. (2021). Historical, pharmacological and toxicological review on a Unani mineral drug *Qalai* (tin). *Indo American Journal of Pharmaceutical Research*, 11(08), 2021–2025.
- Naaz, A., Viqar, U., Ansari, U. A., Jabeen, J., Minhajuddin, A. (2022). A concise review on culinary spice with its potential therapeutic applications *Zanjabeel* (*Zingiber officinale* Roscoe). *International Journal of Botany Studies*, 6(6), 972–975.
- Naaz, A., Viqar, U., Naikodi, M. A. R., Siddiqui, J. I., Zakir, M., Kazmi, M. H., & Minhajuddin, A. (2022). Development of standard operating procedures (SOPs), standardization TLC and HPTLC fingerprinting of a polyherbal Unani formulation. *CellMed*, 11(4), 1–9.
- Naikodi, M. A. R., & Ansari, A. (2021). Role of underground stems as immunomodulators and may assist in the management and treatment of COVID-19. *Annals of Phytomedicine*. 10(1), S231-239.
- Naikodi, M. A. R., Chaithra, D., Venkatesham, B., Siddiqui, J. I., & Kazmi, M. H. (2021). Phytonanotech-nological perspectives and biological activities in Curcuma species. *Annals of Phytomedicine*, 10(2), 82–89.
- Naikodi, M. A. R., Chaithra, D., Venkatesham, B., Siddiqui, J. I., & Kazmi, M. H. (2021). Phytonanotechnological perspectives and biological activities in Curcuma species. *Journal of Phytonanotechnology and Pharmaceutical Sciences*, 1(1), 16–23.
- Naushad, M., Urooj, M., Ahmad, T., Husain, G. M., Kazmi, M. H., & Zakir, M. (2021). Nephroprotective effect of *Apium graveolens* L. against Cisplatin-induced nephrotoxicity. *Journal of Ayurveda and integrative medicine*, 12(4), 607–615. <https://doi.org/10.1016/j.jaim.2021.06.005>
- Naushad, P., Ahmed, N. Z., Basha, A., Aslam, M., & Raheem, A. (2021). Prevalence of arthritis (*Waja- ul- Mafasil*) in Chennai city under scheduled caste sub plan of mobile clinical research programme – An observational study. *International Journal of Research and Analytical Reviews*, 8(4), 850–860.
- Negi, R. K., Rasheed, N. M. A., Jayanthi, A., Sajwan, S., Khan, A. S., Meena, R. P., & Verma, S. C. (2020). Quality evaluation and standardization of traditional unani medicine *Majoon-e-Pambadana*. *World Journal of Pharmaceutical Research*, 9(7), 2128–2136.
- Pasrija, R., & Naime, M. (2022). Resolving the equation between mucormycosis and COVID-19 disease molecular biology reports. 22, 1–8.
- Qaiyyum, I. A., Abdul, Q., Jabeen, A., Nawab, M. (2021). Evaluating clinical efficacy and safety of a Unani formulation in the management of *Nazla-i-Muzmin* (Chronic Rhinosinusitis). *CellMed*, 11(2), 1–5.
- Qaiyyum, I. A., Nawab, M., & Kazmi, M. H. (2020). A clinico-epidemiological study of *Kalaf* (Melasma) and its Impact on Quality of Life. *Hippocratic Journal of Unani Medicine*, 15(4), 61–75.
- Qamar, U., Faiza., Arzeena, J., Azhar, M., Alam, M. A., Munim, A. (2021). Managment of Psoriasis through Unani medince : case study. *CellMed*, 11(2), 1–7.

- Qureshi, M. A., Husain, G. M., Urooj, M., Khan, M. A., Husain, M., Kazmi, M. H. (2021). Preclinical safety, anxiolytic and antidepressant activity of *Sufoof Jawahar Mohra*: A Unani formulation. *Advances in Integrative Medicine*, 8(2), 114–121.
- Raheem, A., Ahmad, I., Khan, P., Shah, A., Nazli, T., Khan, A. A., Parveen, S. (2021). Management of *Humuzat-e-Meda* (Hyperacidity) with *Jawarish Amla* & *Habb-e-Papita* - A multi centric study. *Paripex - Indian Journal of Research*, 10(05), 119–121.
- Raiza, A. J., Mageswari, S. P., Sri, M. D., Meena, R., & Ahmed, N. Z. (2021). Standardization of *Allium cepa* L. Seeds via pharmacognostical, physicochemical and HPTLC finger print profile studies. *International Journal of Research and Analytical Reviews*, 8(4), 111–122.
- Raza, R., & Chishti, D. K. (2021). Incredible health benefits of Glycirrhizaglabra (Liquorice). *Paripex - Indian Journal of Research*, 10(03), 179–181.
- Raza, R., Khan, N., Husain, M. T., & Sajid, M. (2022). Unani system of medicine and *Waja-ul-Mafasil* (Arthritis): A review. *Peripex Indian Journal of Research*, 11(1), 2250–1991.
- Sagar, P. K., Sajwan, S., Khan, A. S., & Ahmed, M. W. (2021). Useful Anti-Cancerous & Anti-tumorous, Immuno-modulator, medicinal potent Asian medicinal Plants (*Curcuma domestica* valetton or *Curcuma longa* L., *Tinospora cordifolia* (Willd.) Miers & *Ocimum tanuiflorum* L., *Ocimum sanctum* L.). *International Journal of Multidisciplinary Education Research*, 10(8:2). 69–79.
- Sajid, M., Husain, M. T., Raza, R., Raza, M. R., Abid, M., & Khan, N. (2021). Haemorrhoids and its management in Unani medicine. *Peripex Indian Journal of Research*, 10(12), 2250-1991.
- Sajwan, S., Khan, A. S., Ansari, S. A., & Meena, R. P. (2021). Botanical and physicochemical standardization of compound formulation - "*Itrifal Shahtara*". *European Journal of Biomedical and Pharmaceutical Sciences*, 8(8), 431–434.
- Sajwan, S., Kumar, J., Sagar, P.K., Negi, R. K., & Khan, A. S. (2021). Identification and authentication of herbal drug "*Gul-e-Neem*" (*Azadirachta indica* A. Juss.). *International Journal of Multidisciplinary Education Research*, 10(8:3), 431–434.
- Samarpita, S., Doss, H. M., Ganesan, R., & Rasool, M. K. (2021). *Majoon Chobchini* attenuates arthritis disease severity and RANKL-mediated osteoclastogenesis in rheumatoid arthritis. *3 Biotech*, 11(10), 436.
- Sehar, N., & Khan, M. N. (2021). *Qurs Dawa-us-Shifa*....A Miraculous Unani drug for Hypertension. *International Journal of Pharmaceutical Research and Application*, 6(2), 159–162.
- Sehar, N., Khan, M. N., & Azeem, M. A. (2021). *Khamira Marwareed* a potent Unani formulation for wellness and immunity. *International Journal of Creative Research Thoughts*, 9(12), 9–14.
- Shafi, S., Ahmad, A., Khazir, M., Kalam, A., & Zargar, M. I. (2021). Antimicrobial activity of '*Qurs Afsanteen*': A classical Unani tablet formulation prepared from *Artemisia absinthium*. *International Journal of Applied Research*, 7(10), 240–246.
- Siddiqui, N. A., Abid, A., Fahamiya, N., Zakir, M., & Arif, S. H. (2021). Nephroprotective effect of *Bisehri Booti* (*Aervalanata* (L.) Juss.) in doxorubicin-induced nephrotoxicity. *Drugs and Cell Therapies in Haematology*, 10(1), 1181–1195.



- Siddiqui, Z. A., Ansari, Z. A., Jabeen, A., Anwar, M., Zakir, M., Siddiqui, Rauf, A., Rahman, A., & Kazmi, M. H. (2021). Standard operational procedures (SOPs) and physicochemical standardization of a classical Unani formulation – *Qurs Mafasil Jadid*. *International Journal of Pharmaceutical Research*, 13(2), 2422–2430.
- Urooj, S., Jahangir, U., Maaz, M., & Azam, R. (2021). Dyslipidemia from Unani prospective and its management with *Safoofe Muhazzil*: An update phytomedicine plus, 100103, 1–8.
- Urooj, S., Shah, A., & Huma. (2020). Effectiveness of Unani regimen in management of over active bladder: An open labeled, single arm clinical study. *Journal of Drug Delivery & Therapeutics*, 10(5), 293–300.
- Venkatesh, B., Chaitra, D., Siddiqui, J. I., Rasheed, M. A., Nazeer, M., Siddiqui, A., & Minhajuddin, A. (2021). Pharmacognostic evaluation, physicochemical standardization and HPTLC fingerprint analysis of pomegranate (*Punica granatum* L.) leaf and seeds. *Annals of Phytomedicine*, 10(2), 187–194.
- Verma, P. (2020). Biomedical waste management in laboratory. *Research & Reviews: Journal of Medical Science and Technology*, 9(2), 1–6.
- Verma, P. (2021). Effect of non vegetarian diet on haemoglobin. *Research and Reviews Journal of Health Professions*, 11(1), 27–30.
- Verma, P. (2022). CRP in different diseases. *Research and Reviews a Journal of Bioinformatics*, 8(4), 35–43.
- Verma, P. (2022). Liquid waste management. *Research and Reviews a Journal of Toxicology*, 11(3), 18–24.
- Verma, R. S., Khan, P., Ayub, S., Afza, S., Akhtar, J., Ahmad, S., & Khan, A. A. (2021). The efficacy and safety of a Unani compound drug Habb-e-Asgand in Waja'al-Mafasil (Rheumatoid Arthritis) cases-A preliminary study. *Indian Journal of Traditional Knowledge*, 20(1), 8–14.
- Verma, R. S., Parveen, S., Rehman, S., Afza, S., Akhtar, J., Ahmad, S., & Khan, A. A. (2021). The efficacy and safety of a Unani compound drug *Damavi* in cases of anemia- A preliminary study. *International Journal of Unani and Integrative Medicine*, 5(1), 43–48.
- Verma, R. S., Parveen, S., Rehman, S., Khan, P., Singh, R., Afza, S., Akhtar, J., Khan, A. A. (2021). Comparative evaluation of efficacy and safety of a Unani coded drug UNIM-221 and Metformin in cases of Diabetes mellitus type-II- A preliminary study. *International Journal of Unani and Integrative Medicine*, 4(3), 09–16.
- Viqar, U., Khan, S., Alam, M. A., Fatima, S. H., Minhajuddin, A., Waheed, M. A., & Nazeer, M. (2022). Detoxification and pharmacological actions of medicinally important herbal drug *Baladur* (*Semecarpus anacardium* L.): A comprehensive review. *EC Pharmacology and Toxicology*, 9(12), 106–114.
- Waseem, A., Ahmad, W., & Fazil, M. (2021). Mental health care during covid-19 pandemic in light of Unani medicine. *European Journal of Biomedical and Pharmaceutical Sciences*, 8(11), 67–75.
- Waseem, A., Ahmad, W., Khan, A. A., & Fazil, M. (2021). Review on *Nyctanthes Arbor-Tristis* (Harsinghar) - A herbal medicament with special reference to Unani medicine. *Indian Journal of Unani Medicine*, 14(1), 61–68.

- Waseem, A., Akram, U., Ahmad, W., & Fazil, M. (2020). Medicinal plants used for treatment of psychiatric disorders in Unani medicine. *ACTA Scientific Neurology*, 6(3), 11–17.
- Waseem, A., Jamal, A., Ahmad, W., & Fazil, M. (2020). Siras (*Albizia lebbek* (L.) Benth.) and its medicinal uses in Unani medicine- A review. *CellMed Orthocellular Medicine*, 10(2), e12.
- Waseem, A., Jamal, A., Siddiqui, A., Khan, A., Ahmad, W., & Fazil, M. (2021). Unani perspective of melancholia (A depressive disorder): concept and management. *International Journal of Botany Studies*, 6(1), 23–28.
- Younis, I., Munshi, & Ansari, M. (2021). Role of Jundi-Shapur in Streamlining of Ilme-Tibb (Medicine). *Journal of Complementary and Alternative Medical Research*, 16(4), 30–34.
- Zahoor, S., Rather, S. A., Iqbal, A., Afzal, A., & Huma. (2021). Clinical study to assess the temperament of patients with different metabolic diseases attending outpatient department of RRIUM Srinagar. *European journal of pharmaceutical and medical research*, 8(8), 385–388.
- Zaki, M. K., Qamar, U. J., Farooqi, A., Minhajuddin, A., Khatoon, F., Munim, A., Qureshi, A., & Asad, M. (2021). Asl (Honey) an important nutraceutical of traditional Unani medicine, a review in context with clinical research. *International J. Pharma. Pharm. Res. Human*, 22(4), 224–234.
- Zaki, M. K., Qamaruddin, Farooqi, A., Minhajuddin, A., Juveria, J., Munim, A., Faiza, K., & Qurishi, A. (2021). Management of Ezema through Unani medicine, the successful treatment of a Chronic relapsing case. *International Journal of Pharm. Pharm. Res. Human*, 23(1), 11–20.
- Zakir, M., Khanam, S., & Kazmi, M. H. (2021). Medicinal Properties of *Hulba* (Fenugreek) in Unani system of medicine. In N. Naseem, T. Aftab & M. M. A. Khan (Eds.) *Fenugreek: Biology and Applications* (pp. 377–393). Springer. [https://doi.org/10.1007/978-981-16-1197-1\\_17](https://doi.org/10.1007/978-981-16-1197-1_17).

### 3.5. Extension of Healthcare Services

#### 3.5.1. School Health Programme

The School Health Programme is aimed at improving the health and hygiene status of school children and to reduce morbidity rate among them through healthcare and health education. Under this programme, the Council's researchers visit selected Primary and Secondary Schools, particularly those in rural areas and urban slums. A baseline health check-up of school children is conducted and those found suffering from any ailment are treated with Unani medicines. Thereafter, health education is provided to them through lectures on different preventive, promotive and curative health aspects, and health related literature is distributed. The children are also educated about the potentialities of the commonly available plants in their vicinity for the management of different diseases. Specific lectures are given on oral hygiene, cleanliness of body and environment, safe drinking water, nutrition, balanced diet, etc.

During the reporting period, the activities under this programme could not take place due to closure of schools in view of Covid-19 pandemic.

### 3.5.2. Unani Medical Centres in Allopathic Hospitals

Under the scheme of collocation of AYUSH centres in allopathic hospitals in Delhi, a Unani Medical Centre was established at Dr. Ram Manohar Lohia (RML) Hospital on January 14, 1998 with a view to provide Unani treatment facility to the patients desirous of taking treatment of this system. On public demand, another Unani Specialty Centre started functioning at Deen Dayal Upadhyay (DDU) Hospital, New Delhi on November 01, 2010. On September 13, 2020, a new Unani Medical Centre was established at VMMC & Safdarjung Hospital, New Delhi. These centres are run by the CCRUM. Besides the General Outpatient Department (GOPD) facilities, these centres provide specialized Unani treatment for some selected disorders like vitiligo, eczema, psoriasis, rheumatoid arthritis, bronchial asthma, sinusitis, infective hepatitis, diabetes mellitus, etc. During the reporting period, 11,655 patients were treated at Unani Medical Centre in Dr. RML Hospital, 8,674 patients at Unani Speciality Centre in DDU Hospital, New Delhi and 5,917 patients at Unani Medical Centre in VMMC & Safdarjung Hospital, New Delhi. The patients visiting the centres were suffering from chronic diseases. Counselling of patients, particularly the senior citizens, was also done to improve their physical activities and mental health.

### 3.5.3. Health Camps

The CCRUM organizes health camps through its institutes/units with a view to create health awareness among the masses and to provide treatment through Unani Medicine. During the reporting period, activities under this programme could not take place due to COVID-19 pandemic.

### 3.5.4. Activities under Gender Component Plan for Women

The CCRUM continued research and treatment facilities for women under Gender Component Plan. Treatment facilities were made available to women at all clinical centres of the CCRUM. Besides, female patients in the pockets adopted under Mobile Clinical Research Programme were also treated by the physicians in the Mobile OPD Scheme. During the reporting period, 1,48,279 female patients in different OPDs were treated. Efficacy of Unani pharmacopoeial formulations was also validated under this component. Health lectures / group meetings on preventive and promotive health aspects were also organized in the pockets adopted under Mobile Clinical Research Programme. Published literature on preventive, promotive and curative health aspects was distributed among the masses. Clinical studies on the diseases specific to women such as *Sū' al-Qinya* (anaemia), *Sayalān al-Raḥīm* (leucorrhoea), *Kathrat al-Ṭamth* (menorrhagia) and *Iḥtibās al-Ṭamth* (amenorrhoea) also continued.

### 3.5.5. Activities in the North-Eastern Region

The Regional Research Centre, Silchar continued Research/GOPD Programmes. During the reporting period, 1,823 patients were treated. The most commonly occurring diseases were *Ḥummā* (fever), *Sayalān al-Raḥīm* (leucorrhoea), *Waja' al-Mafāṣil* (rheumatoid arthritis), *Ḥummā Ajāmiya* (malaria), *Ishāl* (diarrhea), *Sū' al-Haḍm* (dyspepsia), and *Zaḥīr* (dysentery). The patients were treated with Unani pharmacopoeial drugs.

### 3.5.6. Mobile Healthcare Programme under Scheduled Caste Sub-Plan

The CCRUM runs Mobile Healthcare Programme under Scheduled Caste Sub-Plan (SCSP) at NRIUMSD, Hyderabad; CRIUM, Lucknow; RRIUM, New Delhi, Aligarh, Patna, Mumbai, Kolkata and Chennai; RRC, Prayagraj; and CRU, Bhopal to extend healthcare services to

the SC population at their doorstep. The programme aims to screen / examine the SC population for their health status in Mobile OPDs and health camps and to provide Unani treatment to the patients suffering from different diseases. It also aims to create awareness among the masses on preventive, promotive and curative health aspects through lectures, group meetings, health camps and distribution of literature. Five villages predominately having SC population were identified for undertaking the programme at each centre. During the reporting period, 11,93,391 total population including 8,37,825 SC population were covered and a total of 44,933 individuals benefited from the programme.

### 3.5.7. Mobile Healthcare Programme under Tribal Sub Plan

Just like Mobile Healthcare Programme under Scheduled Caste Sub-Plan, the CCRUM runs Mobile Healthcare Programme under Tribal Sub Plan (TSP) at RRIUM, Bhadrak and CRU, Burhanpur and Kurnool to extend healthcare services to the ST population at their doorstep. The programme aims to screen / examine the ST population for their health status in Mobile OPDs and health camps and to provide Unani treatment to the patients suffering from different diseases. It also aims to create awareness among the masses on preventive, promotive and curative health aspects through lectures, group meetings, health camps and distribution of literature. Five villages predominately having ST population were identified for undertaking the programme at each centre. During the reporting period, 1,31,914 total population including 96,614 ST population were covered and 14,177 individuals benefited from the programme.

### 3.6. Linking Education with Research

With a view to link education with research and utilize the comprehensive facilities available at its institutes, the CCRUM is conducting postgraduate (MD) programmes in Unani Medicine at National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and Regional Research Institute of Unani Medicine (RRIUM), Srinagar in affiliation with Kaloji Narayana Rao University of Health Sciences, Warangal (Telangana) and University of Kashmir, Srinagar, respectively.

Twenty-nine students were admitted during the reporting period against the intake of 09 students in each discipline of *Mu'ālajāt* (Medicine) and *'Ilm al-Adwiya* (Pharmacology) at NRIUMSD, Hyderabad and 06 students in *Mu'ālajāt* and 05 students in *'Ilm al-Adwiya* at RRIUM, Srinagar.

The students were trained through a structured academic schedule comprising theory classes, hands-on practical classes, bedside teaching and dissertation work. The institutes also organized monthly meeting for postgraduate training that included clinical and research skills, development of protocols, case presentations and discussions. Students were posted in various OPDs as well as IPD wards for clinical training on rotation basis. The academic activities also included seminars, journal club and tutorials. The faculty members conducted classes as per syllabus prescribed by the National Commission for Indian System of Medicine. The students were also engaged in their theses work, in addition to attending classes.

During the reporting period, several meetings of Departmental Research Committee, Board of Studies and Institutional Ethics Committee were organized to deliberate, evaluate and approve the research proposals for thesis work.

## 4. INFORMATION, EDUCATION & COMMUNICATION

### 4.1. Library Services

The CCRUM has a Library and Information Centre (LIC) at the Headquarters which aims to collect and preserve scattered literature on Unani Medicine, and to disseminate information to the researchers, academicians and practitioners of Unani Medicine and general public.

During the reporting period, services of the LIC remained fully automated through Wide Area Network (WAN). The LIC provided its services to the readers through e-Granthalaya Library Software that controls the Web Online Public Access Catalogue (Web-OPAC), circulation of books, etc. A total of 15 books including 14 purchased and one complimentary books were acquired. As much as 160 MD (Unani) theses were also added to the collection. Data of new additions in the library were uploaded on e-Granthalaya cloud database.

A total of 1,460 books were in circulation including 84 books that were circulated through Inter-Library Loan Service to the Athens Academy Library and DELNET's member libraries. The library subscribed 3,368 issues of daily newspapers along with six e-papers and 210 issues of popular magazines. In addition, 117 issues of journals were received, of which 24 were in Hindi language and 23 issues related to Unani Medicine. Besides the print journals, the Library & Information Centre also subscribes on-line journals of Science Direct Scheme and Elseviers and provide access to all the researchers of the CCRUM.

The LIC carried out physical processing and barcoding of 112 books after binding. The centre provided spiral binding and photocopying, and reference services to the readers. Comb or thermal binding of 192 documents and photocopying of 8,522 pages were carried out. Besides, long and short range reference service was provided through WhatsApp and e-mail to the researchers and allied staff members of the CCRUM. A Facebook page was also maintained during the year with an objective of facilitating the researchers with reference services and recent updates. The LIC collected Rs. 5,230.00 as user charges against annual membership, photocopy and spiral binding services and consultation.

The library continued digital publication and circulation of Medical News Update Service among 780 subscribers on daily basis. The Selective Dissemination of Information (SDI) service also continued at the LIC. Under this service, 362 news clippings were collected, of which important ones were sent to the Director General & Assistant Director (Unani) and displayed on the library notice board as well. Besides the Digitization of Unani rare manuscripts, books & journals and development of digital repository, the LIC also developed "Digital Archives of CCRUM News Clippings" to preserve the news of the CCRUM.

The LIC continued institutional membership of British Council Library, Medical Library Association of India, American Resource Centre and Developing Library Network (DELNET). During the reporting period, 423 member and guest researchers visited the LIC to access its resources.

### 4.2. Organization of Conferences, Seminars, Workshops, etc.

#### 4.2.1. Unani Day Celebration and International Conference on Unani Medicine

The CCRUM organized Unani Day Celebration and International Conference on Unani Medicine at Sher-i-Kashmir International Conference Centre (SKICC), Srinagar during March 10–11, 2022. Themed on 'Diet and Nutrition in Unani Medicine for Good Health and Well-



being', the conference was the first of its kind in the Kashmir Valley and made a very good impact through scientific deliberations.

Shri Sarbananda Sonowal, Hon'ble Cabinet Minister, Ministry of Ayush and Ministry of Ports, Shipping & Waterways, Government of India was the chief guest and Dr. Munjpara Mahendrabhai Kalubhai, Hon'ble Minister of State, Ministry of Ayush and Ministry of Women & Child Development, Government of India was the distinguished guest of honour in the conference.

The conference had a panel discussion and eight scientific sessions on the sub-themes, viz. 'Diet and Nutrition – An Important Branch in Health Sector', 'Unani Medicine for Global Health', 'Diet and Nutrition – An Important Component for Improving Immunity in Unani Medicine', 'Lessons Learned during Pandemic', 'Achieving Good Health & Wellbeing – SDG-3', 'Traditional Systems of Medicine for Non-communicable Diseases (NCDs)' and 'Health & Wellness'.

A number of national and international experts and luminaries from the field of health sciences shared their knowledge, experiences and expertise in the conference. Stakeholders from industry, academia and research organizations engaged in the development of Unani Medicine and related health sciences attended the conference in large number physically as well as in online mode. Unani Day is celebrated on February 11 to mark birth anniversary of Hakim Ajmal Khan. However, Unani Day celebration had to be shifted to March 10-11 this year due to the COVID-10 pandemic.

### Inaugural Session

Shri Sarbananda Sonowal, Hon'ble Cabinet Minister, Ministry of Ayush and Ministry of Ports, Shipping & Waterways, Government of India inaugurated Unani Day Celebration and International Conference on Unani Medicine. Dr. Munjpara Mahendrabhai Kalubhai, Hon'ble Minister of State, Ministry of Ayush and Ministry of Women & Child Development, Government of India was the distinguished guest of honour in the conference.

Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Government of India, Shri Vivek Bhardwaj, Additional Chief Secretary, Health & Medical Education Department, J&K, Vaidya Jayant Deopujari, Chairman, National Commission for Indian System of Medicine, New Delhi, Prof. Talat Ahmad, Vice Chancellor, University of Kashmir, Srinagar, Prof. Akbar Masood, Vice Chancellor, Baba Ghulam Shah Badshah University, Rajouri, Prof. Asim Ali Khan, Director General, CCRUM and Dr. M. A. Qasmi, Adviser (Unani), Ministry of Ayush, Government of India also graced the conference organized in hybrid mode.

Inaugurating the conference, Shri Sarbananda Sonowal said that the Government of India under the visionary leadership of Hon'ble Prime Minister Shri Narendra Modi Ji has accorded great importance to the multifaceted development of Unani Medicine and other Indian systems of medicine. He informed that because of the able leadership of Shri Narendra Modi Ji, the World Health Organization (WHO) has decided to establish Global Centre for Traditional Medicine in India which would provide a great opportunity for researchers and students to lead the world in Traditional Medicine. Talking about Unani Day, he said that it is celebrated on the birth anniversary of Hakim Ajmal Khan which is very significant because it is due to the contributions made by him and many other scholars that we inherited this comprehensive medical system. Referring to Jammu & Kashmir region, he said that we are all proud of this beautiful region which has been successful in positioning itself as an attraction for tourists at global level. He further said that J&K is rich in plant resources and stressed the need to explore them and conduct researches for their medicinal use so that the mankind is benefited. He informed that the Ministry of Ayush has recently approved a grant of Rs. 7.07 crore for



developing an Ayush Centre of Excellence for Regimenal Therapy at the Regional Research Institute of Unani Medicine (RRIUM), Srinagar. He suggested that the youth of J&K should take advantage of the government initiatives being undertaken in the region.

In his address, Hon'ble Minister Dr. Munjpara Mahendrabhai said that diet is very important as it is the basic source of energy. He further said that Unani Medicine provides detailed guidelines for healthy food habits to maintain health and prevent diseases. He lauded the role of Ayush system in immunity enhancement through drugs and medicinal foods and fighting against COVID-19. He also appreciated contributions of the CCRUM in research and development in Unani Medicine.

Speaking on the occasion, Shri Pramod Kumar Pathak said that proper and nutritious diet is key to good health and well-being and Unani Medicine has a holistic approach to correct the imbalances that cause diseases. He informed that the Ministry of Ayush has established National Institute of Unani Medicine with a 200-bedded hospital in Ghaziabad as a part of the vision of Hon'ble Prime Minister Shri Narendra Modi for provision and promotion of quality education, research and healthcare services through Unani Medicine and other Ayush systems.

Shri Vivek Bhardwaj said that Unani Medicine is very popular in J&K and for its further promotion and development the Union Government is making concerted efforts including introduction of MD in Unani Medicine at RRIUM, Srinagar and BUMS at the first Government Unani Medical College of J&K.

Vaidya Jayant Deopujari said that knowledge of Arabic and Urdu languages is very important for education and training in Unani Medicine same as the knowledge of Sanskrit is important for Ayurveda and therefore suitable changes have been made in the Minimum Standards for Indian System of Medicine and colleges have been instructed to appoint full-time teachers for Arabic and Urdu languages.

Prof. Talat Ahmad appreciated the role of the CCRUM in research and development in Unani Medicine and urged to expand collaborations with other institutions for interdisciplinary research in Unani Medicine. Prof. Akbar Masood lauded the contribution of the CCRUM and RRIUM, Srinagar in research, healthcare delivery and higher education in Unani Medicine.

Earlier in his welcome address, Prof. Asim Ali Khan said that indigenous medicine systems have received unprecedented support and patronage from the Government of India led by Hon'ble Prime Minister Shri Narendra Modi. He mentioned that in the last September Hon'ble Ayush Minister inaugurated BUMS course at the first Government Unani Medical College in J&K established with substantial financial support from the Ministry of Ayush. Talking about the activities and achievements of the CCRUM, he said that it has witnessed multifaceted growth and progress in the past few years. The inaugural session concluded with the vote of thanks proposed by Dr. M. A. Qasmi.

The inaugural session also witnessed release of conference souvenir and eight books published by the CCRUM, release of two Unani e-books developed by the National Institute of Indian Medical Heritage functioning under the Central Council for Research in Ayurvedic Sciences at Hyderabad, release of CCRUM apps, presentation of NABH Accreditation Certificate to RRIUM, Srinagar, exchange of MoU between Morarji Desai National Institute of Yoga, New Delhi and Directorate of Ayush, J&K for research and training, distribution of YCB certificates to felicitate Yoga instructors and live Yoga demonstration.

Launching of the apps on 'Single Unani Drugs', 'Unani Treatment Guidelines for Common Diseases' and 'Know Your Temperament' by Hon'ble Minister Shri Sarbananda Sonowal was

highly appreciated by Unani and other stakeholders as it was the first of its kind initiative of the CCRUM, Ministry of Ayush in the field of Unani Medicine.

### Panel Discussion

The panel discussion was held on the theme 'Diet and Nutrition: An Important Branch in Health Sector'. Prof. Asim Ali Khan, Director General, CCRUM, Prof. Akbar Masood, Vice Chancellor, Baba Ghulam Shah Badshah University, Rajouri and Prof. Mohammed Afzal Zargar, Registrar, Central University of Kashmir moderated the session. Prof. Talat Ahmad, Vice Chancellor, University of Kashmir, Srinagar, Vaidya Devendra Triguna, President, Association of Manufacturers of Ayurvedic Medicines, New Delhi, Dr. S. Farooq, President, Himalaya Drug Company, New Delhi, Dr. W. Selvamurthy, President, Amity Science, Technology and Innovation Foundation and Director General, Amity Directorate of Science and Innovation, Noida, Shri Pradeep Multani, President, PHD Chamber of Commerce and Industry, New Delhi, Dr. Mohd. Ashraf Ganie, Professor, Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Prof. Abdul Wadud, Director, National Institute of Unani Medicine, Bengaluru, Prof. K. M. Y. Amin, Aligarh Muslim University, Aligarh, Prof. M. C. Sharma, Chairman, Scientific Advisory Body, Pharmacopoeia Commission for Indian Medicine & Homeopathy, Ghaziabad, Dr. Mohan Singh, Director, Department of Ayush, J&K and Dr. Santosh Joshi, Hamdard Laboratories India participated as the panelists.

In his initial remarks, Prof. Asim Ali Khan emphasized that several disorders like diabetes, heart diseases and dyslipidaemia are directly related to diet and can be prevented by following dietary recommendation of Unani Medicine.

Shri Pradeep Multani said that diet and nutrition play a key role in the management of diseases. He added that several diets and drugs mentioned in Unani literature can decrease various lifestyle disorders including obesity.

Dr. W. Selvamurthy said that the concept of diet and nutrition had been discussed in detail in classical literature of Unani Medicine and added that incompatible diet disturbs the quality and quantity of *Khilf* (humour) which causes diseases. He also discussed the anticancer property of *Dawā' al-Kurkum*.

Dr. S. Farooq laid emphasis on adopting appropriate dietary measures by patients in order to restrict the disease from getting worse. He also discussed health benefits of various foods mentioned in Unani Medicine and informed that radish is useful in piles and cucumber is beneficial in kidney diseases.

Prof. Talat Ahmad stressed the need for modernization of traditional systems of medicine and said that more research should be carried out on Unani drugs.

Dr. Santosh Joshi, Hamdard Laboratories India said that the prevalence of various diseases can be decreased by adopting appropriate dietary measures.

Dr. M. A. Waheed said that barley water is useful in cases of hemiplegia, paraplegia and other cerebro-vascular diseases. He also said that immunomodulation can be done through the use of *Ghidhā'-i-Dawā'ī* and *Dawā'-i-Ghidhā'ī*.

Prof. M. C. Sharma shared his experiences regarding the use of various diets in many disease conditions. He emphasized that incompatible diets may be harmful in many diseases particularly autoimmune disorders.

Prof. K. M. Y. Amin stressed that diet should be recommended according to the temperament of patients and diseases. He suggested that monographs on Unani diets should be prepared.

Prof. Abdul Wadud suggested that '*Ilāj bi'l-Ghidhā*' (dietotherapy) should be given priority while treating diseases. He emphasized that even healthy individuals should take diet according to the season and temperament.

Dr. Mohan Singh shared his personal experiences about the use of garlic in hypertension. Prof. Mohammed Afzal Zargar also shared his experiences about diet and nutrition. Prof. Akbar Masood summed up the discussion with his observations and concluding remarks.

Use of compatible and appropriate diets, preferring dietotherapy to other modes of treatment, role of *Asbāb Sitta Darūriyya* (six essential factors), importance of *Akhlāṭ* (humours) and *Mizāj* (temperament) were highlights of the session.

#### Scientific Session-I

In Scientific Session-I on 'Unani Medicine for Global Health', Dr. Mohammad Kamil, Director General, Lotus Holistic Healthcare Institute, Abu Dhabi, UAE, Dr. Goh Cheng Soon, Director, Traditional and Complementary Medicine, Ministry of Health, Malaysia, Prof. Arman Zargaran, Coordinator, International Affairs for Traditional Medicine, Ministry of Health & Professor, School of Persian Medicine, Tehran University of Medical Sciences, Iran and Dr. Mujeeb Hoosen, Coordinator, Unani Tibb, School of Community and Health Sciences, University of the Western Cape, South Africa delivered their addresses. Prof. Akbar Masood, Vice-Chancellor, Baba Ghulam Shah Badshah University, Rajouri and Prof. Suhail Fatima, Jamia Hamdard, New Delhi chaired the session.

In his address on 'Quality and Safety of Unani Medicine – A Global and Dire Need Today', Dr. Mohammad Kamil stated that due to the increased commercialization of herbal medicines, there is a need to establish certain quality control measures and standardization techniques to ensure the quality and safety of Unani drugs.

In her talk on 'Practice of Traditional and Complementary Medicine in Malaysia', Dr. Goh Cheng Soon presented government policy and regulatory aspects as well as state of Traditional and Complementary Medicine in Malaysia.

Prof. Arman Zargaran presented his talk on the 'Current Scenario of Traditional Medicine in Iran' and briefed about the government policies for the development and integration of Unani/Persian Medicine into the medical health system. He informed that more than 100 research projects on Traditional Medicine were carried out during the pandemic of COVID-19.

Dr. Mujeeb Hoosen talked about the 'Scope of Unani Medicine in South Africa' and said that various Unani Tibb therapies like cupping and hydrotherapy are provided at the University of the Western Cape and Unani practitioners are allowed to practice according to the pharmacopoeias. He informed that the university targets to develop international collaborations, introduce PG courses and promote Unani Medicine through inter-professional education and practice.

#### Scientific Session-II

Scientific Session-II had Prof. Dr. Md. Abdul Mannan, Former Vice-Chancellor, Hamdard University Bangladesh, Dr. S. M. Raeesuddeen, Senior Lecturer, Institute of Indigenous Medicine, University of Colombo, Sri Lanka, Dr. Saifullah Khalid Adamji, Incharge, Licensing and Medical Policies, Sharjah Health Authority, Sharjah, UAE and Ms. Umedakhon Yuldasheva, Assistant Professor, Department of Pharmacology and Dean, Faculty of Dentistry, Avicenna Tajik State Medical University, Tajikistan as speakers. Dr. Mohd. Ashraf Ganie, Professor, Department of Endocrinology, SKIMS, Srinagar, Prof. Nasir Ali Khan, Principal, Jamia Tibbiya Deoband, Saharanpur, Dr. Anwar Saeed, Director, Jamia Tibbiya

Deoband, Saharanpur and Dr. G. V. R. Joseph, Director, Homeopathic Pharmacopoeia Laboratory, Ministry of Ayush, Government of India chaired the session.

Dr. Md. Abdul Mannan shared Bangladesh policy to scale up Unani, Ayurveda and Homoeopathic Medicine services throughout the country along with allopathic treatment to ensure quality and equitable health services for all citizens of Bangladesh.

Dr. S. M. Raeesuddeen shared his experiences about the effects of dietary modifications in the management of psoriasis, mucosal dominant pemphigus vulgaris and hirsutism. He said that Unani physicians have always laid great emphasis on diet.

Dr. Saifullah Khalid Adamji presented the state of Traditional Medicine in UAE and stressed the need for implementing a comprehensive policy and legislation for the development and registration of Unani pharmaceutical products.

Ms. Umedakhon Yuldasheva delivered her presentation on the 'Study of the Antidiabetic Effects of Medicinal Plants of Tajikistan' and stated that the test drug was found very effective. She shared that a lot of research works on some medicinal herbs have been carried out in Tajikistan showing definite action on various systems of the body. The session advocated for the adoption of Unani Medicine for the improvement of immunity and maintenance of good health at international level.

### Scientific Session-III

Scientific Session-III themed on 'Diet and Nutrition – An Important Component for Improving Immunity in Unani Medicine' had five addresses by Prof. Hakim Syed Zillur Rahman, Founder President, Ibn Sina Academy of Medieval Medicine and Sciences, Aligarh, Prof. Shahul Hameed, Principal, Markaz Unani Medical College & Hospital, Kozhikode, Kerala, Dr. Altaf Hussain Shah, Senior Medical Officer, Ayush, J&K, Dr. Waheed-ul-Hasan, Nodal Officer, J&K Medicinal Plants Board and Dr. Hilal Ahmad Punoo, Associate Professor, Department of Food Science & Technology, University of Kashmir, Srinagar. Prof. Raies A. Qadri, Head, Department of Biotechnology and Dr. Rabia Hamid, Head, Department of Nanotechnology, University of Kashmir, Srinagar chaired the session.

Prof. Hakim Syed Zillur Rahman presented historical insights in diet and nutrition in Unani Medicine. He also talked about the contributions of various Unani physicians in the field of diet and nutrition.

Prof. Shahul Hameed talked about hepato-protective diet and nutrition. He discussed some important foods and drugs with their chemical constituents used in Unani Medicine for their hepatoprotective actions.

Dr. Altaf Hussain Shah elaborated on '*Ilāj bi'l-Ghidhā*' (dietotherapy) and discussed its general principles and significance in the promotion and maintenance of health as well as treatment of diseases. He also talked about certain Unani modified diets which serve as a preventive measure as well as therapeutic aid in certain metabolic disorders. Dr. Waheed-ul-Hassan focused on medicinal plants in Kashmir Valley for health and immunity and informed that J&K has 5000 medicinal plant species and about 60% of medicinal plants used in herbal industry are found in J&K. He discussed a few plants that hold medicinal importance and are used as diet and for immunomodulation as well.

Dr. Hilal Ahmad Punoo talked about recent advances in nutraceuticals and mentioned certain food sources of nutraceuticals with their potential benefits like milk, meat, fish oils, mustard, fruits, vegetables, tea, soyabean, cocoa, chocolates, etc. and nutraceuticals available in market.

### Scientific Session-IV

In Scientific Session-IV, Prof. Mohd. Anwar, Chairman, Department of Ilaj-bit-Tadbeer, Aligarh Muslim University, Aligarh, Dr. Mariya Amin Qureshi, Assistant Professor, Department of Social and Preventive Medicine, Government Medical College, Srinagar, Prof. Geer Mohammad Ishaq, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, Dr. Shabbir Ahmad Parray, Medical Officer, Department of Ayush, J&K and Dr. Khalid Zaffar Masoodi, Assistant Professor, Division of Plant Biotechnology, Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir (SKUAST-Kashmir), Srinagar delivered their presentations on 'Diet and Nutrition – An Important Component for Improving Immunity in Unani Medicine'. Dr. Naveed Nazir Shah, Head, Chest Medicine, CD Hospital, Srinagar and Dr. Mohammad Farooq Naqshbandi, Medical Superintendent, Government Unani Hospital, Srinagar chaired the session.

Prof. Mohd. Anwar made an online presentation on 'Holistic Approach of Management of Metabolic Syndrome with Reference to Unani Dietetics'. He spoke about how '*Ilāj bi'l-Tadbīr*' can provide a better solution in the forms of proper dietary management and lifestyle modification through moderation and modification in *Asbāb Sitta Darūriyya*.

Dr. Mariya Amin Qureshi focused on 'Importance of Diet in COVID Times' and asserted that 'No foods or dietary supplements can prevent COVID-19 infection, but by maintaining a healthy diet we can keep our immune system strong for fighting the disease'.

Prof. Geer Mohammad Ishaq delivered his presentation on 'Improving Immunity (*Quwwat-i-Mudāfa'at*) with Unani Medicine, Nutrition and Diet' and highlighted the role of *Asbāb Sitta Darūriyya* (six essentials), '*Anāṣir Arba'a*' (four elements) and *Akhlāt Arba'a* (four humours). Further he described, in length, the immunomodulatory effects of various drugs.

In his presentation on 'Role of '*Ilāj bi'l-Ghidhā*': An Important Mode of Treatment in Unani Medicine', Dr. Shabbir Ahmad Parray discussed the need of *Ghidhā*, theory and philosophies behind the categorization of *Ghidhā*, and general principles of '*Ilāj bi'l-Ghidhā*' with examples of two diseases: obesity and tuberculosis. He emphasized the fact that *Ghidhā* can be preventive, promotive and curative.

Dr. Khalid Zaffar Masoodi delivered his presentation on 'Medicinal Plants with Dietary Value – An Evidence-based Approach' and talked about shifting food habits and how it can cause various diseases like diabetes and obesity. He also spoke about prostate cancer and modifying the old therapies, gene discovery and drug discovery against prostate cancer.

### Scientific Session-V

Scientific Session-V was held on 'Lessons Learned during Pandemic'. The session was chaired by Dr. Mohan Singh, Director, Indian Systems of Medicine (Ayush), J&K and Prof. Irshad A. Nawchoo, Dean Research, University of Kashmir, Srinagar. Prof. Imamuddin Ahmad, Former Principal, Government Unani Medical College, Chennai, Dr. Yasir Ahmad Rather, Professor, Government Psychiatry Hospital, Srinagar, Dr. Mushtaq Ahmed, Divisional Nodal Officer, Ayush Health & Wellness Centres, Kashmir Division and Dr. Iftikhar Hussain Gazi, Medical Superintendent, Kashmir Tibbia College & Hospital & Research Centre, Sumbul, J&K were speakers of the session. The session focused on diet, nutrition, Unani drugs and Ayush interventions in the management of COVID-19. The topics highlighted during the session were 'Post COVID-19 Complications and Care in Unani Medicine', 'Taking Care of Mental Health during and after COVID-19', 'Role of '*Ilāj bi'l-Ghidhā*' in the Management of COVID-19' and 'Ayush Interventions in the Management of



COVID-19 – Experiences from Field’. The speakers emphasized the use of compatible and appropriate diet to avoid diseases especially non-communicable and life style disorders. Some speakers highlighted the significance of six essential factors (*Asbāb Sitta Darūriyya*) of life in the maintenance of health and prevention of diseases.

#### Scientific Session-VI

Scientific Session-VI themed on ‘Achieving Good Health and Well-being SDG-3’ was chaired by Prof. Geer Mohammad Ishaq, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar and Dr. Manzoor Shah, Professor, Department of Botany, University of Kashmir, Srinagar. Dr. Poonam Sharma, Associate Professor, Division of Food Science and Technology, SKUAST-Kashmir, Srinagar and Dr. Ajaz Hasan Ganai, Department of Botany, University of Kashmir, Kargil Campus, Laddakh delivered their presentations on ‘Role of Nutrition in Maintaining Health’ and ‘Traditional Medicinal Plants of Kashmir Himalayas – Diversity & Prospects’. Dr. Poonam Sharma discussed the role of nutrition (proteins, vitamins, fats, carbohydrates, etc.) in body growth and how it provides resistance to infection and prevents certain diseases like diabetes, obesity and cardiovascular diseases.

Dr. Ajaz Hasan Ganai shared information about the medicinal plants in Kashmir Himalayas and some diets like Qahwa, Khambir, Araq-i-Banafsha, Murabba Behi, etc. having plants and fruits of medicinal benefits in treating various respiratory ailments.

#### Scientific Session-VII

‘Traditional Systems of Medicine for Non-communicable Diseases (NCDs)’ was the theme of Scientific Session-VII which was chaired by Prof. Zulfiqar Ali Bhatt, Former Head, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar and Prof. Mubashir Hussain Masoodi, Head, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar. Prof. Mohd. Idris, Ayurvedic & Unani Tibbia College, New Delhi, Dr. Inaamul Haq, Assistant Professor, Government Medical College, Srinagar, Dr. Irfan Banday, Senior Medical Officer (Unani), Directorate of Ayush, Jammu & Kashmir and Prof. S. M. Arif Zaidi, Dean, School of Unani Medical Education & Research, Jamia Hamdard, New Delhi were speakers of the session.

In his presentation on ‘Experience Sharing during COVID-19 Pandemic’, Prof. Mohd. Idris discussed the role of his college in dealing with the pandemic of Influenza in 1918 and his personal experiences of dealing with COVID-19 pandemic. He also discussed some long-term and common post COVID-19 symptoms like fatigue, shortness of breath and cognitive dysfunction. Dr. Inaamul Haq spoke on ‘Environmental Risks and Noncommunicable Diseases’. He discussed various risk factors of noncommunicable diseases and said that 23 percent of the global deaths are linked to the environmental risk factors, 15 percent of ischemic heart diseases are attributed to household air pollution, another 15 percent to ambient air pollution and 3 percent and 2 percent to second hand tobacco smoke and lead, respectively. He concluded with examples of interventions to reduce environmental risks to NCDs. Dr. Irfan Banday delivered his presentation on ‘Role of Unani Medicine in Combating NCDs’. He presented preventive measures of Unani Medicine and emphasized ABCDE strategy, viz. avoid alcohol, be physically active, cut down on salt and sugar, don’t use tobacco products, and eat plenty of vegetables and fruits.

In his presentation on ‘Dietary Recommendations in Metabolic Disorders’, Prof. S. M. Arif Zaidi briefed the burden of malnutrition and metabolic disorders and presented the role of diet in their treatment. He also explained the components of good health and lifestyle that can be controlled through nutritious diet, physical activity, behavioral modifications, etc.



### Scientific Session-VIII

Scientific Session-VIII themed on 'Health & Wellness' was chaired by Prof. Geer Mohammad Ishaq, Department of Pharmaceutical Sciences, University of Kashmir, Srinagar and Prof. Bashir Ganai, Former Director, CORD, University of Kashmir, Srinagar. Dr. S. M. Salim Khan, Department of Social and Preventive Medicine, Government Medical College, Srinagar, Prof. F. S. Sherani, Dean, Ajmal Khan Tibbiya College, AMU, Aligarh, Dr. Shazia Banday, Medical Officer, Directorate of Ayush, J&K and Dr. Shazia Noor, Principal, Kashmir Tibbiya College and Hospital and Research Centre, Sumbul, J&K were speakers of the session. They delivered their addresses on 'Preventive Medicine for Maintenance of Health', 'Asbāb Sitta Āarūriyya in Modern Perspective', 'Unani Medicine for General Wellbeing' and 'Prospects of Medical Tourism in Unani Medicine in Kashmir', respectively.

Dr. S. M. Salim Khan explained the concept of maintenance of good health and different types of prevention. He emphasized the need for promotion of health education and maintaining the emotional, social, physical and mental health by health counselling.

Dr. F. S. Sherani discussed the relevance of emotional understanding with reference to Asbāb Sitta Āarūriyya and focused on doctor-patient relationship in clinic as well as on holistic approach to treat the disease.

Dr. Shazia Banday discussed Unani Medicine as a comprehensive medical system providing promotive, preventive, curative and rehabilitative health care for general well-being with a holistic approach considering each individual in relation to his/her environment and emphasizing the health of body, mind and soul.

Dr. Shazia Noor said that Kashmir is the paradise on the earth and has rich tradition of Unani medical practices. He added that with the scenic beauty, Kashmir is blessed with lush green meadows, flowing water resources and moderate temperature that provide a natural atmosphere for a patient to feel healthy and that the valley has great potential for Unani Medicine in medical tourism.

#### 4.2.2. Ayush Minister visits CCRUM, appreciates research work

Hon'ble Union Cabinet Minister, Ministry of Ayush and Ministry of Ports, Shipping and Waterways Shri Sarbananda Sonowal visited Central Council for Research in Unani Medicine and other research councils and the two national commissions situated in the Central Councils Combined Building Complex (CCBC) at Janakpuri, New Delhi on September 18, 2021.

During his address on the occasion, Shri Sonowal said that Ayush Aahaar should be promoted throughout the country. This would help saving the youth from the ills of junk food. He laid emphasis on the involvement of people at the grass root level. He also added that team spirit and hard work were needed to bring in effective change.

During the interaction, Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush stressed that competency building should be the priority of all councils and 'our research councils should develop such modalities that various units attached with them get more freedom to innovate'. Hon'ble Minister interacted with Director General Prof. Asim Ali Khan and senior officers of the CCRUM about the research activities and appreciated its functioning and research endeavours. He also appreciated the infrastructure of CCRUM's institute in Srinagar that he visited a week ago. Further, he visited CCRUM library and was briefed about the large collection of about 200 manuscripts and as many as 17000 scientific documents. He was also informed about the scientific activities and publications of the CCRUM. Hon'ble Minister

showed keen interest in the research publications of the CCRUM. He also interacted with officers and scientists of all the offices in the premises of the CCCBC.

Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Ms. Kavita Garg, Joint Secretary, Ministry of Ayush, Shri D. Senthil Pandiyan, Joint Secretary, Ministry of Ayush, Prof. Asim Ali Khan, Director General, CCRUM, Dr. N. Srikanth, Director General, Central Council for Research in Ayurvedic Sciences, Dr. Anil Khurana, Director General, Central Council for Research in Homoeopathy and Chairperson, National Commission for Homoeopathy, Vaidya Jayant Deopujari, Chairman, National Commission for Indian System of Medicine, Dr. Raghvendra Rao, Director, Central Council for Research in Yoga and Naturopathy, and Dr. Manoj Nesari, Adviser (Ayurveda), Ministry of Ayush were present on the occasion.

#### 4.2.3. Ayush Minister inaugurates BUMS at GUMC&H, J&K

Shri Sarbananda Sonowal, Hon'ble Union Cabinet Minister, Ministry of Ayush and Ministry of Ports, Shipping and Waterways inaugurated the first batch of Bachelor of Unani Medicine and Surgery (BUMS) course at Government Unani Medical College and Hospital (GUMC&H), Nawab Bagh, Ganderbal in Jammu & Kashmir on September 17, 2021.

Hon'ble Lieutenant Governor of the UT of J&K Shri Manoj Sinha virtually graced the event of GUMC&H established with the financial assistance of Rs. 17.00 Crore from the Ministry of Ayush under its erstwhile Central Sector Scheme, Rs. 18.25 Crore from the UT Government and Rs. 38.82 lakhs under the National Ayush Mission for operationalization of the college.

During his inaugural address at the first government Unani institution in the Union Territory of J&K, Hon'ble Minister said that the Ayush Ministry is determined to provide basic healthcare services to the people of UT especially through Unani Medicine which is very popular in the region. Terming the inauguration of BUMS course as a historic moment, he said that the institution will go a long way to promote the indigenous systems of medicine in the UT of J&K. He further said that it is always refreshing to be present in Kashmir – the paradise on the earth. This master piece of earth's creation and the repository of ancient cultural heritage of India have nurtured Unani Medicine, one of our Ayush systems of medicine, for centuries. He said that it has been playing a vital role in the present day health care delivery system. He further said that the significant features of Unani Medicine are accessibility, affordability and holistic approach towards healthy living.

On this occasion, Prof. Asim Ali Khan, Director General, Central Council for Research in Unani Medicine and Adviser (Unani), Ministry of Ayush said that Unani Medicine is a comprehensive medical system, which meticulously deals with the various states of health and disease. It provides promotive, preventive, curative and rehabilitative healthcare. He further said that the CCRUM has a vision to strive for excellence and global leadership in the field of Unani Medicine by comprehensive research for quality assured and cost effective products to prevent, manage and cure diseases.

Later, Hon'ble Minister took round of OPD, operation theatre, various labs and all blocks of the academic building of the college with intake capacity of 60 BUMS students and a 60-bedded hospital. He also kick started a plantation drive by planting a medicinal sapling in the premises of the college.

Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Government of India, Dr. Mohan Singh, Director, Indian Systems of Medicine (Ayush), J&K and Dr. Seema Akbar, Assistant Director, Regional Research Institute of Unani Medicine, Srinagar were present on the occasion.

On 16th September and early 17th September, Hon'ble Minister was in Baramulla district for a public outreach programme. He interacted with Deputy Commissioner, Baramulla about the challenges and opportunities in the district. He inspected the exhibition of Ayush and inaugurated the seminar on Ayush interventions with a special focus on Ayush Health & Wellness Centres for the development of modern Kashmir at Dak Bungalow, Baramulla. Speaking on this occasion, he assured that district Baramulla will be provided every possible assistance and manpower for vibrant integrated Ayush system of medicine. Hon'ble Minister also inaugurated a cricket tournament at Showkat Ali Stadium, Khawaja Bagh, Baramulla and interacted with the teams. During his address on this occasion, he appreciated the youth for organizing the tournament to defeat the menace of drugs and antisocial activities. Hon'ble Minister also had an interactive session with the Presidents of District Development Council, Block Development Council and Municipal Corporation at Dak Bungalow, Baramulla and took account of issues faced by them and their demands.

#### 4.2.4. Ayush Minister visits RRIUM, Srinagar, leads plantation drive

Shri Sarbananda Sonowal, Hon'ble Union Cabinet Minister, Ministry of Ayush and Ministry of Ports, Shipping and Waterways led a plantation drive in Srinagar to mark Hon'ble Prime Minister Shri Narendra Modi's 71<sup>st</sup> birthday on September 17, 2021. Under this drive, a total of 71 saplings of medicinal plants were planted in the premises of the Regional Research Institute of Unani Medicine (RRIUM), Srinagar - a regional institute of the Central Council for Research in Unani Medicine (CCRUM), Ministry of Ayush, Government of India located in the campus of the University of Kashmir, Srinagar.

Shri Pramod Kumar Pathak, Special Secretary, Ministry of Ayush, Government of India, Prof. Asim Ali Khan, Director General, CCRUM, Dr. Mohan Singh, Director, Indian Systems of Medicine (Ayush), J&K, Dr. Abdul Kabir Dar, Director General, Stationery & Office Supplies, J&K and Dr. Seema Akbar, Assistant Director, RRIUM, Srinagar were present on the occasion and participated in the plantation drive.

Speaking on the occasion, Hon'ble Minister applauded the role of Unani Medicine and other Indian systems of medicine in public healthcare delivery and said that the Government of India has accorded great importance to their multifaceted development. He further said that the CCRUM has made great progress in clinical research, drug standardization, survey and cultivation of medicinal plants and literary research in Unani Medicine. He visited the different types of Unani treatment facilities available at the RRIUM and interacted with OPD and IPD patients to know about their health condition and get their feedback about the quality of health care provided to them. He also visited and appreciated testing and research labs as well as various research sections of the institute and stressed for their further strengthening.

Earlier in his welcome address, Prof. Asim Ali Khan expressed his gratitude to the Hon'ble Minister for visiting the institute and informed about the research projects being conducted at the institute. He said that the institute also provides various health care facilities such as OPD, IPD and medical investigation facilities.

#### 4.2.5. Ayush Minister visits RRIUM, Srinagar

Shri Kiren Rijiju, Hon'ble Minister of State (IC), Youth Affairs & Sports, Minister of State, Ministry of Minority Affairs, and Additional Charge, Minister of State (IC), Ministry of Ayush, Government of India visited CCRUM's Regional Research Institute of Unani Medicine, Srinagar on April 09, 2021 and took overall review of its functioning as well as physical infrastructure and laboratories.

During his visit, Shri Rijiju oversaw the different types of Unani treatment including cupping without scarification, cupping with scarification, *Inkibāb* (steam inhalation), *Naṭūl* (irrigation) and *Dalk* (massage) provided to patients. On the occasion, Hon'ble Minister said that he is impressed with the ISM treatment and stressed for its further promotion so that maximum people get its benefit. Hon'ble Minister took round of all testing and research labs including biochemistry, radiology, photochemistry, histology and other labs and took on-spot review of their functioning. Speaking on the occasion, Shri Rijiju said that he is pleased to visit the institute and oversee the treatment given to ailing patients. He appreciated research work being carried at the institute and emphasised improvising the treatment and other activities of the institute. He assured that the government would provide all necessary support for further development and promotion of infrastructure of the institute. "Every disease has specific treatment and can be cured by Unani, Ayurveda or Psychological treatment", Shri Rijiju said. While referring to the history of Unani Medicine, he said Kashmir had adopted Unani Medicine much earlier. In relation to the prevailing pandemic, Hon'ble Minister said that traditional system of medicine has become a vital method to fight the pandemic in recent times. He also interacted with the patients admitted in the institute and enquired about their wellbeing and recovery. Patients on the occasion apprised him regarding the facilities available to them and the quality of treatment provided.

Earlier, Shri Kiren Rijiju planted a sapling of *Prunus armeniaca* L. (apricot) in the premises of the institute and watered it. He was briefed regarding the benefits of the tree by the officers of the institute. Among others present on the occasion were Prof. Asim Ali Khan, Director General, CCRUM, Prof. Nisar Ahmad, Registrar, University of Kashmir, Prof. Shabir Ahmad Bhat, Dean-Academic Affairs, University of Kashmir, Dr. Seema Akhbar, Assistant Director, RRIUM, Srinagar and other officers, staff and students of the institute.

#### 4.2.6. National seminar on IPR

The CCRUM, in collaboration with the National Medicinal Plants Board (NMPB), Ministry of Ayush, Government of India, organized National Seminar on Intellectual Property Rights (IPR) at its National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad on November 25, 2021.

Shri Pramod Kumar Pathak, Special Secretary to the Government of India, Ministry of Ayush presided over the function. He highlighted the mandate of the Ministry of Ayush and support provided for overall development of Unani Medicine. He stressed the importance of obtaining patents particularly for innovations in the field of Ayush systems.

Prof. (Dr.) M. Afshar Alam, Vice Chancellor, Jamia Hamdard, New Delhi, the chief guest on the occasion, emphasized the potential of Unani Medicine as well as other Indian traditional systems of medicine, and their possible applications in intellectual property rights.

Speaking on the occasion, Prof. Asim Ali Khan, Director General, CCRUM gave a brief overview of the functioning of the CCRUM and highlighted its achievements in the area of intellectual property rights. He informed that the CCRUM has been granted 17 patents by the Indian Patent Office (IPO), and seven patent applications are under consideration of the IPO. He also informed that measures are being taken to further strengthen activities related to IPR at the CCRUM headquarters and its peripheral institutes.

Dr. Waseem ur Rehman, Additional Commissioner, Income Tax Department, Hyderabad urged the CCRUM to evolve an IP strategy for inventors and make efforts for obtaining patents at the national and international levels.



Dr. Ahmed Minhajuddin, Deputy Director Incharge, NRIUMSD, Hyderabad shed light on various activities of the institute and assured to take the institute to greater heights.

Dr. Ghazala Javed, Research Officer (Unani) Scientist-IV at CCRUM headquarters and nodal officer for NRIUMSD, Hyderabad coordinated the proceedings of the inaugural event. Dr. Pawan Kumar, Research Officer (Pathology) Scientist-IV and his associates Dr. Usama Akram, Research Officer (Unani) and Dr. Saad Ahmed, Consultant (Unani), CCRUM coordinated the seminar. Around 200 delegates from academia, industry, regulators and researchers in the field of Unani Medicine from various organisations participated in the seminar.

The seminar covered various aspects of IPR and related issues in three technical sessions which had invited experts from various institutions like National Research Development Corporation, New Delhi; National Institute of Pharmaceutical Education and Research, Hyderabad; CSIR-Indian Institute of Chemical Technology, Hyderabad; Government Nizamia Tibbi College, Hyderabad; Dr. BRKR Govt. Ayurvedic Medical College, Hyderabad; Dr. Reddy's Laboratories, Hyderabad, etc. The seminar provided a platform to academia, researchers, regulators, industries and students to develop an understanding of intellectual property rights, innovations and practices, and promoting Unani Medicine across the globe.

#### 4.2.7. Training programme on implementation of NABH accreditation

The CCRUM, in collaboration with the National Accreditation Board for Hospitals and Health Care Providers (NABH), organised a 3-day training programme on implementation of NABH accreditation standards for Unani hospitals during July 28–30, 2021 in virtual mode.

Inaugurating the training programme, Prof. Asim Ali Khan, Director General, CCRUM highlighted the importance of Unani Medicine and other Ayush systems in the health care delivery. He said that Ayush systems play a very important role in providing health care to the society. He also highlighted the importance of standardization of health care services and hospitals and role of the NABH in this area. He informed that CCRUM's National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad has already been accredited by the NABH and other institutes are going to be accredited in due course.

Speaking about the background of the programme, Dr. Atul Mohan Kocchar, CEO, NABH said that the aim of the programme is to develop internal counsellors within Unani hospitals for helping them to work towards the implementation of quality and patient safety standards, achieving accreditation and maintaining the same.

The 3-day training programme was attended by Unani professionals from different parts of the country. Dr. Ghazala Javed, Research Officer (Unani) Scientist-IV, CCRUM and Dr. Vandana Siroha, Deputy Director, NABH coordinated the training programme.

#### 4.2.8. National seminar on research methodology

The CCRUM organized National Seminar on Research Methodology at India Habitat Centre, New Delhi on November 11, 2021.

Speaking on the occasion, Prof. Asim Ali Khan, Director General, CCRUM and Adviser (Unani), Ministry of Ayush, Government of India thanked Prof. Najma Akhtar, Vice Chancellor, Jamia Millia Islamia, New Delhi for gracing the occasion as the chief guest. Prof. Khan elaborated upon the achievements of the CCRUM in the area of clinical research, drug standardization, survey and cultivation of medicinal plants and literary research and highlighted the contributions of collaborating institutes. He made a special mention of the contributions of Jamia-based Hakim Ajmal Khan Institute for Literary and Historical Research



in Unani Medicine in preservation, translation, documentation and reproduction of classical texts and knowledge of Unani Medicine. Prof. Khan also appreciated featuring of 16 researchers from Jamia Millia Islamia in Stanford list of top scientists and congratulated Prof. Najma Akhtar for this achievement under her leadership.

Prof. Najma Akhtar during her address informed about the recent accolades bestowed on Jamia Millia Islamia, especially securing sixth rank among the 'Top 10 Universities' of the country in the National Institutional Ranking Framework (NIRF)-2021. Prof. Najma Akhtar also recalled her close and cordial association of more than 25 years with Prof. Asim Ali Khan and was hopeful that this association would lead to strong interactions between academia and researchers of their institutions for the betterment of each other's organisation in particular and society at large. She acknowledged the national and global presence of Unani Medicine and expressed her appreciation for the work done by the CCRUM. She lauded Prof. Asim Ali Khan and his team for the commendable milestones achieved through various research programmes.

Prof. Akhtar and Prof. Khan also had detailed discussions on strengthening collaborations between the two institutes. In the coming days, both the leaders plan to have a series of meetings to take forward the work in multifaceted area of research and reaping maximum benefit from the expertise available in both the organisations. Prof. Najma Akhtar and Prof. Khan felt that the CCRUM and Jamia Millia Islamia can carry forward the existing association in a more structured manner by some permanent and sustainable mechanism in the mutually agreed areas related to academic and research activities. While responding to the media, both Prof. Akhtar and Prof. Khan appreciated the efforts done by the CCRUM and JMI and felt that there is a need for research in Traditional Medicine and herbal sciences for finding solutions to various healthcare challenges.

Dr. R. K. Manchanda, Director of Ayush, Govt. of NCT of Delhi highlighted the importance of research methodology and appreciated contributions of the CCRUM in the area of research and development in Unani Medicine. Dr. Mukhtar Ahmad Qasmi, Joint Adviser (Unani), Ministry of Ayush, Government of India said that with the support and patronage of the Ministry of Ayush, the CCRUM has done commendable work. The inaugural session of the seminar concluded with vote of thanks proposed by Dr. Ghazala Javed, Research Officer (Unani) Scientist-IV, CCRUM.

The seminar had two technical sessions during which lectures were delivered by Dr. Jugal Kishore, Head, Department of Community Medicine, Safdarjung Hospital, New Delhi, Prof. K. M. Y. Amin, Aligarh Muslim University, Aligarh, Prof. Manish Goel, Lady Hardinge Medical College, New Delhi, Dr. Shekhar Grover, Maulana Azad Institute of Dental Sciences, New Delhi and Dr. Tanu Anand, Scientist-D, Indian Council of Medical Research, New Delhi. Scientists, academicians, researchers and students from Jamia Millia Islamia, Jamia Hamdard, A&U Tibbia College, Delhi University, Amity University and other research and academic institutions as well as researchers from the CCRUM headquarters and institutes participated in the seminar. Dr. Pawan Kumar, Research Officer (Pathology) Scientist-IV and his associates Dr. Usama Akram, Research Officer (Unani) and Dr. Saad Ahmed, Consultant (Unani), CCRUM coordinated the seminar and Dr. Nighat Anjum, Research Officer (Unani) Scientist-III conducted the seminar proceedings.

#### 4.2.9. National seminar on IPR

The CCRUM organized a national seminar on 'Intellectual Property Rights (IPR)' at its Chennai-based Regional Research Institute of Unani Medicine (RRIUM) on March 30, 2022.

Prof. Mohammad Afshar Alam, Vice Chancellor, Jamia Hamdard, New Delhi addressed the seminar as the chief guest.

Speaking on the occasion, Prof. Mohammad Afshar Alam said, 'Unani Medicine is flourishing well in India and it is satisfying that we are partners in the development of this medical system'. He further said that the CCRUM is the apex body for research and development in Unani Medicine and we have signed an MoU with the CCRUM to extend our contributions to the cause. Speaking about the theme of the seminar, he said that creation of IPR is very important for the progression of science and economic prosperity.

In his presidential address, Prof. Asim Ali Khan, Director General, CCRUM said that the Government of India under the dynamic leadership of Hon'ble Prime Minister Shri Narendra Modi has been providing increasing patronage and funds for multifaceted development of Unani Medicine as well as other Indian systems of medicine. Prof. Khan informed that the CCRUM has been making concerted efforts for setting up standards for research, training and practice of Unani Medicine and has obtained NABH accreditation for National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad and RRIUM, Srinagar and efforts are on for accreditation of other healthcare facilities under the CCRUM. He apprised that the WHO in collaboration with the Ministry of Ayush has recently published 'WHO Benchmarks for the Training of Unani Medicine' and 'WHO Benchmarks for the Practice of Unani Medicine'. Speaking about the seminar, Prof. Khan said that it is a continuum of our efforts to train researchers, academicians and other stakeholders about intellectual property rights. He informed that the CCRUM has already obtained 17 patents on its intellectual property rights and more are in pipeline.

Shri S. Thangapandian, Deputy Controller of Patents and Design, Indian Patent Office, Chennai and Prof. Abdul Wadud, Director, National Institute of Unani Medicine, Bengaluru were guests of honour on the occasion and addressed the inaugural function of the seminar. Earlier, Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai delivered welcome address and spoke about the background of the seminar. The seminar had three technical sessions including a panel discussion, wherein eminent speakers articulated the intellectual property rights with focus on herbal drugs and products.

#### 4.2.10. Webinar on healthcare standards

The Regional Research Institute of Unani Medicine (RRIUM), New Delhi organized a webinar on 'healthcare standards' on January 21, 2022 as a part of pre-activities of Unani Day 2022. Dr. Vandana Siroha, Deputy Director, National Accreditation Board for Hospitals & Healthcare Providers (NABH) and Dr. Munawwar Husain Kazmi, Former Director, National Research Institute of Unani Medicine for Skin Disorders, Hyderabad delivered their talks on 'healthcare standards and accreditation in Unani Medicine'. The webinar started with introductory remarks by Dr. Rahat Raza, Deputy Director, RRIUM, New Delhi. Dr. Shaista Urooj, Research Officer (Unani), RRIUM, New Delhi conducted the proceedings of the webinar which was attended by a hundred participants comprising researchers and scientists.

The webinar concluded with vote of thanks proposed by Dr. Abdul Raheem, Research Officer (Unani) Scientist-IV and Incharge, Unani Medical Centre, Dr. Ram Manohar Lohia Hospital, New Delhi.

#### 4.2.11. Webinar on 'Bio-ethics with emphasis on GCP guidelines'

The CCRUM through its Regional Research Institute of Unani Medicine (RRIUM), Chennai organized a webinar on 'Bioethics with Emphasis on GCP Guidelines' on February 05, 2022. The webinar was organized as a part of pre-activities of Unani Day 2022.

Speaking on the occasion, Prof. Asim Ali Khan, Director General, CCRUM emphasized the importance and significance of bioethics for research and development activities. He also highlighted the activities and contributions of the CCRUM and its peripheral institutes with regard to the development of safe and quality healthcare culture in Unani hospitals and research organizations across the country.

Addressing the webinar, Dr. Nandini K. Kumar, formerly Deputy Director General, Indian Council of Medical Research (ICMR) and Vice President, Forum of Ethical Review Committees in India highlighted ethical issues arising during medical practice as well as biasness and discrepancies while publishing research articles. Prof. Abdul Wadud, Director, National Institute of Unani Medicine (NIUM), Bengaluru underscored the historical aspects of bioethics in Unani Medicine and ancient civilizations and highlighted its importance in the current scenario. The webinar had lectures and presentations in two technical sessions on the basic ethical principles of biomedical research as reflected in GCP guidelines impacting on the role and responsibilities of each stakeholder. Dr. Jugal Kishore, Head, Department of Community Medicine, Safdarjung Hospital, New Delhi, Dr. G. Narendran, Scientist-E, ICMR-National Institute of Research in Tuberculosis (NIRT), Chennai, Prof. Mohd Aleemuddin Quamri, Head, Department of Amraze Jild wa Tazyeeniyat, NIUM, Bengaluru, Dr. Bano Rekha, Scientist-E, ICMR-NIRT, Chennai, Dr. Melvin George, Associate Professor, SRM Medical College Hospital & Research Centre, Chennai and Dr. C. Ponnuraja, Scientist-E, ICMR-NIRT, Chennai were speakers of the webinar. Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai and his team comprising Dr. T. Shahida Begum, Dr. Noman Anwar and others organized and managed the proceedings of the webinar. Researchers from the CCRUM and other institutions participated in the webinar in large number.

#### 4.2.12. Seminar on mental health

The Regional Research Institute of Unani Medicine (RRIUM), Mumbai, a peripheral institute of the CCRUM, organised a national seminar on mental health on February 08, 2022 in hybrid mode. The seminar was themed on 'Opening doors to quality mental health care through Unani system of medicine'. Addressing the seminar, Prof. Asim Ali Khan, Director General, CCRUM emphasized the need to address the silent pandemic of mental illness which has been accentuated by the COVID-19 pandemic. He urged to plan research activities of various institutes under the CCRUM in such a way that Unani Medicine may become a major contributor for awareness and upkeep of mental health. He said that mental health is the national priority today; hence, there cannot be a better time for Unani Medicine to explore its potential in this field and deliver comprehensive mental health care regimens.

Dr. Nirmala Devi, Research Officer Incharge, RRIUM, Mumbai stressed the need for collective efforts from all medical systems to deliver integrated mental healthcare management system for alleviating the turmoil faced by those suffering from any sort of mental illness. Dr. Varsha Dawani, Chief Psychiatrist, Central Hospital, Mumbai, Dr. Archana Gadkari, Head, Department of Psychiatry, Central Hospital, Mumbai and Dr. Isa Nadvi, Professor, Dr. M. I. J. Tibbia Unani Medical College, Mumbai were speakers of the seminar. Poster and paper presentations by researchers gave the programme a further scientific touch

and highlighted the research work of the CCRUM in the field of mental health. Dr. Humaira Bano, Dr. Nikhat Shaikh, Dr. Irfan Ahmed, Dr. Mohd. Adil and other officers of RRIUM, Mumbai organized and managed the proceedings of the seminar.

#### 4.2.13. Webinar on research methodology

As a pre-activity to mark Unani Day 2022, the Central Research Institute of Unani Medicine (CRIUM), Lucknow organized a webinar on 'Research Methodology' on January 20, 2022.

Dr. Arshiya Sultana, Associate Professor, Department of Ilmul Qabalat wa Amraz-e-Niswan, National Institute of Unani Medicine (NIUM), Bengaluru delivered a detailed talk on 'Writing of clinical trial protocol'. Dr. Vahab Ali, Scientist G, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna delivered his presentation on 'Ethics in research and publication'. The webinar started with introductory remarks by Dr. Mohammad Nafees Khan, Deputy Director, CRIUM, Lucknow. Dr. Mahboobus Salam conducted the proceedings and Dr. Najmus Sehar proposed vote of thanks. More than a 100 participants attended the webinar.

#### 4.2.14. Webinar on managerial effectiveness

The Regional Research Institute of Unani Medicine (RRIUM), Mumbai organised a national webinar on 'Introduction to Managerial Effectiveness' on January 28, 2022. It was organized as a pre-activity to mark Unani Day 2022. Colonel Naresh Rajendra Sinha, Coach for Managerial & Leadership Skills delivered a very informative lecture on capacity building, skill development and managerial effectiveness. Dr. Nirmala Devi, Research Officer Incharge, RRIUM, Mumbai chaired the webinar which was attended by more than a 100 participants from different walks of life. Dr. Nikhat Shaikh, Research Officer (Unani), RRIUM, Mumbai coordinated the proceedings of the webinar.

#### 4.2.15. Webinar on drug development

The CCRUM's Regional Research Institute of Unani Medicine (RRIUM), Chennai organized a national webinar on 'Drug Development in Unani Medicine' on January 27, 2022 as part of pre-activities of Unani Day 2022. The webinar aimed at exploring the scope and challenges of Unani drug development and enabling the participants to upscale their knowledge about novel drug discovery, phases of clinical trials and regulatory issues that arise during drug discovery and development. Prof. K. M. Y. Amin, Aligarh Muslim University, Aligarh delivered a comprehensive talk on 'Drug Development in Unani Medicine – Scope and Challenges', whereas Dr. Sayeed Ahmad, Jamia Hamdard, New Delhi highlighted 'Regulatory Issues in Drug Development'. The webinar was very successful in terms of content and deliberations. About 250 delegates from various Ayush institutions attended the webinar with great zeal and enthusiasm.

#### 4.2.16. Webinar on lifestyle

The Regional Research Institute of Unani Medicine (RRIUM), Aligarh organized a webinar on 'lifestyle' on January 05, 2022 to raise awareness about the impact of way of living on physical and mental health.

Dr. Asia Sultana, Department of Ilaj-bit-Tadbeer, Aligarh Muslim University, Aligarh as the resource person of the webinar delivered an extensive talk on healthy lifestyle as advocated in Unani Medicine. The webinar started with welcome address by Dr. Sheereen Afza, Research Officer Incharge, RRIUM, Aligarh. Dr. Parvez Khan, Dr. Rashidul Islam Ansari, Dr. Sada Akhtar, Dr. Sajid Aqeel and other officers from the RRIUM and about a 100 participants attended the webinar.

#### 4.2.17. Webinar on Unani Medicine

The National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad organized a webinar on 'Fundamental Aspects of Unani Medicine' on January 31, 2022. Prof. Dr. Ghulamuddin Sofi, Head, Department of Ilmul Advia and Dr. Wasim Ahmad, Assistant Professor, Department of Kulliyat, National Institute of Unani Medicine (NIUM), Bengaluru delivered invited talks on 'Understanding Basic Principles of Unani Medicine' and 'Hypertension in the Viewpoint of Unani System of Medicine – An Interpretation'. In his opening remarks, Dr. Ahmed Minhajuddin, Director Incharge, NRIUMSD, Hyderabad accentuated the importance of understanding the fundamentals of Unani Medicine. The webinar concluded with the vote of thanks presented by Dr. Anwar Ahmad, Research Officer (Unani) Scientist-IV, NRIUMSD.

#### 4.2.18. Webinar on Pharmacovigilance

The CCRUM through its Regional Research Institute of Unani Medicine (RRIUM), Mumbai organized a webinar on 'Pharmacovigilance Programme of ASU&H Drugs' on March 16, 2022. The webinar aimed to create awareness about pharmacovigilance and inculcate the habit of reporting adverse drug reactions among Ayush professionals and other stakeholders.

Speaking on the occasion, Dr. N. Zaheer Ahmed, Deputy Director, RRIUM, Chennai presented basic information and introduction of pharmacovigilance. He also elaborated on the scope and key functionality of peripheral pharmacovigilance centres of the CCRUM. Dr. Humaira Bano, Research Officer (Unani), RRIUM, Mumbai and Dr. Mohd Aleemuddin Quamri, National Institute of Unani Medicine, Bengaluru delivered their lectures on 'Pharmacovigilance of Ayush drugs – An appraisal' and 'Importance of forms of drugs in Unani system of medicine in perspective of pharmacovigilance', respectively. Earlier, Dr. Nirmala Devi, Research Officer Incharge, RRIUM, Mumbai highlighted the aims and objectives of the webinar. Dr. Nikhat Shaikh, Research Officer (Unani), RRIUM, Mumbai presented vote of thanks.

#### 4.2.19. Webinar on COV ID-19

The CCRUM organized a webinar on 'Stress Management during COVID-19 Pandemic: Role of Yoga & Unani Practices' on June 19, 2021.

The webinar began with the introductory address by Prof. Asim Ali Khan, Director General, CCRUM. He highlighted the potential of Unani Medicine in dealing with the stress due to COVID-19 pandemic. He said that Unani Medicine has much to offer for stress management. He added that the Traditional Healthcare Systems of the country provide lifestyle advocacies to boost immunity which helps in the prevention of various kinds of infectious diseases. He further said that in Unani Medicine more emphasis is given to strengthen the immune status of the patient in order to make body's resistance stronger.

Dr. Arzeena Jabeen, Research Officer (Unani) Scientist-IV, National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad spoke on "Unani Medicine for Mental Health" and said that according to Unani Medicine Quwwat-e-Mutafakkirah (faculty of thinking) is the natural power that controls anxiety. She added that there are high protein seeds which are used by Unani physicians to provide stimulus as brain tonic and strengthen the nervine activity. She further said that massage with certain herbal oils is also recommended to overcome anxiety.

In his lecture on 'Effectiveness of Unani regimenal therapies in stress management', Dr. K. T. Ajmal, Director, Calicut Unani Hospital & Research Centre (CUHRC), Calicut, Kerala said that regimental therapies are mostly non-medicinal techniques or procedures by which Unani physicians modulate the patient's habitat, lifestyle and dietary habits. He added that these



practices are very useful in the prevention and treatment of various health issues including stress and anxiety.

Dr. Vadiraja H. S., Research Officer (Yoga & Naturopathy), Central Council for Research in Yoga & Naturopathy (CCRYN) delivered a lecture on the “Role of Yoga in Stress Management during COVID-19”. In his address, Dr. Vadiraja said that Yoga gives us better body alignment and posture, stronger muscle strength, increased self-awareness, greater flexibility, lower blood pressure, and more resilient mental and physical capacities. The webinar concluded with vote of thanks proposed by Dr. Ghazala Javed, Research Officer (Unani) Scientist-IV, CCRUM.

#### 4.2.20. Webinars on information technology

The CCRUM organised four webinars on information technology during July 12–28, 2021. Inaugurating the webinar series, Prof. Asim Ali Khan, Director General, CCRUM said that information technology is instrumental to scientific research and this webinar series aims at training Unani researchers to effectively use different IT tools for research and development purposes. He highlighted the importance of IT in combatting COVID-19 crisis. He said that when the government authorities across the world resorted to impose lockdown to contain the spread of COVID-19 pandemic, IT came in to play a very crucial role to resume essential activities through different platforms. During the webinar series, basic know-how of various IT-based communication platforms like Google Meet, MS Team, Cisco Webex and some essential software for research data collection and analysis were discussed and their live application was demonstrated. The webinar series was coordinated by IT Section as well as Statistics Section of the CCRUM.

#### 4.2.21. Webinar on pharmacovigilance

The Central Research Institute of Unani Medicine (CRIUM), Lucknow as the Peripheral Pharmacovigilance Centre (PPvC) organized a webinar on ‘Awareness Programme on Pharmacovigilance of ASU&H Drugs’ on November 12, 2021 through Google Meet. Addressing the webinar, Dr. Muhammad Nafees Khan, Deputy Director, CRIUM, Lucknow highlighted the objectives of the pharmacovigilance programme and significance of quality control of Ayurveda, Siddha, Unani and Homoeopathy drugs. Dr. Tarique Mahmood, Integral University, Lucknow and Dr. Md. Aleemuddin Quamri, National Institute of Unani Medicine, Bengaluru delivered their lectures on the pharmacovigilance of ASU drugs and emphasized the importance of adverse drug reaction monitoring and reporting. Ayush professionals including practitioners, academicians, researchers, pharmacists, nurses as well as students and Ayush stakeholders from different parts of the country attended the webinar.

### 4.3. Participation in Arogya Fairs/ Expos

The Ministry of Ayush, Government of India in collaboration with state governments and other stakeholders organizes and participates in Arogya fairs/expos and similar events to propagate Indian systems of medicine, highlight activities and achievements of its research councils, provide free-of-cost diagnosis and treatment to the ailing visitors, and impart awareness about health, hygiene, and curative aspects of ill-health. The CCRUM and its institutes on the direction of the Ministry of Ayush participated in national and state level Arogya fairs and similar events held during the reporting period.

During all these events, the CCRUM showcased its progress in the area of clinical research, drug standardization, survey and cultivation of medicinal plants, and literary research. It also

displayed posters and charts highlighting various concepts of Unani Medicine. Besides, some important publications of the CCRUM like Unani Pharmacopoeia of India, National Formulary of Unani Medicine, Hippocratic Journal of Unani Medicine, Standard Unani Medical Terminology, and Standard Unani Treatment Guidelines for Common Diseases were put on display. With a view to create awareness about healthy living and intervention of Unani Medicine in curing diseases and promoting health, free-of-cost literature on Unani Medicine and success stories on treatment of some chronic and common diseases were distributed among the visitors. The CCRUM also deployed its physicians to provide free consultation and treatment to the ailing visitors seeking Unani treatment. Lectures on various health issues were also delivered by CCRUM researchers. The list of the events is as follows:

S. N.	Name of Event	Place	Duration
1.	National Level Arogya Fair	Ahmedabad, Gujarat	9–12 April 2021
2.	Ayurveda Parv	Jalandhar, Punjab	19–21 March 2021
3.	State Arogya Fair	Greater Noida, U.P.	25–27 September 2021
4.	National Health Exhibition	Kolkata, West Bengal	28–31 October 2021
5.	Ayurveda Day	Jaipur, Rajasthan	1-2 November 2021
6.	Ayurveda Parv	Chandigarh	12-14 November 2021
7.	India International Trade Fair	New Delhi, Delhi	14-27 November 2021
8.	State Arogya Fair	Tanakpur, Uttarakhand	18–21 November 2021
9.	Ayurveda Parv	New Delhi, Delhi	26–28 November 2021
10.	Punjab International Trade Expo	Amritsar, Punjab	2-6 December 2021
11.	Ayurveda Parv	Rajgir, Bihar	11–13 December 2021
12.	National Level Arogya Fair	Bengaluru, Karnataka	8–12 December 2021
13.	India International Science Festival	Goa	10–13 December 2021
14.	Ayush Mela	Ayodhya, U.P.	24 December 2021
15.	North East Festival	Guwahati, Assam	7–9 January 2022
16.	Yoga Fest	Nathdwara, Rajasthan	8-10 January 2022
17.	Vigyan Sarvatra Pujiyate Mega Expo	New Delhi, Delhi	22-28 February 2022
18.	International Ayuryog Expo	Virtual	24–26 February 2022
19.	Ayush Expo and Food Festival	Jaipur, Rajasthan	11–13 March 2022
20.	State Level Arogya Fair at IHC	New Delhi, Delhi	24–26 March 2022
21.	Shining Maharashtra	Pune, Maharashtra	25–27 March 2022
22.	Bharat Bhagya Vidhata	New Delhi	25 March–3 April 2022

#### 4.4. Participation in Promotion of Official Language

The CCRUM puts its best efforts for promotion of the official language in day-to-day functioning and adopts appropriate measures as per time-to-time instructions and guidance from the Department of Official Language. The CCRUM has central as well regional official language implementation committees at its headquarters and regional research institutes/centers that monitor and review the status of the use of Hindi language in official dealings.

During the reporting period, the CCRUM conducted review meetings, organized Hindi workshops and observed Hindi Pakhwada at its headquarters and institutes. The Pakhwada was observed to mark Hindi Diwas on September 14 and motivate employees to create an environment for implementation of the Official Language Policy in day-to-day work.

Apart from organizing the Hindi Pakhwada, the CCRUM participated in the meetings of Town Official Language Implementation Committee and meetings of the Ministry of Ayush pertaining to the official language. The Rajbhasha Section conducted quarterly meetings of official language implementation committee wherein matters related to the organization of workshops, promotion of letter writing in Hindi, review of Hindi works in various sections of the CCRUM, review of quarterly reports of various institutes/centres, etc. were discussed and specific strategy was formulated. Besides, information, education and communication materials related to the promotion of Unani Medicine were printed in Hindi for distribution in health camps, Arogya fairs and exhibitions.

#### 4.5. Appointments

- Dr. Lubna Fatima was appointed Research Officer (Unani) at RRIUM, New Delhi on March 31, 2022.
- Dr. Shah Alam was appointed Research Officer (Unani) at RRIUM, Mumbai on March 28, 2022.
- Dr. Yasmeen Ansari was appointed Research Officer (Unani) at RRIUM, New Delhi on March 25, 2022.
- Dr. Ritu Karwasara was appointed Research Officer (Clinical Pharmacology) at RRIUM, New Delhi on March 25, 2022.
- Shri Aipuri Lingaraju was appointed Research Assistant (Chemistry) at NRIUMSD, Hyderabad on March 25, 2022.
- Shri Mahesh Kancherla was appointed Research Assistant (Chemistry) at RRIUM, Chennai on March 25, 2022.
- Shri Sidama Gopal was appointed Research Assistant (Chemistry) at DSRI, Ghaziabad on March 03, 2022.
- Shri Md. Sajid was appointed Research Assistant (Chemistry) at RRIUM, Srinagar on January 29, 2022.
- Shri Tirumala Santosh Kumar S. was appointed Research Assistant (Chemistry) at RRIUM, Chennai on January 20, 2022.
- Shri Suryansh Kashyap was appointed Research Assistant (Chemistry) at DSRI, Ghaziabad on January 11, 2022.
- Smt. Sadaf Subhani was appointed Research Assistant (Chemistry) at CCRUM Headquarters on December 17, 2021.

#### 4.6. Promotions

- Shri Taiyab Ali was promoted as Senior Stenographer on May 25, 2021.
- Shri Masroor Ahmad was promoted as Personal Assistant to Director General, CCRUM on May 21, 2021.

#### 4.7. Retirements

- Shri Bijender Singh Bisht, Lab Technician at RRIUM, New Delhi retired on superannuation on April 30, 2021.
- Smt. Pushpa Vishwanathan, Stenographer at RRIUM, Mumbai retired on superannuation on May 31, 2021.
- Shri Upendra Sahu, MTS at RRIUM, Bhadrak retired on superannuation on May 31, 2021.
- Dr. Haseeb Alam, Deputy Director (Unani) at RRIUM, Mumbai retired on superannuation on May 31, 2021.

- Shri Jitendra Singh, Lab Attendant at RRC, Prayagraj retired on superannuation on May 31, 2021.
- Dr. Munawwar Husain Kazmi, Director, NRIUMSD, Hyderabad retired on superannuation on June 30, 2021.
- Shri Tufail Ahmad, Ward Boy at RRIUM, Chennai retired on superannuation on June 30, 2021.
- Shri Rajesh Kumar, MTS at CRIUM, Lucknow retired on superannuation on June 30, 2021.
- Dr. Asiya Khanam, Assistant Director (Unani) at NRIUMSD, Hyderabad retired on superannuation on June 30, 2021.
- Smt. Nancy Priscilla, Social Worker at RRIUM, Chennai retired on superannuation on July 31, 2021.
- Smt. Tayyaba Mubeen, Assistant at NRIUMSD, Hyderabad retired on superannuation on August 31, 2021.
- Shri M. A. Bari Faruqi, Hindi Assistant at NRIUMSD, Hyderabad retired on superannuation on September 30, 2021.
- Shri Masroor Ahmed, Personal Assistant to Director General, CCRUM retired on superannuation on October 31, 2021.
- Shri G. Gopala Krishnan, Safaiwala at RRIUM, Chennai retired on superannuation on November 11, 2021.
- Smt. Khaja Begum, Aya at NRIUMSD, Hyderabad retired on superannuation on December 31, 2021.
- Smt. Shaheen Kosar, Lab Technician at CRU, Bhopal retired voluntarily on December 01, 2021.
- Shri Prasana K. Jena, Pharmacy Attendant at RRIUM, Bhadrak retired on superannuation on January 31, 2022.
- Shri Md. Quasim Khan, Pharmacist at CRIUM, Lucknow retired on superannuation on February 28, 2022.
- Shri Md Latif Dar, Lab Technician at RRIUM, Srinagar retired on superannuation on February 28, 2022.
- Shri Bashir A. Rather, Upper Division Clerk at RRIUM, Srinagar retired on superannuation on March 31, 2022.
- Shri R. Narender, Chowkidar at NRIUMSD, Hyderabad retired on superannuation on March 31, 2022.
- Shri Syed Shakeel Ahmad, Pharmacist at CRIUM, Lucknow retired on superannuation on March 31, 2022.

#### 4.8. Deaths

- Dr. Nusrat Hameed Khan, Research Officer (Unani) at RRIUM, New Delhi died in harness on May 06, 2021.
- Shri Hakimuddin Khan, Kitchen Servant at RRIUM, Bhadrak died in harness on June 07, 2021.
- Shri Md. Asadullah Khan, Field Attendant at NRIUMSD, Hyderabad died in harness on July 19, 2021.

## 5. FINANCIAL STATEMENT

### 5.1. Audit Report

SEPARATE AUDIT REPORT OF THE COMPTROLLER & AUDITOR GENERAL OF INDIA ON THE ACCOUNTS OF CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE FOR THE YEAR ENDED 31 MARCH 2022

We have audited the attached Balance Sheet of Central Council for Research in Unani Medicine (Council) as at 31 March 2022, the Income & Expenditure Account and Receipts & Payments Account for the year ended on that date under Section 20(1) of the Comptroller and Auditor General's (Duties, Powers & Conditions of Service) Act, 1971. The audit has been entrusted for the period upto 2023–24. These financial statements include the accounts of nine regional offices of the Council. These financial statements are the responsibility of the Council's management. Our responsibility is to express an opinion on these financial statements based on our audit.

2. This Separate Audit Report contains the comments of the Comptroller and Auditor General of India on the accounting treatment only with regard to classification, conformity with the best accounting practices, accounting standards and disclosure norms, etc. Audit observations on financial transactions with regard to compliance with the Laws, Rules & Regulations (Propriety and Regularity) and efficiency-cum-performance aspects, etc., if any, are reported through Inspection Reports/Comptroller and Auditor General's Audit Reports separately.

3. We have conducted our audit in accordance with auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements. An audit includes examining, on a test basis, evidences supporting the amounts and disclosure in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall presentation of financial statements. We believe that our audit provides a reasonable basis for our opinion.

4. Based on our audit, we report that:

- (i) We have obtained all the information and explanations, which to the best of our knowledge and belief, were necessary for the purpose of our audit;
- (ii) The Balance Sheet, Income & Expenditure Account and Receipts & Payments Account dealt with by this report have been drawn up in the format approved by the Ministry of Finance, Government of India.
- (iii) In our opinion, proper books of accounts on double entry system of accounting have been maintained by the Council in so far as it appears from our examination of such books.
- (iv) We further report that:
  - A. Balance Sheet**
  - A.1. Liabilities**
  - A.1.1. Current Liabilities and Provisions (Schedule–7) - ₹115.32 crore**



- A.1.1.1. The Council did not provide for salary and wages (for the month of March 2022) amounting ₹4.38 crore in annual accounts which has resulted in understatement of Current Liabilities as well as Expenditure to the same extent.

**B. Income and Expenditure Account**

- B.1. Above includes an amount of ₹44.47 lakh under the head “Misc. Receipts” of Schedule–18 (Other Income). These receipts are refund of unspent balance, recovery of pay, refund against advances, etc. which is the receipt, not the income, of Council. This resulted in overstatement of Income and overstatement of Balance being excess of Income over Expenditure by ₹44.47 lakh.
- B.2. Above includes an amount of ₹95.43 lakh under the head “Other Receipts (Decentralized Institutes)” of Schedule-18 (Other Income). Out of the above, an amount of ₹87.90 lakh pertains to receipts from decentralized institutes which are not income of the Council. This resulted in overstatement of Income as well as overstatement of Balance being excess of Income over Expenditure by ₹87.90 lakh.
- B.3. As per uniform format of accounts, Grant-in-Aid should be properly segregated and only grant for revenue purpose is recognised as income in Income & Expenditure Accounts. The grant for capital expenditure should be routed through Balance Sheet. The Council received ₹6.56 crore as Capital Grants which has been taken as income in Income & Expenditure Accounts by the Council. This has resulted in overstatement of Income as well as overstatement of Excess of Income over Expenditure by ₹6.56 crore.

Similar observation (Comment No. A.I.I.I.) was issued to the Council on accounts for the year 2020–21. However, no remedial action has been taken by the Council.

**C. Receipt & Payment Account - (₹181.85 crore)**

- C.1. During the year, an amount of ₹22.08 lakh has been received as Security Deposit. However, in the Receipt & Payment Account, it was shown only ₹0.95 lakh. This resulted in understatement of Receipt by ₹21.13 lakh.
- C.2. Payment of ₹48.31 lakh has been made on account of refund of Security Deposit. However, in the Receipt & Payment Account, it was shown only ₹6.65 lakh. This resulted in understatement of Payment by ₹41.66 lakh.

**D. General**

- D.1. As the Provident Fund Accounts and the New Pension Scheme Accounts are owned by the members of those funds and not by the Organisation, these accounts should not be included in Organisation's main account. A Receipts & Payments Account, an Income & Expenditure Account and a Balance Sheet of the Provident Fund Accounts as well as the New Pension Scheme should be shown separately. However, the Council has included assets and liabilities

of Provident Fund Accounts and the New Pension Scheme in its main account. This observation was also made during the previous year audit but no action has been taken so far.

D.2. The Council had not disclosed the details of lands purchased/received as gift or received on lease basis, etc. in the Annual Accounts.

D.3. The provision for retirement benefit was not made as per actuarial valuation as prescribed in AS 15.

E. **Grants-in-Aid**

(i) **Health Account**

The Council had received Grants-in-Aid of ₹157.73 crore during 2021–22 and had an unspent balance of Grants-in-Aid of ₹1.44 crore of previous year. The Council had generated ₹22.68 crore from its own resources. Thus, out of available amount of ₹181.85 crore, the Council utilized a sum of ₹177.56 crore leaving unspent balance of ₹4.29 crore as on 31.03.2022.

(ii) **Specific Project Account**

The Council also received grants of ₹84 lakh during the year for specific projects from various agencies, in addition to unspent balance of previous year of ₹2.85 crore. It had its own receipt of ₹7 lakh. Thus, out of available amount of ₹3.76 crore, the Council utilized ₹3.12 crore, leaving an unutilized balance of ₹64 lakh as on 31.03.2022.

(v) Subject to our observations in the preceding paragraphs, we report that the Balance Sheet, Income and Expenditure Account and Receipts and Payments Account dealt with by this report are in agreement with the books of accounts.

(vi) In our opinion and to the best of our information and according to the explanations given to us, because of the effects of the observation discussed above at **comment no. B.3.**, the financial statements read together with the Accounting Policies and Notes on Accounts **do not give a true and fair view** in conformity with accounting principles generally accepted in India.

a. In so far as it relates to the Balance Sheet of the state of affairs of the Central Council for Research in Unani Medicine as at 31 March 2022 and

b. In so far as it relates to Income and Expenditure Account of the surplus for the year ended on that date.

**For and on behalf of C&AG of India**

(Sd/)

**Sanjay Kumar Jha**  
**Director General of Audit**  
**(Central Expenditure)**

**Place: New Delhi**  
**Date: 25.10.2022**

## ANNEXURE

### 1. Adequacy of internal audit system

The internal audit of the Council was conducted upto 2018-19 by the Ministry of Health & Family Welfare. However, report is yet to be received.

### 2. Adequacy of internal control system

Internal control system was not adequate as risk assessment was not done by the management. Further, 18 paras pertaining to the period 2014-19 were outstanding for settlement.

### 3. System of physical verification of fixed assets

The physical verification of fixed assets was conducted up to 2021-22 and no discrepancy was reported.

### 4. System of physical verification of inventory

The physical verification of Books and Publications was conducted up to 31.03.2022. The physical verification of stationery and consumables etc. was conducted upto 2021-22.

### 5. Regularity in payment of statutory dues

As per accounts, no payments for over six months in respect of statutory dues were outstanding as on 31.03.2022.

## 5.2. Audited Statement of Accounts

### Index of the Annual Accounts for the Year 2021–2022

S. No.	Name of the Accounts	Page No.	Schedules at Page No.
1.	Balance Sheet	110	119–131
2.	Income & Expenditure Account	111	132–143
3.	Receipt & Payment Account	112–118	144–177
4.	Notes on Accounts	178	-

Balance Sheet as on 31<sup>st</sup> March 2022

Corpus/Capital Fund and Liabilities		Schedule	Current Year	Previous Year
Corpus/Capital Fund		1	133,47,59,265.00	1,24,76,35,862.00
Reserve and Surplus		2	-	-
Earmarked/Endowment Funds		3	61,54,940.50	2,85,06,985.00
Secured Loans and Borrowings		4	-	-
Unsecured Loans and Borrowings		5	-	-
Deferred Credit Liabilities		6	-	-
Current Liabilities and Provisions		7	115,32,34,172.00	1,01,07,50,906.00
<b>Total</b>			<b>249,41,48,377.00</b>	<b>2,28,68,93,753.00</b>
Assets		Schedule	Current Year	Previous Year
Fixed Assets		8	1,25,94,35,575.00	1,27,19,85,609.00
Investments-from Earmarked/Endowment Funds		9	-	-
Investments Others		10	66,08,31,200.00	55,12,80,967.00
Current Assets, Loans, Advances, etc.		11	57,38,81,602.00	46,36,27,177.00
Miscellaneous Expenditure (To the Extent not Written off or Adjusted)				-
<b>Total</b>			<b>249,41,48,377.00</b>	<b>2,28,68,93,753.00</b>

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General



Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

Income	Schedule	Current Year	Previous Year
Income from Sales/Services	12	-	-
Grants	13	1,56,28,56,498.00	1,62,60,56,498.00
Fees	14	37,36,420.00	46,85,871.00
Income from Investments (Income on Invest from earmarked/endow. Funds transferred to Funds)	15	-	-
Income from Publication, etc.	16	1,38,471.00	2,49,096.00
Interest Earned	17	66,55,613.00	62,89,583.00
Other Income	18	2,92,55,460.00	1,75,16,144.00
Less: Capitalized	19	(-)84,29,056.00	(-)2,65,75,012.00
<b>Total (A)</b>		<b>1,59,42,13,406.00</b>	<b>1,62,82,22,180.00</b>
Expenditure	Schedule	Current Year	Previous Year
Establishment Expenses	20	107,82,86,226.00	(+)3,22,042.00
Other Administrative Expenses etc.	21 (A- D)	41,62,57,619.00	1,04,01,50,121.00
Expenditure on Grants, Subsidies etc.	22	-	37,28,89,286.00
Interest	23	-	4,62,88,583.00
Unspent Balance 2020-2021	FW -21 (E)	-	3901.00
Depreciation (Net Total at the Year End – Corresponding to Schedule 8)	H - 21 (E)	2,09,79,090.00	2,91,81,578.00
<b>Total (B)</b>		<b>1,51,55,22,935.00</b>	<b>(H) - 1,48,88,31,610.00</b> <b>(FW) - (+) 3901.00</b>
Balance Being Excess of Income Over Expenditure (A-B) (1594213406/- (-)1515522935/-)		7,86,90,471.00	(H) - 13,93,90,570.00
Prior period transaction (Unspent Balance of 2020-2021 Refundable to M/o AYUSH		1,44,43,502.00	(H) (-)2,23,70,581.00
Balance being Surplus/(Deficit) Carried to Capital Fund		6,42,46,969.00	(H) - 11,70,19,989.00 <b>(F.W) - (-)3901.00</b>

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Receipts	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
I.	Opening Balance								
a.	Cash-in-Hand (Imprest)	4,48,000.00	-	-	4,48,000.00	4,60,855.00	-	-	4,60,855.00
b.	Cash at Bank	1,39,95,502.00	2,85,06,985.00	7,97,98,638.57	12,23,01,125.57	2,19,09,726.00	2,49,61,507.00	2,64,85,710.00	7,33,56,943.00
	Total (I)	1,44,43,502.00	2,85,06,985.00	7,97,98,638.57	12,27,49,125.57	2,23,70,581.00	2,49,61,507.00	2,64,85,710.00	7,38,17,798.00
II.	Grant in Aid From Govt. of India								
a.	Capital	6,56,00,000.00	-	-	6,56,00,000.00	19,00,00,000.00	-	-	19,00,00,000.00
b.	Revenue	151,17,00,000.00	84,00,000.00	-	152,01,00,000.00	1,45,05,00,000.00	55,00,000.00	-	1,45,60,00,000.00
	Total (II)	157,73,00,000.00	84,00,000.00	-	158,57,00,000.00	1,64,05,00,000.00	55,00,000.00	-	1,64,60,00,000.00
III.	Income from Investments of GPF/GIS/Pension fund & NPS Funds	-	-	-	-	-	-	57,14,869.00	57,14,869.00
	Total (III)	-	-	-	-	-	-	57,14,869.00	57,14,869.00
IV	Interest Received								
a.	Bank Interest	62,34,578.00	6,65,085.00	66,22,547.00	1,35,22,210.00	54,29,112.00	7,35,427.00	-	61,64,539.00
	Total (IV)	62,34,578.00	6,65,085.00	66,22,547.00	1,35,22,210.00	54,29,112.00	7,35,427.00	-	61,64,539.00
V.	Other Income								
a.	Interest on Refundable Advances	4,21,035.00	-	-	4,21,035.00	8,60,471.00	-	-	8,60,471.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Receipts	Current Year			Total	Previous Year				Total
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c		
b.	Other Misc. Income (As per Schedule H/8)	2,92,57,554.00	-	-	2,92,57,554.00	1,75,16,144.00	3,50,500.00	1,04,511.00	1,79,71,155.00	
c.	Sale of Publications	1,38,431.00	-	-	1,38,431.00	2,49,096.00	-	-	2,49,096.00	
d.	Unani Academic Courses Fee, etc.	37,36,420.00	-	-	37,36,420.00	46,85,871.00	-	-	46,85,871.00	
	Total (V)	3,35,53,440.00	-	-	3,35,53,440.00	2,33,11,582.00	3,50,500.00	1,04,511.00	2,37,66,593.00	
VI.	Amount Borrowed	-	-	-	-	-	-	-	-	
VII	Other Receipts									
a.	Refund against by Adjustment of Advances Pertaining to Previous Year	11,80,860.00				4,85,584.00	13,039.00	-		
b.	Recoveries of Refundable Advances to Govt. Servants	18,05,883.00				17,66,683.00	-	-		
c.	Recoveries for Remittances	13,40,27,532.00	17,356.00	1,02,01,093.00	14,42,45,981.00	13,24,42,195.00	26,261.00			
d.	Recoveries of Subscription & Advance	-	-	4,97,99,106.00	4,97,99,106.00	-	-	5,94,00,393.00		
e.	Security Deposit (CCRUM)	95,000.00			95,000.00	6,00,000.00	-	-		
f.	Receivable Amount Received	-		39,57,095.00	39,57,095.00	-	-	1,65,57,058.00 (Accrued Interest)		

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Receipts	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
g	In-Transit Amount Received	10,825.00			10,825.00	36,22,402.00		-	
h.	Amount Received but to be Refunded to Other Decentralized Institutes	22,78,569.00			22,78,569.00	78,823.00		-	
i.	Investment Received			34,23,34,937.90	34,23,34,937.90			53,34,15,387.00	
j.	LIC Amount Received from LIC for Disbursement			5,00,000.00	5,00,000.00			12,00,000.00	
k.	Pension Fund Transfer from Health A/c Received in Pension Fund A/c			36,62,17,877.00	36,62,17,877.00			32,00,00,000.00	
l.	Govt. Contribution of Non-Pran Member	62,56,317.00		62,56,317.00	1,25,12,634.00				
m.	Receipts on Closing Bank A/c	2,02,17,495.70			2,02,17,495.70				
n.	NPS Corpus Amount	1,84,46,591.37		1,00,06,342.40	2,84,52,933.77				
o.	Unspent Balance (Previous Year)	6,41,214.00			6,41,214.00				
p.	Unspent Balance (Current Year)	20,61,940.00			20,61,940.00				
q.	Interest on FDRs	-		2,95,49,938.00	2,95,49,938.00				
	Total (VII)	18,70,22,227.07	17,356.00	90,88,79,784.30	100,58,62,289.30	13,89,95,686.00	39,300.00	93,05,72,838.00	1,06,96,07,825.00
	Grand Total (I to VII) of Receipt Side	181,85,53,747.07	3,75,89,426.00	90,52,43,891.80	2,76,13,87,064.87	1,83,06,06,962.00	3,15,86,734.00	96,28,77,928.00	2,82,50,71,624.00

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
I. Expenses									
a. Establishment Expense		107,82,86,226.00			107,82,86,226.00	104,01,50,121.00		-	104,01,50,121.00
Total I		107,82,86,226.00			107,82,86,226.00	104,01,50,121.00			104,01,50,121.00
II. Administrative Expense (Corresponding to Schedule 21)		22,94,97,876.00			22,94,97,876.00				
i. Admn. Expenses						19,74,45,628.00			
ii. Material & Supplies		9,45,10,750.00			9,45,10,750.00	5,26,65,487.00			
iii. Other Charges		10,33,06,088.00	63,48,563.00		10,96,54,651.00	12,27,78,171.00	30,49,678.00		
iv. Publication Expenses						-	-		
Total (II)		42,73,14,714.00	63,48,563.00		43,36,63,277.00	37,28,89,286.00	30,49,678.00	-	37,59,38,964.00
III. Investment Made Out of GPF, GIS, Pension Fund & NPS A/c				45,18,85,170.90	45,18,85,170.90	-		55,43,89,375.00	55,43,89,375.00
Total (III)				45,18,85,170.90	45,18,85,170.90	-		55,43,89,375.00	55,43,89,375.00
IV. Expenditure on Fixed Assets and Capital Work in Progress		6,56,00,550.00			6,56,00,550.00				
a. Purchase of Fixed Assets		64,59,180.00	-	-	64,59,180.00	64,89,281.00 11,55,391.00		-	-

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General



Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
						31,090.00			
						1,88,99,250.00			
b.	Expenditure on Capital Work in Progress	-	-	-	-	-	-	-	-
c.	IPR Fund Transfer	20,00,000.00	-	-	20,00,000.00				
	Total (IV)	7,40,59,730.00	-	-	7,40,59,730.00	2,65,75,012.00			2,65,75,012.00
V.	Refund of Surplus Money & Loans					-	-	-	-
a.	To Govt. of India					-	-	-	-
b.	To the States Govt.					-	-	-	-
c.	To Other Provider of Funds					-	-	-	-
VI.	Finance Charges (Interest)					-	-	-	-
VII	Other Payments								
a.	Advances to Govt. Servants	37,23,500.00			37,23,500.00	38,12,500.00			
b.	Remittance of Recoveries	15,03,87,441.30	10,170.00	1,02,70,067.00	16,06,67,678.30	13,58,27,512.00	30,071.00		
c.	Amount Payable Paid/Adjusted	54,02,503.00	-	1,44,615.00	55,47,118.00	4,03,21,111.00			
d.	Refund of EMD	6,64,920.00	-	-	6,64,920.00	3,27,825.00			
e.	Amount with Decentralized					7,42,885.00			

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
	Instts Pertains to Other Councils Paid/Transferred								
f.	Unspent Balance Refunded to the Ministry of AYUSH (2019-20)	1,44,43,502.00	46,68,757.00	-	1,91,12,259.00	2,23,70,581.00			
g.	LIC Amount Received from LIC Disbursed	-	-	4,00,000.00	4,00,000.00	8,00,000.00		8,00,000.00	
h.	Other Misc. Payments, Transfer	8,90,190.00	-	32,32,87,071.00	32,41,77,261.00			32,78,89,915.00	
i.	Undisbursed Amount Disbursed	78,823.00	-	-	78,823.00	-	-	-	-
j.	Excess Paid to be Received/ Adjusted								
k.	Funds Transfer on Specific A/c Closure	-2,02,16,763.88	-2,02,16,763.88	-	2,02,16,763.88				
l.	Outstanding Advances	119,53,234.00	-		1,19,53,234.00	20,45,877.00 17,11,00,750.00			
m.	NPS Employees Contribution Paid (Non-Pran)	84,40,249.00	-	1,23,17,208.00	2,07,57,457.00				

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Receipt & Payment A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Payments	Current Year				Previous Year			
		Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total	Health A/c	Other Specific A/c	GPF/GIS/ Pension NPS A/c	Total
	Total (VII) (a to m)	19,59,84,362.30	2,48,95,691.38	34,64,18,961.00	56,72,99,014.18	37,65,49,041.00	30,071.00	32,86,89,915.00	70,52,69,027.00
VIII	Closing Balance								
a.	Cash-in-Hand (Imprest)	3,88,250.00				4,48,000.00			
b.	Cash at Bank	4,25,20,464.97				1,39,95,502.00	2,85,06,985.00	7,97,98,638.00	12,27,49,125.00
	Total VIII (a+b)	4,29,08,714.97	63,45,172.50	10,69,39,760.00	15,61,93,647.47	1,44,43,502.00	2,85,06,985.00	7,97,98,638.00	12,27,49,125.00
	Total (I to VIII) of Payment Side	181,85,53,747.27	3,75,89,426.38	90,52,43,891.90	276,13,87,065.55	1,83,06,06,962.00	3,15,86,734.00	96,28,77,928.00	2,82,50,71,624.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Capital Fund of Balance Sheet for the Year Ending 31<sup>st</sup> March 2022 (Schedule – I)

S. N.		Current Year		Previous Year	
		Health A/c	F.W.	Health A/c	F.W.
	Balance at the Beginning of the Year	1,24,76,37,800.00	1,938.00	1,62,19,82,065.00	1,93,523.00
	Addition During the Year	84,29,056.00	-	2,65,75,012.00	-
	Less: Refunds	-	-	-	-
	Less: Write off	-	-	(-)27,46,768.00	-
	Total (Rs.)	125,60,66,856.00	1,938.00	1,64,58,10,309.00	1,93,523.00
	Add/Deduct Balance of Net Income/Expenditure Transferred from the Income and Expenditure A/c	7,86,90,471.00	-	(-)39,81,72,509.00	(-)1,95,461.00
	Total (Rs.)	133,47,57,327.00	1,938.00	1,24,76,37,800.00	(-)1938.00
	Net Balance	133,47,59,265.00		1,24,76,35,862.00	

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule Forming Part of Balance Sheet as on 31<sup>st</sup> March 2022  
(Schedule -3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	I.T. A/c	Herb Garden A/c	Publication of Text Books	UPS A/c I	DSOP A/c	Pharmacovigilance A/c	Unani Day	AIUM A/c	WHO A/c
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
(a)	Opening Balance	35,95,499.00	74,256.00	61,249.00	51,484.82	2,33,631.00	6,90,000.00	4,66,057.00	36,58,322.00	2,456.00
	Total (a)									
(b)	Additions									
	Grant-in-Aid							64,00,000.00		
	Other Additions A/c of									
	Bank Interest		1,15,976.00	1,497.00	542.00	5,711.00		41,011.00	45,188.00	60.00
	From Health A/c									
	Recoveries for Remittances							17,356.00		
	Receivable received									
	Misc. Receipts									
	Total (b)		1,15,976.00	1,497.00	542.00	5,711.00		64,58,367.00	45,188.00	60.00
	Total (a+b)	35,95,499.00	1,90,232.00	62,746.00	52,026.82	2,39,342.00	6,90,000.00	69,24,424.00	37,03,510.00	2,516.00
(c)	Utilization/Expenditure									
	i) Capital expenditure									
	Assets									
	Others									
	ii) Revenue Expenditure									
	Salaries/Wages Allowances									
	Other Administrative Expenditure							55,16,563.00		

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General



Schedule Forming Part of Balance Sheet as on 31<sup>st</sup> March 2022  
(Schedule -3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	I.T. A/c	Herb Garden A/c	Publication of Text Books	UPS A/c I	DSOP A/c	Pharmacovigilance A/c	Unani Day	AIUM A/c	WHO A/c
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Material & Supplies									
	Remittance of Recoveries	1,492.00						8,678.00		
	Amount Payable Paid									
	Unspent Balance Refunded to Ministry						6,90,000.00	6,250.00	37,03,510.00	-
	Transfer to Health A/c on A/c of Closure			62,746.00	52,026.82	2,39,342.00	-	-	-	-2,516.00
	Total (c)	1,492.00	-	62,746.00	52,026.82	2,39,342.00	6,90,000.00	55,31,491.00	37,03,510.00	2,516.00
	Net Balance (a+b (-) c)	35,94,007.00	1,90,232.00	NIL	NIL	NIL	NIL	13,92,933.50	NIL	NIL

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule Forming Part of Balance Sheet as on 31<sup>st</sup> March 2022  
(Schedule -3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	IPR (10)	International Events Conference A/c (11)	DST A/c (12)	CRISM A/c (13)	South African A/c (14)	Total	
							Current Year (15)	Previous Year (16)
(a)	Opening Balance	2,68,997.00	7,98,334.00	7,64,357.00	1,72,93,526.00	5,48,815.68	2,85,06,985.00	2,49,61,506.50
	Total (a)							
(b)	Additions							
	Grant-in-Aid	20,00,000.00					84,00,000.00	55,00,000.00
	Other Additions A/c of							
	Bank Interest		17,399.00	129.20	4,24,155.00	13,417.00	6,65,085.00	7,35,427.00
	From Health A/c							
	Recoveries for Remittances						17,356.00	26,261.00
	Receivable Received							
	Misc. Receipts							3,63,539.00
	Total (b)	20,00,000.00	17,399.00	129.20	4,24,155.00	13,417.00	90,82,441.00	66,25,227.00
	Total (a+b)	22,68,997.00	8,15,733.00	7,64,486.20	1,77,17,681.00	5,62,232.68	3,75,89,426.00	3,15,86,733.50
(c)	Utilization/Expenditure							
	i) Capital Expenditure							
	Assets							19,05,993.00
	Others							
	ii) Revenue Expenditure							
	Salaries/Wages Allowances							

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule Forming Part of Balance Sheet as on 31<sup>st</sup> March 2022  
(Schedule -3) Earmarked/Endowment Funds

S.N.	Name of the Scheme	IPR (10)	International Events Conference A/c (11)	DST A/c (12)	CRISM A/c (13)	South African A/c (14)	Total	
							Current Year (15)	Previous Year (16)
	Other Administrative Expenditure	8,32,000.00					63,48,563.00	11,43,685.00
	Material & Supplies							
	Remittance of Recoveries							
	Amount Payable Paid						10,170.00	30,071.00
	Unspent Balance Refunded to Ministry	2,68,997.00					46,68,757.00	
	Transfer to Health A/c on A/c of Closure	-	8,15,733.00	7,64,486.20	1,77,17,681.00	5,62,232.68	2,02,16,763.70	
	Total (c)	11,00,997.00	8,15,733.00	7,64,486.20	1,77,17,681.00	5,62,232.68	3,12,44,253.70	30,79,749.00
	Net Balance (a+b (-) c)	11,68,000.00	NIL	NIL	NIL	NIL	63,45,172.30	2,85,06,985.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Current Liabilities & Provisions [Schedule 7 (2021-2022)]

S. N.	Name of the Scheme	Current Year	Previous Year
7(A)(5)	Statutory Liabilities: • Professional tax • TDS • Income Tax • GIS • GST	13,537.30 32.00 2,776.00 - 1,08,574.70	15,645.30 32.00 2,776.00 - 1,13,878.00
	Total 7 (A) (5)	1,24,920.00	1,32,331.00
7(A)(6)	Other Current Liabilities		
	Secured Deposits (CCRUM)	14,67,443.00	20,37,363.00
	Short Payments Payable	23,798.00	23,798.00
	Undisbursed Amounts (Decentralized Instt.)	16,103.00	16,103.00
	Undisbursed Amounts (Decentralized Instt)	63,845.00	63,845.00
	Recoveries not Received Details	2,289.00	2289.00
	New Pension Scheme Recoveries	-	10,974.00
	Advances from Vldya Peeth (Decentralized Instt Srinagar)	2,50,000.00	2,50,000.00
	Amount Received but Detail not Received (Kol)	16,469.00	16,469.00
	Received from CCRAS for UPC	30,00,000.00	30,00,000.00
	Payable by RRI., New Delhi to Hqrs, ND	36.00	36.00
	Security Deposit (CCCCBC)	4,03,000.00	4,03,000.00
	Unspent Balance Payable to Ministry of Ayush (2021-2022)	2,26,91,219.27	1,44,43,502.00
	Unspent Balance of Specific Accounts	2,02,17,495.70	-
	Amount Received from RRIUM, Chennai Wrongly on A/c of Unspent Refunds in R/O AIA to be Refunded to RRIUM, Chennai	-	78,823.00
	Payable to AIIA	-	-
	Total	4,81,51,697.97	2,03,46,202.00

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Current Liabilities & Provisions [Schedule 7 (2021-2022)]

S. N.	Name of the Scheme	Current Year	Previous Year
7(B)	Provisions For Retirement Benefits	28,23,29,258.87	30,22,83,563.00
	Total 7 (B)	28,23,29,258.87	30,22,83,563.00
	Total 7 (A+B) C/f	33,06,05,876.84	32,27,62,096.00
7(C)	FW A/c	17,090.00	17,090.00
7(D)	NPS A/c		
	• NPS Liability to NPS Subscribers	64,11,064.00	1,16,27,163.00
	• Bank Interest Earned and Accrued	1,30,53,053.00	1,37,08,087.00
7(E)	GPF A/c		
	• GPF Liability to GPF Subscribers	28,41,64,862.00	28,41,64,862.00
	• GPF Current Liability	0.00	10,825.00
	• Bank Interest Earned and Accrued	16,81,24,355.33	16,33,13,803.00
	• GPF Advance	58,50,583.00	76,94,133.00
7(F)	GIS A/c		
	• Amount from LIC to be Disbursed	5,00,000.00	4,00,000.00
	• GIS Liability to GIS Subscribers	2,46,24,209.84	2,80,19,469.00
	• Excess Received	1,026.00	1026.00
	• CGHS Wrongly Credited in GIS A/c to be Transferred to Health A/c	0.00	650.00
7(G)	Pension Fund A/c		
	• Pension Funds Bank Interest and Payment of Pension, FP Commutation of Pension From	31,98,82,051.53	17,90,31,701.00
	Total 7(C) to 7(G) Rs.	82,26,28,294.70	68,79,88,809.00
	Total 7(A) to 7(G) Rs.	115,32,34,171.54	101,07,50,906.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Consolidated Schedule of Fixed Assets as on 31<sup>st</sup> March 2022  
(Schedule 8)

S.N.	Name of the Assets	Opening Balance as on 01.04.2021	Gross Block			
			Addition	Deductions	Transferred to/from M/E A/c from WLP A/c	Total
		(1)	(2)	(3)	(4)	(5)
	Machinery (H)	16,58,90,330.00	41,25,398.00			17,00,15,728.00
	Equipment (FW)	31527.00				31527.00
	Furniture & (H)	9,63,28,138.00	12,15,895.00			9,75,44,033.00
	Fixture (FW)	16158.00				16158.00
	Computers	3,35,67,432.00	25,36,467.00			3,61,03,899.00
	Land	27,85,336.00				27,85,336.00
	Works in Progress	1,11,13,04,634.00				1,11,13,04,634.00
	Books & Journals (H)	3,50,66,800.00	5,51,296.00			3,56,18,096.00
	(FW)	5427.00				5427.00
	Vehicles	79,24,684.00				79,24,684.00
	Building	13,43,46,873				13,43,46,873.00
	Council's Publications (Priced)	-				
	Total					
	Councils Publications Priced not Fixed Assets so Deducted from here					
	Total (H)	1,58,72,14,227.00	84,29,056.00			159,56,43,283.00
	(FW)	53112.00				53112.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General



Consolidated Schedule of Fixed Assets as on 31<sup>st</sup> March 2022  
(Schedule 8)

S.N.	Name of the Assets	Depreciation				Net Block		
		Rate of Deprecia (6)	Opening Balance As on 01.04.21 (7)	On addition (8)	On Deductions (9)	Total (10)	As on 31.03.2022 (11)	As on 31.03.2021 (12)
	Machinery (H)	10%	8,46,13,023.00	84,67,167.00		9,30,80,190.00	7,69,35,538.00	8,12,77,307.00
	Equipment (FW)		24,968.00	656.00		25624.00	5,903.00	6559.00
	Furniture & (H)	10%	6,25,62,525.00	34,42,772.00		6,60,05,297.00	3,15,38,736.00	3,37,65,613.00
	Fixture (FW)		11369.00	479.00		11848.00	4,310.00	4789.00
	Computers	40%	2,98,37,527.00	15,50,720.00		3,13,88,247.00	47,15,652.00	37,29,905.00
	Land	-	-				27,85,336.00	27,85,336.00
	Works in Progress	-	-				1,11,13,04,634.00	1,11,13,04,634.00
	Books & Journals (H)	40%	2,34,83,083.00	47,64,651.00		2,82,47,734.00	73,70,362.00	1,15,83,717.00
	(FW)		3671.00	702.00		4373.00	1,054.00	17,156.00
	Vehicles	10%	65,19,915.00	1,40,477.00		66,60,392.00	12,64,292.00	14,04,769.00
	Building	10%	10,82,25,649.00	26,12,122.00		11,08,37,771.00	2,35,09,102.00	2,61,21,224.00
	Council's Publications (Priced)							
	TOTAL							
	Councils Publications Priced not Fixed Assets so Deducted from here							
	Total (H)		31,52,41,722.00	2,09,79,090.00		33,62,19,631.00	1,25,94,24,308.00	1,27,19,72,505.00
	(FW)		40008.00			41,845.00	11,267.00	13,104.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Investments Out of the Following Funds as on 31<sup>st</sup> March 2022  
(Schedule 10)

S. N.		Current Year	Previous Year
1.	GPF	36,43,49,895.00	38,40,33,991.01
2.	GIS	1,87,02,242.00	1,87,02,242.00
3.	Pension Fund	27,31,86,589.00	13,07,52,260.00
4.	NPS	45,92,473.99	177,92,473.99
	Total S/5C	66,08,31,199.99	55,12,80,967.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Current Assets (Schedule 11)

(A)	Health A/c	Current Year	Previous Year
1.	Contingent advance	11,05,99,722.00	10,04,14,604.00
2.	Exhibitions advance	73,000.00	73,000.00
3.	T.A. Advance	2,01,785.00	2,01,785.00
4.	Excess paid to be recovered/adjusted	8,107.00	8,107.00
5.	LTC Advance	6,93,083.00	9,25,424.00
6.	Advance for Seminar	16,51,019.00	8,62,215.00
7.	Capital Advance	23,67,01,300.00	17,11,00,750.00
8.	Scooter Advance	39,456.00	56,376.00
9.	Fan Advance	768.00	768.00
10.	Car Advance	-	-
11.	Computer Advance	7,65,972.00	9,84,545.00
12.	House Building Advance	75,84,327.00	53,32,787.00
13.	In Transit Amount	18,200.15	18,200.15
14.	Security Deposits	4,70,311.00	4,70,311.00
15.	Medical Advance	3,28,265.00	3,28,265.00
16.	Receivable from IPR A/c	-	-
17.	Receivable from LIC	1,351.50	1,351.50
18.	Excess TDS to be recovered/adjusted	19,706.00	19,706.00
19.	Training Advance	4,50,225.00	4,50,225.00
20.	Ethics Committee Advance	97,024.00	72,024.00
21.	Share amount receivable from CCRYN, N. Delhi	2,62,992.00	2,62,992.00
22.	Advance for A-HMIS	1,34,200.00	1,34,200.00
23.	Receivable from F.W. A/c	17,090.00	17,090.00
24.	Swachhta Action Plan Advance	18,55,596.00	15,77,402.00
25.	NPS	-	-
26.	Bank Balance lying with RRI Kolkata to be received/adjustments	19,323.00	19,323.00

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Schedule of Current Assets (Schedule 11)

(A)	Health A/c	Current Year	Previous Year
27.	Hindi Pakhwada Advance	1,38,100.00	1,38,100.00
28.	Advance for Health Camp	1,59,928.00	1,59,928.00
29.	Excess Transfer to Pension Fund A/c to be received in Health A/c	-	-
30.	Arogya Advance	51,706.00	51,706.00
31.	DD received from decentralized Institutes returned due to time barred now to be received therefrom.	-	-
32.	International Conference & Unani Day Advance	3,02,705.00	3,02,705.00
33.	Receivable from (Plan)	-	-
	Total (Rs.)	36,26,45,261.15	28,39,83,889.00
(B)	Family Welfare A/c:		
	(i) Current Assets	2,047.94	2,047.94
(C)	NPS A/c		
	(ii) Accrued Bank Interest on FDRs Invested	16,16,750.00	16,16,750.00
(D)	GPF A/c		
	(i) Current Assets	33,852.98	33,852.98
	(ii) GPF Advance	58,50,583.00	76,94,133.00
	(iii) Accrued Bank Interest on FDRs Invested	3,98,04,614.54	398,04,614.54
(E)	GIS A/c		
	(i) Current Assets Subscription in Transit	180.00	180.00
	(ii) Accrued Bank Interest on FDRs Invested	200.00	200.00
	(iii) Receivable from NPS A/c as Payment Wrongly Paid from GIS A/c	19,50,331.00	19,50,331.00
		0.00	7920.00
(F)	Pension Fund A/c		
	• Accrued Bank Interest on FDRs Invested	57,84,134.00	57,84,134.00
	Total (A to C) Rs. C/f	41,76,87,954.61	34,08,78,052.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Break-up of Closing Balance as on 31<sup>st</sup> March 2022  
(Schedule 11)

(G) Bank of India (A)	16602		4,09,26,464.97	Health A/c
	Decentralized Institutes Bank Balances		17,92,250.00	
	Imprest- Decentralized Institutes		1,90,000.00	
	Imprest Headquarters, New Delhi & Centralized Institutes		-	
	Total (A)		4,29,08,714.97	
-do- (B)	16601		5,02,49,455.29	GPF A/c
-do-	16640		50,09,435.84	GIS A/c
Bank of Baroda	8477		4,39,92,321.53	Pension A/c
SBI	1088		76,88,547.31	NPS A/c
	Total (B)		10,69,39,759.97	
	Grand Total (A + B) Schedule S/5A		14,98,48,474.94	
-do- (C)	3988		35,94,007.00	IT A/c
			NIL	CRISM A/c
-do-	11685		NIL	AIUM A/c
Bank of India	19612		NIL	UPS Aligarh
-do-	17450		1,90,232.00	Herb Garden A/c
-do-	17450		11,68,000.00	IPR A/c
-do-	2226		NIL	Publication of Text Books
-do-	25291		NIL	DSOP A/c
-do-	3654		NIL	International Events Conferences
-do-	6063		NIL	Unani Chair South African
-do-	190312		NIL	DST A/c
-do-	24656		NIL	WHO A/c
State Bank of India	7704		NIL	(i) Pharmacovigilance A/c
			13,92,933.50	(ii) Unani Day Conferences A/c
Total (C)			63,45,172.50	
		Total (A + B + C) of G	57,38,81,602.05	

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Grant-in-Aid for the Year Ending 31<sup>st</sup> March 2022

Schedule of Income & Expenditure A/c

Schedule 13- Grants

Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S. N.	Grant in aid	Current Year	Previous Year
A.	Central Government	1,57,73,00,000.00	164,05,00,000.00
	Less – Unspent balance 2020-2021 returned	(-) 144,43,502.00	
	Total	1,56,28,56,498.00	164,05,00,000.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General



Schedule 14- Fees/Subscription  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S.N.		Current Year	Previous Year
B.	Unani Academic Course/Fees	37,36,420.00	46,85,871.00
	Total	37,36,420.00	46,85,871.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule 16- Income from Publication  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

	Current Year	Previous Year
Income from Sale of Publication	1,38,471.00	2,49,096.00
Total	1,38,471.00	2,49,096.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule 17(2) Interest Earned  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

	Current Year	Previous Year
On Saving Accounts	62,34,578.00	54,29,112.00
On Refundable Advances	4,21,035.00	8,60,471.00
Total	66,55,613.00	62,89,583.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule 18- Other Income  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2022

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
•	OPD/Regn Fee from Patients	1,34,39,196.00	1,32,26,539.00
•	Recoveries of Excess Payment/Provision in Previous Year	-	18,72,770.00
•	RTI	786.00	60.00
•	Sale of Tender Form	-	41800.00
•	Sale of Raddi, etc.	7,121.00	16700.00
•	Application Fees	-	30765.00
•	NPS Dormant A/c	-	3,36,848.00
•	LS & PC	-	67710.00
•	Library User Charges	-	4920.00
•	CGHS Recovery	12,47,800.00	17,28,000.00
•	Water and Electricity Charges	33,485.00	37180.00
•	Licence Fees	1,31,088.00	1,25,458.00
•	Postal Orders	-	189.00
•	I Card Fees	-	100.00
•	Auction Money	39,500.00	27105.00
•	Cancellation of DD	3,600.00	-
•	Sale of Magazine	860.00	-
•	Photocopy Charges	442.00	-
•	VAT A/c Closed	767.00	-
•	Unspent Research Project	2,49,930.00	-
•	Security Deposit	15,000.00	-
•	Tender Fee	2,000.00	-
•	GIS Recovery	2,000.00	-
•	Lab Fee	38,470.00	-

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Schedule 18- Other Income  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31st March 2022

S.N.	18(4) Miscellaneous Income	Current Year	Previous Year
•	Sale of Security Paper	10,000.00	-
•	Admn. Fee	8,205.00	-
•	Room Rent	10,800.00	-
•	Sale of Stamps	17,325.00	-
•	Scrap/Condemn Items	9,047.00	-
•	Misc. Receipts	44,47,403.00	-
•	Other Receipts (Decentralized Institute)	95,42,729.00	-
	Total	2,92,57,554.00	1,75,16,144.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Non-recurring/Capital Expenditure (Schedule-19)  
Schedule of Income Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S.N.	Non-Recurring/Capital Expenditure	Current Year	Previous Year
•	Machinery & Equipment SAP	40,61,515.00 63,883.00	39,60,548.00 11,55,391.00
•	Capital Expenditure	-	1,88,99,250.00
•	Furniture & Fixture (SAP) F/F	12,15,895.00	6,48,216.00 31,090.00
•	Books & Journal	5,51,296.00	5,35,246.00
•	Computers	6,30,474.00 19,05,993.00	13,45,271.00
	Total	84,29,056.00	2,65,75,012.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General



Income & Expenditure A/c - Schedule 20- Establishment Expenses

S.N.		Current Year	Previous Year
(A)	Salaries	60,51,11,877.00	63,22,67,015.00
	Contribution to Other Fund	40,22,87,245.00	34,24,64,614.00
	NPS 3,59,49,368.00		
	Pension 36,62,17,877.00		
	DLIS 1,20,000.00		
	40,22,87,245.00		
	Expenses on Employees Retirement Benefits	7,08,87,104.00	6,54,18,492.00
	Total (A)	107,82,86,226.00	104,01,50,121.00
(B)	Expenditure Against by Adjustment of Advances Pertaining to Previous Years		+3,22,042.00
(C)	Total (A+B)	107,82,86,226.00	1,04,04,72,163.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule 21 – Other Administrative Expenses, etc.  
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S.N.	Other Administrative Expenses	Current Year	Previous Year
A.	Other Administrative Expenses		
	• T.A.	20,52,623.00	10,90,105.00
	• Wages Including Contractual Staff Remuneration	11,34,53,917.00	10,72,39,552.00
	• Office Expenses (Stationary & Printing, Electricity, Water, Telephone, Cartage/Freight, Advocate Fees, Refreshment, Advertisement Charges, etc.)	5,68,74,016.00	5,65,43,386.00
	• Rent & Taxes (Rent of Building & Property Tax)	51,73,982.00	49,57,762.00
	• Maintenance & Repair, Petrol Diesel Expenses, etc.	1,20,66,845.00	90,39,281.00
	• Information Technology (Recurring Expenses, i.e. Repair of Computers Cartridge, Net Charges, Website Charges, etc.)	1,05,95,100.00	43,57,725.00
	• Consolidated Expenses on A/c SCP/TSP Wages/Remuneration of Staff/Stationary & Other Miscellaneous expenses	1,44,13,341.00	1,42,17,817.00
	Total Schedule -21 (A)	21,46,29,824.00	19,74,45,628.00
B.	Material & Supplies (Medicines, Chemicals, Glasswares & Lab Investigation Charges, etc.)	9,45,10,750.00	5,26,65,487.00
	Total 21-(B)	9,45,10,750.00	5,26,65,487.00
C.	Other Charges		
	• Medical Expenses	1,48,68,052.00	84,08,080.00
	• Survey Expenses	-	2,05,000.00
	• Arogya Fair	15,52,680.00	16,912.00
	• Health Camps	-	1900.00
	• Unani Academic Course	5,86,22,053.00	5,34,32,717.00
	• Swatchta Action Plan	24,20,173.00	28,43,167.00
	• COVID-19 Expenses	50,886.00	39,28,622.00
	• Mobile Health Visits	22,66,280.00	20,11,741.00
	• EMR Expenses	2000.00	84,000.00
	• Collaborative/ IMR Projects	1,84,44,879.00	2,13,42,280.00

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General

Schedule 21 – Other Administrative Expenses, etc.  
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S.N.		Current Year	Previous Year
	• Training Programmes	1,41,600.00	2838.00
	• Seminar Expenses	7,74,787.00	3,17,989.00
	• Ethics Committee Expenses	-	71,205.00
	• Unani Day Expenses	54,100.00	25,29,101.00
	• Hindi Pakhwada	-	20,945.00
	• GIA CRU Aligarh	-	3,00,000.00
	• IEC Expenses	-	17,13,301.00
	• Health Mela Expenses	3,44,350.00	82,600.00
	• Ayurveda Parv	-	1,00,000.00
	• NPCDCS	42,48,812.00	2,53,65,773.00
	• AHMIS	71,803.00	-
	• Hindi Workshop	60,000.00	-
	• Council CGHS Contribution	24,75,829.00	-
	• Exhibition Mela	1,41,600.00	-
	• EOI Project Review Committee Expenses	3990.00	-
	• Council Contribution to GIS	5,36,503.00	-
	• IPR Expenses	12,658.00	-
	Total S. No. 21 (C)	10,71,17,045.00	12,27,78,171.00
	Grand Total Schedule 21 (A to C)	41,62,57,619.00	37,28,89,286.00
D.	Expenses Against Adjustment of Advances Pertaining to Previous Years		4,62,88,583.00

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General

Schedule 21(E)  
Schedule of Expenditure Forming Part of Income & Expenditure A/c for the Year Ending 31<sup>st</sup> March 2022

S.N.		Current Year			Previous Year		
		Health	(F.W)	Total	Health	(F.W)	Total
(D)	Depreciation						
(i)	Machinery & Equipment	84,67,167.00	-	84,67,167.00	61,79,620.00		
(ii)	Furniture & Fixtures	34,43,251.00	-	34,43,251.00	32,72,334.00		
(iii)	Computers	15,50,720.00	-	15,50,720.00	(-)3,16,801.00		
(iv)	Books & Journals	47,65,353.00	-	47,65,353.00	1,69,87,982.00		
(v)	Vehicles	1,40,477.00	-	1,40,477.00	1,56,085.00		
(vi)	Building	26,12,122.00	-	26,12,122.00	29,02,358.00		
	Total Rs.	2,09,79,090.00	-	2,09,79,090.00	2,91,81,578.00	3901.00	2,91,85,479.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Income & Expenditure A/c (Unspent Balance Refundable to M/o Ayush)

S.N.	Unspent Balance	Current Year	Previous Year
•		2,26,91,219.27	1,44,43,502.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Opening Balance		GIA		Bank Interest	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
1.	(i) Health Scheme A/c						
	(a) Cash-in-Hand (Imprest)	4,48,000.00	4,56,867.60			62,34,578.00	54,29,112.00
	(b) Cash-in-Hand (Other than Imprest)		3987.15	Cap- 6,56,00,000.00 Rev – 151,17,00,000.00	Cap- 19,00,00,000.00 Rev – 1,45,05,00,000.00		
	(c) Cash-at-bank	1,39,95,502.00	2,19,09,726.56				
	Total (Health A/C) S.N.1	1,44,43,502.00	2,23,70,581.31	157,73,00,000.00	1,64,05,00,000.00	62,34,578.00	54,29,112.00
2.	Other Specific Accounts						
	(i) IPR	2,68,997.00	6,27,025.00			-	
	(ii) Herb Garden A/c	74,256.00	52,706.00			1,15,976.00	21,550.00
	(iii) Pub. of Text Books A/c	61,249.00	59,400.00			1,497.00	1849.00
	(iv) UPS A/c I	51,485.00	46,705.00			542.00	4780.00
	(v) DSOP	2,33,631.00	2,26,648.00			5,711.00	6,983.00
		36,58,322.00	35,49,777.00			45,188.00	1,08,545.00
		35,95,499.00	-		55,00,000.00	-	
		4,66,057.00	8,60,318.00	64,00,000.00		41011.00	33,159.00
	(x) WHO A/c	2,456.00	2382.00			60.00	74.00
	(xi) International Events Conference A/c	7,98,334.00	7,74,604.00			17,399.00	23,730.00
	(xii) DST A/c	7,64,357.00	7,64,357.00			129.00	

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General



Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Opening Balance		GIA		Bank Interest	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
	(xiii) Pharmacovigilance Workshop A/c	6,90,000.00	6,90,000.00			-	
	(xiv) CRISM A/c	1,72,93,526.00	1,67,75,100.00			4,24,155.00	5,18,426.00
	(xv) South African A/c	5,48,816.00	5,32,485.00			13,417.00	16,331.00
	Total S.N. 2	2,85,06,985.00	2,49,61,507.00	84,00,000.00	55,00,000.00	6,65,085.00	7,35,427.00
	(i) NPS A/c	59,26,026.31	49,92,769.00			1,60,157.00	1,42,843.00
	(ii) CPF/GPF A/c	2,36,17,032.29	29,27,663.00			48,10,552.00	44,22,014.00
	(iii) GIS A/c	77,60,272.84	86,52,230.00			1,90,108.00	2,39,010.00
	(iv) Pension Fund A/c	4,24,95,307.13	99,13,048.00			14,61,730.00	9,11,002.00
	Total S. N. 3	7,97,98,638.57	2,64,85,710.00			66,22,547.00	57,14,869.00
	Grand Total S. N. 1 to 3	12,27,49,125.60	7,38,17,798.00	158,57,00,000.00	1,64,60,00,000.00	1,35,22,210.00	1,18,79,408.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Miscellaneous Receipts		Interest on Refundable Advances		Refunds against by Adjustment of Advances Pertaining to Previous Years	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
1.	Health Scheme A/c	2,92,57,554.00	1,75,16,144.00	4,21,035.00	8,60,471.00	11,80,860.00	4,85,584.00
	Total (H) S.N.1	2,92,57,554.00	1,75,16,144.00	4,21,035.00	8,60,471.00	11,80,860.00	4,85,584.00
2.	Other Specific Accounts						
	(i) ROTP A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) South African Unani Chair A/c						
	(vi) DSOP						
	(vii) IPR						
	(viii) I. T. A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICST A/c						
	(xiii) Donation A/c						
	(xiv) International Events Conference A/c						
	(xv) DST A/c						

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Miscellaneous Receipts		Interest on Refundable Advances		Refunds against by Adjustment of Advances Pertaining to Previous Years	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day		3,50,500.00				13,039.00
	Total S.N. 2		3,50,500.00		-		13,039.00
3.	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c		1,04,511.00				
	Total S.N. 3		1,04,511.00				
	Grand Total S.N. 1 to 3	2,92,57,554.00	1,79,71,155.00	4,21,035.00	8,60,471.00	11,80,860.00	4,98,623.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Recoveries of Refundable Advances		Sale of Council's Publications	
		Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)	
1.	(i) Health Scheme A/c	18,05,883.00	17,66,683.00	1,38,431.00	2,49,096.00
	Total S.N.1	-	-	-	-
2.	Other Specific Accounts:	18,05,883.00	17,66,683.00	1,38,431.00	2,49,096.00
	(i) ROTP A/c				
	(ii) Herb Garden A/c				
	(iii) Pub. of Text Books A/c				
	(iv) UPS A/c I				
	(v) South African Unani Chair A/c				
	(vi) DSOP				
	(vii) EMR				
	(viii) I.T. A/c				
	(ix) WHO A/c				
	(x) NMPB A/c				
	(xi) UPS A/c II				
	(xii) ICST A/c				
	(xiii) Donation A/c				
	(xiv) International Events Conference A/c				
	(xv) DST A/c				

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Recoveries of Refundable Advances		Sale of Council's Publications	
		Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)	
	(xvi) CRISM A/c				
	(xvii) National Conference on Unani Day				
	Total S. N. 2				-
3.	(i) NPS A/c				
	(ii) CPF/GPF A/c				
	(iii) GIS A/c				
	(iv) Pension fund A/c				
	Total S.N. 3				
	Grand Total S.N. 1 to 3	18,05,883.00	17,66,683.00	1,38,431.00	2,49,096.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Recoveries for Remittance		Recovery of Subscription/Advances		Interest on FDRs	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(9)		(10)		(11)	
1.	Health Scheme A/c						
	Health Scheme A/c	13,40,27,532.00	13,24,42,195.00				
	Health Scheme A/c						
	Total (H) S.N.1	13,40,27,532.00	13,24,42,195.00				
2.	Other Specific Accounts :-						
	(i) ROTP A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) South African Unani Chair A/c						
	(vi) DSOP						
	(vii) IPR A/c		9,539.00				
	(viii) I.T. A/c		2,238.00				
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICST A/c						
	(xiii) Donation A/c						

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General



Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Recoveries for Remittance		Recovery of Subscription/Advances		Interest on FDRs	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(9)		(10)		(11)	
	(xiv) International Events conference A/c						
	(xv) DST A/c						
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day	17,356.00	14,484.00				
	Total S.N. 2	17,356.00	26,261.00		-		
3.	(i) NPS A/c	-		8,52,712.00	14,64,283.00		
	(ii) CPF/GPF A/c	-		4,82,50,114.00	5,71,35,730.00	2,71,15,609.00	
	CPF/GPF A/c subscription						
	CPF/GPF A/c advance						
	(iii) GIS A/c			6,96,280.00	8,00,380.00		
	(iv) Pension fund A/c	1,02,01,093.00				24,34,329.00	
	Total S.N. 3	1,02,01,093.00		4,97,99,106.00	5,94,00,393.00	2,95,49,938.00	
	Grand Total S.N. 1 to 3	14,42,45,981.00	13,24,68,456.00	4,97,99,106.00	5,94,00,393.00	2,95,49,938.00	

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Receivable Amount Received		Security Deposit Lying with the Council	
		Current Year	Previous Year	Current Year	Previous Year
		(12)		(13)	
1.	Health Scheme A/c			95,000.00	6,00,000.00
	Total S.N.1			95,000.00	6,00,000.00
2.	Other Specific Accounts:				
	(i) ROTP A/c				
	(ii) Herb Garden A/c				
	(iii) Pub. of Text Books A/c				
	(iv) UPS A/c I				
	(v) South African Unani Chair A/c				
	(vi) DSOP				
	(vii) EMR				
	(viii) I.T. A/c				
	(ix) WHO A/c				
	(x) NMPB A/c				
	(xi) UPS A/c II				
	(xii) ICST A/c				
	(xiii) Donation A/c				
	(xiv) International Events Conference A/c				
	(xv) DST A/c				
	(xvi) CRISM A/c				

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Receivable Amount Received		Security Deposit Lying with the Council	
		Current Year	Previous Year	Current Year	Previous Year
		(12)		(13)	
	(xvii) National Conference on Unani Day				
	Total S.N. 2				
3.	(i) NPS A/c		1,70,621.00		
	(ii) CPF/GPF A/c	39,49,175.00	1,03,81,465.00		
	(iii) GIS A/c		3,84,241.00		
	(iv) Pension Fund A/c	7,920.00	56,20,731.00		
	Total S.N. 3		1,65,57,058.00		
	Grand Total S.N. 1 to 3	39,57,095.00	1,65,57,058.00	95,000.00	6,00,000.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S.N.		In Transit Amount Received		Academic Course Fee		Amount Received but Payable to Other Institute/Units	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(14)	(15)	(15)	(16)	(16)	(16)
1.	(i) Health Scheme A/c	10,825.00	36,17,148.00	37,36,420.00	46,85,871.00	2,78,569.00	78,823.00
	(ii) Health Scheme A/c		5254.00			20,00,000.00	
	(iii) T.D.S.						
	Total S.N.1	10,825.00	36,22,402.00	37,36,420.00	46,85,871.00	22,78,569.00	78,823.00
2.	Other Specific Accounts						
	(i) ROTP A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) South African Unani Chair A/c						
	(vi) DSOP						
	(vii) EMR						
	(viii) I.T. A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICST A/c						
	(xiii) Donation A/c						
	(xiv) International Events Conference A/c						
	(xv) DST A/c						

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S.N.		In Transit Amount Received		Academic Course Fee		Amount Received but Payable to Other Institute/Units	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(14)		(15)		(16)	
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day						
	Total S.N. 2						
3.	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N. 3						
	Grand Total S.N. 1 to 3	10,825.00	36,22,402.00	37,36,420.00	46,85,871.00	22,78,569.00	78,823.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Investment Received		LIC Amount for Disbursement	
		Current Year	Previous Year	Current Year	Previous Year
		(17)	(18)	(17)	(18)
1.	Health Scheme A/c				
	(i) Health Scheme				
	Total S. N. 1				
2.	Other Specific Accounts				
	(i) ROTP A/c				
	(ii) Herb Garden A/c				
	(iii) Pub. Of Text Books A/c				
	(iv) UPS A/c I				
	(v) South African Unani Chair A/c				
	(vi) DSOP				
	(vii) EMR				
	(viii) I.T. A/c				
	(ix) WHO A/c				
	(x) NMPB A/c				
	(xi) UPS A/c II				
	(xii) ICST A/c				
	(xiii) Donation A/c				
	(xiv) International Events Conference A/c				
	(xv) DST A/c				
	(xvi) CRISM A/c				
	(xvii) International Conference on Unani Day				
	Total S.N. 2				

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General



Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Investment Received		LIC Amount for Disbursement	
		Current Year	Previous Year	Current Year	Previous Year
		(17)	(18)	(18)	(18)
3.	(i) NPS A/c	1,32,00,000.00	77,60,035.00		
	(ii) CPF/GPF A/c	30,01,96,359.90	37,59,97,543.00		
	(iii) GIS A/c		1,74,60,082.00	5,00,000.00	12,00,000.00
	(iv) Pension Fund A/c	2,89,38,578.00	13,21,97,727.00	-	
	Total S.N. 3	34,23,34,937.90	53,34,15,387.00	5,00,000.00	12,00,000.00
	Grand Total S.N. 1 to 3	34,23,34,937.90	53,34,15,387.00	5,00,000.00	12,00,000.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Pension Fund Transfer from Health Account		Govt. Contribution of Non-Pran Members		Receipts on Closing of Bank	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
1.	Health Scheme A/c						
	(i) Health Scheme			62,56,317.00		2,02,17,495.70	
	Total S.N. 1			62,56,317.00		2,02,17,495.70	
2.	Other Specific Accounts						
	(i) IPR A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) DSOP						
	(vi) AIUM						
	(vii) I. T. A/c						
	(viii) WHO A/c						
	(ix) International Events Conference A/c						
	(x) International Conference on Unani Medicine						
	(xi) DST A/c						

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		Pension Fund Transfer from Health Account		Govt. Contribution of Non-Pran Members		Receipts on Closing of Bank	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
	(xii) CRISM A/c						
	(xiii) South Africa Unani Chair A/c						
	(xiv) Pharmacovigilance workshop A/c						
	Total S.N. 2						
3.	(i) NPS A/c						
	(ii) CPF/GPF A/c						
	(iii) GIS A/c						
	(iv) Pension fund A/c	32,00,00,000.00	31,87,00,000.00	62,56,317.00			
	Total S.N. 3	32,00,00,000.00	31,87,00,000.00	62,56,317.00			
	Grand Total S.N. 1 to 3	32,00,00,000.00	31,87,00,000.00	1,25,12,634.00		2,02,17,495.70	

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		NPS Corpus Amount		Unspent Balance (Previous Year )		Unspent Balance (Current Year)		Total Receipts	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	(23)	(24)	(25)	(26)	(27)	(28)	(29)
1.	Health Scheme A/c								
	(i) Health Scheme	1,84,46,591.37	6,41,214.00	20,61,940.00		181,85,53,747.00	183,06,06,962.00		
	Total S.N. 1	1,84,46,591.37	6,41,214.00	20,61,940.00		181,85,53,747.00	183,06,06,962.00		
2.	Other Specific Accounts								
	(i) IPR A/c					22,68,997.00	6,36,564.00		
	(ii) Herb Garden A/c					1,90,232.00	74,256.00		
	(iii) Pub. of Text Books A/c					62,746.00	61,249.00		
	(iv) UPS A/c I					52,027.00	51,485.00		
	(v) DSOP					2,39,342.00	2,33,631.00		
	(vi) AIUM					37,03,510.00	36,58,322.00		
	(vii) I. T. A/c					35,95,499.00	55,02,238.00		
	(viii) WHO A/c					2,516.00	2456.00		
	(ix) International Events Conference A/c					8,15,733.00	7,98,334.00		

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Receipts & Payments A/c  
Schedule of Receipts for the Year Ending 31<sup>st</sup> March 2022

S. N.		NPS Corpus Amount		Unspent Balance (Previous Year)		Unspent Balance (Current Year)		Total Receipts	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(22)	(23)	(24)	(25)				
	(x) International Conference on Unani Medicine							69,24,424.00	12,71,500.00
	(xi) DST A/c							7,64,486.00	7,64,357.00
	(xii) CRISM A/c							1,77,17,681.00	1,72,93,526.00
	(xiii) South Africa Unani Chair A/c							5,62,233.00	5,48,816.00
	(xiv) Pharmacovigilance workshop A/c							6,90,000.00	6,90,000.00
	Total S.N. 2							3,75,89,426.00	3,15,86,734.00
3.	(i) NPS A/c							2,40,88,070.31	1,45,30,551.00
	(ii) CPF/GPF A/c							40,39,89,667.10	45,08,64,416.00
	(iii) GIS A/c							91,54,580.84	2,87,35,943.00
	(iv) Pension fund A/c	1,00,06,342.40						46,80,11,573.50	46,87,47,019.00
	Total S.N. 3	1,00,06,342.40						90,52,43,891.80	96,28,77,928.00
	Grand Total S.N. 1 to 3	2,84,52,933.77		6,41,214.00		20,61,940.00		2,76,13,87,065.00	2,82,50,71,624.00

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Establishment Expenses		Administrative Expenses		Material & Supplies Expenses	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
1.	Health Scheme						
	(i) Health scheme A/c	107,82,86,226.00	104,01,50,121.00				
	Total(H) S.N.1	107,82,86,226.00	104,01,50,121.00	22,94,97,876.00	19,74,45,628.00	9,45,10,750.00	5,26,65,487.00
2.	Other Specific Accounts						
	(i) ROTP A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) South African Unani Chair A/c						
	(vi) DSOP						
	(vii) EMR						
	(viii) I.T. A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICST A/c						
	(xiii) Donation A/c						
	(xiv) International Events conference A/c						
	(xv) DST A/c						
	(xvi) CRISM A/c						

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General



Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Establishment Expenses		Administrative Expenses		Material & Supplies Expenses	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(1)		(2)		(3)	
	(xvii) South African A/c						
	Total S.N.2						
	(i) NPS A/c						
	(ii) GPF A/c						
	(iii) GIS A/c						
	(iv) Pension fund A/c						
	Total S. No.3						
	Total S.N. 1 to 3	107,82,86,226.00	104,01,50,121.00	22,94,97,876.00	19,74,45,628.00	9,45,10,750.00	5,26,65,487.00

Sd/-  
 (Shakaib Hasan)  
 Office Assistant (Internal Audit)

Sd/-  
 (Mohammad Parvez)  
 Accounts Officer

Sd/-  
 (Krishan Kumar Sapra)  
 Assistant Director (Admn.)

Sd/-  
 (Prof. Asim Ali Khan)  
 Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Assets		Publications (Priced)		Advances to Government Servants	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
1.	Health Scheme						
	(i) Health scheme A/c	64,59,180.00	64,89,281.00			37,23,500.00	38,12,500.00
	Total(H) S.N.1	64,59,180.00	64,89,281.00			37,23,500.00	38,12,500.00
2.	Other Specific Accounts						
	(i) ROTP A/c						
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) South African Unani Chair A/c						
	(vi) DSOP						
	(vii) EMR						
	(viii) I.T. A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICST A/c						
	(xiii) Donation A/c						
	(xiv) International Events conference A/c						
	(xv) DST A/c						

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Assets		Publications (Priced)		Advances to Government Servants	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(4)		(5)		(6)	
	(xvi) CRISM A/c						
	(xvii) South African A/c						
	Total S.N.2						
	(i) NPS A/c						
	(ii) GPF A/c						
	(iii) GLS A/c						
	(iv) Pension fund A/c						
	Total S. No.3						
	Total S.N. 1 to 3	64,59,180.00	64,89,281.00			37,23,500.00	38,12,500.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Outstanding Advances		Other Charges		Capital Payment	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)		(9)	
1.	Health Scheme A/c						
	SAP	5,43,775.00	20,45,877.00	10,33,06,088.00	12,39,64,652.00	6,56,00,550.00	Exp M/E – 1,88,99,250.00 Adv. for Cons.work – 17,11,00,750.00
	Ethics	25,000.00					
	Seminar	7,88,804.00					
	LTC	1,58,333.00					
	Contingency	1,04,37,322.00					
	Total S.N.1	1,19,53,234.00	20,45,877.00	10,33,06,088.00	12,39,64,652.00	6,56,00,550.00	19,00,00,000.00
2.	Other Specific Accounts						
	(i) IPR			8,32,000.00	3,62,798.00		
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) AIUM A/c						
	(vi) DSOP A/c						
	(vii) EMR A/c						
	(viii) I.T. A/c			-	19,05,993.00		
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Outstanding Advances		Other Charges		Capital Payment	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(7)		(8)		(9)	
	(xii) Pharmacovigilance workshop						
	(xiii) Donation A/c						
	(xiv) International Events conference A/c						
	(xv) DST A/c						
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day			55,16,563.00	7,80,887.00		
	(xviii) South African A/c						
	Total S.N. 2			63,48,563.00	7,80,887.00		
3.	(i) NPS A/c						
	(ii) GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c						
	Total S.N.3						
	Total S.N. 1 to 3	1,19,53,234.00	20,45,877.00	10,96,54,651.00	12,70,14,330.00	6,56,00,550.00	19,00,00,000.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	IPR Fund Transfer		Remittance of Recoveries		Amount Disbursed to RRIUM, Chennai	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)	(11)	(12)	(13)	(14)	(15)
1.	Health Scheme						
	(i) Health Scheme A/c	20,00,000.00	-	15,03,87,420.00	13,58,27,512.00	78,823.00	-
	Health Scheme A/c			21.30	-		
	Total S.N. 1	20,00,000.00	-	15,03,87,441.30	13,58,27,512.00	78,823.00	-
2.	Other Specific Accounts						
	(i) IPR			-	4,769.00		
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) AIUM A/c						
	(vi) DSOP A/c						
	(vii) EMR A/c						
	(viii) I.T. A/c			1,492.00	746.00		
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICSJ A/c						
	(xiii) Donation A/c						
	(xiv) International Events Conference A/c						
	(xv) DST A/c						

Sd/- (Shakaib Hasan)  
 Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
 Accounts Officer

Sd/- (Krishan Kumar Sapra)  
 Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
 Director General



Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	IPR Fund Transfer		Remittance of Recoveries		Amount Disbursed to RRIUM, Chennai	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(10)		(11)		(12)	
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day			8,678.00	24,556.00		
	(xviii) South African A/c						
	Total S.N. 2			10,170.00	30,071.00		
3.	(i) NPS A/c						
	(ii) GPF A/c						
	(iii) GIS A/c						
	(iv) Pension Fund A/c			1,02,70,067.00	-		
	Total S.N. 3			1,02,70,067.00	-		
	Total S.N. 1 to 3	20,00,000.00	-	6,06,67,678.30	13,58,57,583.00	78,823.00	-

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	NPS Employee Contribution Paid to Non Pran		Investments A/c		Received from LIC Disbursed	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(13)		(14)		(15)	
1.	Health Scheme						
	(i) Health Scheme A/c	84,40,249.00	-				
	Total S.N.1	84,40,249.00	-				
2.	Other Specific Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. of Text Books A/c						
	(iv) UPS A/c I						
	(v) AIUM A/c						
	(vi) DSOP A/c						
	(vii) EMR A/c						
	(viii) I.T. A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICSJ A/c						
	(xiii) Donation A/c						
	(xiv) International Events Conference A/c						
	(xv) DST A/c						

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	NPS Employee Contribution Paid to Non Pran		Investments A/c		Received from LIC Disbursed	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(13)		(14)		(15)	
	(xvi) CRISM A/c						
	(xvii) International Conference on Unani Day						
	(xviii) South African A/c						
	Total S.N. 2						
3.	(i) NPS A/c	1,23,17,208.00	-	-	79,15,359.00		
	(ii) GPF A/c			28,05,12,263.90	33,17,15,026.00		
	(iii) GIS A/c			-	1,78,09,561.00	4,00,000.00	8,00,000.00
	(iv) Pension Fund A/c			17,13,72,907.00	19,69,49,429.00		
	Total S.N. 3	1,23,17,208.00	-	45,18,85,170.90	55,43,89,375.00	4,00,000.00	8,00,000.00
	Grand Total S.N. 1 to 3	2,07,57,457.00	-	45,18,85,170.90	55,43,89,375.00	4,00,000.00	8,00,000.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Amount Payable Paid/Adjusted		Other Misc. Payments/Transfer		Refund of EMD	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(16)	(17)	(18)	(19)	(20)	(21)
1.	Health Scheme						
	(i) Health Scheme A/c			8,90,190.00	-	6,64,920.00	3,27,825.00
	Health Scheme A/c	54,02,503.00	4,03,21,111.00				
	Total S.N. 1	54,02,503.00	4,03,21,111.00	8,90,190.00	-	6,64,920.00	3,27,825.00
2.	Other Specific Accounts						
	Other Accounts						
	(i) IPR						
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Books A/c						
	(iv) UPS A/c I						
	(v) AIUM A/c						
	(vi) DSOP A/c						
	(vii) EMR A/c						
	(viii) Digitization of Manuscript A/c						
	(ix) WHO A/c						
	(x) NMPB A/c						
	(xi) UPS A/c II						
	(xii) ICSJ A/c						
	(xiii) Donation A/c						
	(xiv) International Events Conference A/c						

Sd/- (Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/- (Mohammad Parvez)  
Accounts Officer

Sd/- (Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/- (Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Amount Payable Paid/Adjusted		Other Misc. Payments/Transfer		Refund of EMD	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(16)	(17)	(18)	(19)	(20)	(21)
(xv)	DST A/c						
(xvi)	CRISM A/c						
(xvii)	International Conference on Unani day						
	Total S.N. 2						
3.	(i) NPS A/c	1,33,140.00		39,49,175.00	6,89,166.00		
	(ii) GPF A/c	10,825.00		7,32,17,123.00	9,55,32,357.00		
	-do-						
	-do-						
	-do-						
	(iii) GIS A/c	650.00		37,44,495.00	23,66,109.00		
	(iv) Pension fund A/c			24,23,76,278.00	22,93,02,283.00		
	Total S.N. 3	1,44,615.00	-	32,32,87,071.00	32,78,89,915.00		
	Grand Total S.N.1 to 3	55,47,118.00	4,03,21,111.00	32,41,77,261.00	32,78,89,915.00	6,64,920.00	3,27,825.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Payable to Other Councils Paid Transferred by Decentralized Institutes		Unspent Balance Transferred to Ministry		Fund Transfer on A/c of Closer	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
1.	Health Scheme						
	(i) Health scheme A/c	-	7,42,885.00	1,44,43,502.00	2,23,70,581.00		
	Total S.N.1	-	7,42,885.00	1,44,43,502.00	2,23,70,581.00		
2.	Other Specific Accounts						
	(i) Pharmacovigilance workshop A/c			6,90,000.00	-		
	(ii) Herb Garden A/c						
	(iii) Pub. Of Text Book A/c					62,746.00	
	(iv) UPS A/c I					52,027.00	
	(v) DSOP A/c					2,39,342.00	
	(vi) AIUM A/c			37,03,510.00	-		
	(vii) I.T. A/c						
	(viii) WHO A/c					2,516.00	
	(ix) International Events Conference					8,15,733.00	
	(x) IPR						
	(xi) DST A/c					7,64,486.20	
	(xii) CRISM A/c					1,77,17,681.00	
	(xiii) South African A/c					5,62,232.68	
	(xiv) International Conference on Unani Day			6,250.00	-		
	Total S.N. 2 (ii to xiv)			46,68,757.00	-	2,02,16,763.88	

Sd/- (Shakaib Hasan) Office Assistant (Internal Audit)      Sd/- (Mohammad Parvez) Accounts Officer      Sd/- (Krishan Kumar Sapra) Assistant Director (Admn.)      Sd/- (Prof. Asim Ali Khan) Director General



Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Payable to Other Councils Paid Transferred by Decentralized Institutes		Unspent Balance Transferred to Ministry		Fund Transfer on A/c of Closer	
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year
		(19)		(20)		(21)	
3.	(i) NPS A/c						
	(ii) GPF A/c						
	(iii) GIS A/c						
	(iv) Pension fund A/c						
	Total S.N. 3						
	Grand Total S.N. 1 to 3	-	7,42,885.00	1,91,12,259.00	2,23,70,581.00	2,02,16,763.88	-

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Closing Balance		Total payments	
		Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)	
	Health Scheme				
	(i) Health scheme A/c				
	Health scheme A/c	4,09,26,464.97	1,44,43,502.00		
	Health scheme A/c	1,98,250.00	-		
	Total S.N. 1	4,29,08,714.97	1,44,43,502.00	181,85,53,747.00	181,54,20,575.00
2.	Other Specific Accounts				
	(i) Pharmacovigilance workshop A/c	-	6,90,000.00	6,90,000.00	-
	(ii) Herb Garden A/c	1,90,232.00	74,256.00	1,90,232.00	-
	(iii) Pub. of Text Book A/c	-	61,249.00	62,746.00	-
	(iv) UPS A/c I	-	51,485.00	52,027.00	-
	(v) DSOP A/c	-	2,33,631.00	2,39,342.00	-
	(vi) AIUUA A/c	-	36,58,322.00	37,03,510.00	-
	(vii) I.T. A/c	35,94,007.00	35,95,499.00	35,95,499.00	19,06,739.00
	(viii) WHO A/c	-	2456.00	2,516.00	-
	(ix) International Events Conference	-	7,98,334.00	8,15,733.00	-
	(x) IPR	11,68,000.00	2,68,997.00	22,68,997.00	3,67,567.00
	(xi) DST A/c	-	7,64,357.00	7,64,486.20	-
	(xii) CRISM A/c	-	1,72,93,526.00	1,77,17,681.00	-
	(xiii) South African A/c	-	5,48,816.00	5,62,232.68	-
	(xiv) International Conference on Unani Day	13,92,933.50	4,66,057.00	69,24,424.50	8,05,443.00.00
	Total S.N. 2 (ii to xiv)	63,45,172.50	2,85,06,985.00	3,75,89,426.38	30,79,749.00
3.	(i) NPS A/c	76,88,547.31	59,26,026.00	2,40,88,070.31	86,04,525.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

Schedule of Payments for the Year Ending 31<sup>st</sup> March 2022

S.N.	Name of the Scheme	Closing Balance		Total payments	
		Current Year	Previous Year	Current Year	Previous Year
		(22)		(23)	
	(ii) GPF A/c	5,02,49,455.29	2,36,17,032.00	40,39,89,667.10	42,72,47,383.00
	(iii) GIS A/c	50,09,435.84	77,60,273.00	91,54,580.84	2,09,75,670.00
	(iv) Pension fund A/c	4,39,92,321.53	4,24,95,307.00	46,80,11,573.50	42,62,51,712.00
	Total S.N. 3	10,69,39,760.00	7,97,98,638.00	90,52,43,891.80	88,30,79,290.00
	Grand Total S.N. 1to 3	15,61,93,647.40	12,27,49,125.00	2,76,13,87,065.00	2,70,15,79,614.00

Sd/-  
(Shakaib Hasan)  
Office Assistant (Internal Audit)

Sd/-  
(Mohammad Parvez)  
Accounts Officer

Sd/-  
(Krishan Kumar Sapra)  
Assistant Director (Admn.)

Sd/-  
(Prof. Asim Ali Khan)  
Director General

### 5.3. Notes on Accounts

1. Annual accounts of the Council for the year 2021–2022 have been prepared on the uniform format of account for Central Autonomous Bodies (Non-profit organization).
2. The Central Council for Research in Unani Medicine is fully financed by Govt. of India Ministry of Ayush through grant-in-aid. Therefore, income tax is not applicable on the organization.
3. The said accounts prepared on accrual basis.
4. Schedules are attached wherever necessary.
5. Depreciation has been charged on assets on diminishing balance method.
6. The construction works are done by the CPWD & NPCC.
7. There is no valuation of Inventories since it is not a profit earning organization but a Research Organization under Ministry of Ayush, Government of India.
8. A schedule of Investment prepared every year & given to audit which is duly reconciled with actual documents figures mentioning there the rate of interest duration amount & name of Institutions, etc.
9. Retirement benefits are treated as per GOI Rules.
10. Depreciation has been charged under expenditure.
11. Earmarked/Endowment fund has been shown separately in the Balance Sheet with necessary Schedule.
12. The annual accounts of the Council for the year 2021-2022 have been approved by the competent authority, i.e. Standing Finance Committee on July 25, 2022.

Sd/-  
Assistant Director (Admn.)  
CCRUM, New Delh

## APPENDIX-I

### INSTITUTIONAL NETWORK OF CCRM

- |  |   |
|--|---|
| <p><b>1 Central Council for Research in Unani Medicine</b><br/>61-65, Institutional Area, Opposite D Block, Janakpuri, New Delhi – 110 058<br/>Phone: +91-11-28521981<br/>Fax: +91-11-28522965<br/>E-mail: unanimedicine@gmail.com</p> | <p><b>2 National Research Institute of Unani Medicine for Skin Disorders</b><br/>Opp. ESI Hospital, AG Colony Road Erragadda, Hyderabad – 500 038 Telangana<br/>Phone: +91-40-23811551, 23810246<br/>E-mail: criumhyderabad@gmail.com</p> |
| <p><b>3 Central Research Institute of Unani Medicine</b><br/>Basaha, Kursi Road, Lucknow – 226 026 Uttar Pradesh<br/>Phone: +91-522-2361720<br/>E-mail: crium_lko@yahoo.co.in</p>  | <p><b>4 Hakim Ajmal Khan Institute for Literary &amp; Historical Research in Unani Medicine</b><br/>Dr. MA Ansari Health Centre<br/>Jamia Millia Islamia, Okhla<br/>New Delhi – 110 025<br/>E-mail: Iriumnew1986@gmail.com</p>            |
| <p><b>5 Regional Research Institute of Unani Medicine</b><br/>1, West Meda Church Street, Royapuram Chennai – 600 013, Tamil Nadu<br/>Phone: +91-44-25955519<br/>E-mail: rriumchennai@gmail.com</p>                                    | <p><b>6 Regional Research Institute of Unani Medicine</b><br/>Chandbali Bypass Road, Near Rural Police Station, Bhadrak – 756 100, Odisha<br/>Phone: +91-6784-240289<br/>E-mail: rriumbdk_unani@yahoo.co.in</p>                           |
| <p><b>7 Regional Research Institute of Unani Medicine</b><br/>Guzri, Patna City, Patna – 800 008, Bihar<br/>Phone: +91-612-2631106<br/>E-mail: rriumpatna@gmail.com</p>  | <p><b>8 Regional Research Institute of Unani Medicine</b><br/>Shahjahan Manzil<br/>Near AMU Riding Club, Qila Road, Aligarh – 202 001, Uttar Pradesh<br/>Phone: +91-571-2704781, 2701399<br/>E-mail: rrium_aligarh@rediffmail.com</p>     |
| <p><b>9 Regional Research Institute of Unani Medicine</b><br/>JJ Hospital Compound, Byculla, Mumbai – 400 008, Maharashtra<br/>Phone: +91-22-23718706<br/>E-mail: rrium_mumbai@gmail.com</p>   | <p><b>10 Regional Research Institute of Unani Medicine</b><br/>University of Kashmir Campus, Hazrat Bal Srinagar – 190 006, Jammu &amp; Kashmir<br/>Phone: +91-194-2421604<br/>E-mail: rrium.srinagar@gmail.com</p>                       |
| <p><b>11 Regional Research Institute of Unani Medicine</b><br/>250A/29, GT Road (North), Liluah Howrah – 711 204, West Bengal<br/>Phone: +91-33-26550108<br/>E-mail: kolrrium@gmail.com</p>  | <p><b>12 Regional Research Institute of Unani Medicine</b><br/>D-11/1, Abul Fazal Enclave, Jamia Nagar New Delhi – 110 025<br/>Phone: +91-11-26922759<br/>E-mail: rriumdelhi@gmail.com</p>  |
| <p><b>13 Drug Standardization Research Institute</b><br/>PLIM, Sector-23, Kamla Nehru Nagar Ghaziabad – 201 002, Uttar Pradesh<br/>Phone: +91-120-2783029<br/>E-mail: dsriccrum@gmail.com</p>  | <p><b>14 Regional Research Centre</b><br/>B-501/4, GTB Nagar, Opp. Dulhan Palace Kareli, Prayagraj – 211 016, Uttar Pradesh<br/>Phone: +91-532-2551223<br/>E-mail: rrcallahabad@gmail.com</p>   |

- 15 **Regional Research Centre**  
SM Dev Civil Hospital, Silchar – 788 001  
(Cachar) Assam  
Phone: +91-3843-267522  
E-mail: crukxj522@gmail.com
- 16 **Drug Standardization Research Unit**  
61-65, Institutional Area, Opposite D Block  
Janakpuri, New Delhi – 110 058  
Phone: +91-11-28521981  
E-Mail: dsru.newdelhi@gmail.com
- 17 **Clinical Research Unit**  
Kurupatil Nina Memorial, Near Panchayat  
Office, Edathala (N)  
Alweye – 683 564, Kerala  
Phone: +91-484-2836006  
E-mail: crukerala@gmail.com
- 18 **Clinical Research Unit**  
National Institute of Unani Medicine  
Kotigepaliya, Magadi Main Road  
Bengaluru – 560 091, Karnataka  
Phone: +91-80-25480863  
E-mail: crubangalore2000@yahoo.com
- 19 **Clinical Research Unit**  
Dr. Abdul Haq Unani Medical College  
40/23 Park Road, Kurnool – 518 001  
Andhra Pradesh  
E-mail: cru.kurnool@gmail.com
- 20 **Clinical Research Unit**  
Cantonment General Hospital, Soti Ganj  
Begumpul, Meerut – 250 001, Uttar Pradesh  
Phone: +91-9012843253  
E-mail: doctormtk@gmail.com
- 21 **Clinical Research Unit**  
Gandhi Medical College, Bhopal – 462  
001, Madhya Pradesh  
Phone: +91-755-2540590  
E-mail: cruu\_incharge@yahoo.com
- 22 **Clinical Research Unit**  
SH Unani Tibbiya College, Ganpati Naka  
Burhanpur – 450 331, Madhya Pradesh  
Phone: +91-7325-252250  
E-mail: cruburhanpur@rediffmail.com
- 23 **Chemical Research Unit**  
Department of Research in Unani  
Medicine, Near Office of Dean, Faculty of  
Science, Aligarh Muslim University  
Aligarh – 202 001, Uttar Pradesh
- 24 **Unani Medical Centre**  
(Extension Centre of RRIUM, New Delhi)  
Dr. Ram Manohar Lohia Hospital  
New Delhi – 110 001  
Phone: +91-11-23404594
- 25 **Unani Speciality Centre**  
(Extension Centre of RRIUM, New Delhi)  
Deen Dayal Upadhyay Hospital  
Ghantaghar, Harinagar  
New Delhi – 110 064
- 26 **Unani Medical Centre**  
(Extension Centre of RRIUM, New Delhi)  
VMC & Safdarjung Hospital  
New OPD Block, Ansari Nagar East, New  
Delhi – 110029  
Phone: +91-11-26707121



## This image shows a full page of white paper with horizontal dotted lines. The lines are evenly spaced and run across the width of the page, providing a guide for handwriting or typing. There are no margins, text, or other markings on the page.

## NOTES

[illegible]

## This image shows a full page of white paper with horizontal dotted lines. The lines are evenly spaced and run across the width of the page, providing a guide for handwriting or typing. There are no margins, text, or other markings on the page.



CENTRAL COUNCIL FOR RESEARCH  
IN UNANI MEDICINE  
Ministry of Ayush, Government of India



**CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE**

Ministry of Ayush, Government of India

61–65, Institutional Area, Janakpuri, New Delhi – 110 058

Telephone: +91-11-28521981, 28525982

E-mail: [unanimedicine@gmail.com](mailto:unanimedicine@gmail.com)

Website: <https://ccrum.res.in>





## **CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE**

Ministry of Ayush, Government of India  
61 - 65, Institutional Area, Janakpuri, New Delhi - 110 058  
Telephone: +91-11-28521981, 28525982  
Email: [unanimedicine@gmail.com](mailto:unanimedicine@gmail.com)  
Website: [www.ccrum.res.in](http://www.ccrum.res.in)